{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T12:31:43Z","timestamp":1793277103878,"version":"4.5.0"},"reference-count":521,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000041","name":"American Diabetes Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000041","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007885","name":"European Association for the Study of Diabetes","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007885","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"DOI":"10.1007\/s00125-026-06855-7","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:01:16Z","timestamp":1790913676000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Management of type 2 diabetes, 2026. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9987-9371","authenticated-orcid":false,"given":"Melanie J.","family":"Davies","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7706-4585","authenticated-orcid":false,"given":"Vanita R.","family":"Aroda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7263-5425","authenticated-orcid":false,"given":"Mandeep","family":"Bajaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1217-4916","authenticated-orcid":false,"given":"Nuha A.","family":"ElSayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7372-2678","authenticated-orcid":false,"given":"Francesco","family":"Giorgino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5061-9632","authenticated-orcid":false,"given":"Jennifer","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1530-6884","authenticated-orcid":false,"given":"Rita R.","family":"Kalyani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5799-104X","authenticated-orcid":false,"given":"Nisa M.","family":"Maruthur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4055-5233","authenticated-orcid":false,"given":"Chantal","family":"Mathieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9903-4002","authenticated-orcid":false,"given":"Sylvia E.","family":"Rosas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1531-4294","authenticated-orcid":false,"given":"Peter","family":"Rossing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2764-3148","authenticated-orcid":false,"given":"Tommy","family":"Slater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7572-1131","authenticated-orcid":false,"given":"Tsvetalina","family":"Tankova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7119-8569","authenticated-orcid":false,"given":"Pinar","family":"Topsever","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0221-4072","authenticated-orcid":false,"given":"Apostolos","family":"Tsapas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9723-3876","authenticated-orcid":false,"given":"John B.","family":"Buse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,2]]},"reference":[{"issue":"1","key":"6855_CR1","doi-asserted-by":"publisher","first-page":"e1004326","DOI":"10.1371\/journal.pmed.1004326","volume":"21","author":"WT Gattrell","year":"2024","unstructured":"Gattrell WT, Logullo P, van Zuuren EJ et al (2024) ACCORD (ACcurate COnsensus Reporting Document): a reporting guideline for consensus methods in biomedicine developed via a modified Delphi. PLoS Med 21(1):e1004326. https:\/\/doi.org\/10.1371\/journal.pmed.1004326","journal-title":"PLoS Med"},{"issue":"12","key":"6855_CR2","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1007\/s00125-022-05787-2","volume":"65","author":"MJ Davies","year":"2022","unstructured":"Davies MJ, Aroda VR, Collins BS et al (2022) Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 65(12):1925\u20131966. https:\/\/doi.org\/10.1007\/s00125-022-05787-2","journal-title":"Diabetologia"},{"issue":"11","key":"6855_CR3","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.2337\/dci22-0034","volume":"45","author":"MJ Davies","year":"2022","unstructured":"Davies MJ, Aroda VR, Collins BS et al (2022) Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 45(11):2753\u20132786. https:\/\/doi.org\/10.2337\/dci22-0034","journal-title":"Diabetes Care"},{"issue":"32","key":"6855_CR4","doi-asserted-by":"publisher","first-page":"E901","DOI":"10.1503\/cmaj.200077","volume":"192","author":"S Schandelmaier","year":"2020","unstructured":"Schandelmaier S, Briel M, Varadhan R et al (2020) Development of the Instrument to assess the Credibility of Effect Modification Analyses (ICEMAN) in randomized controlled trials and meta-analyses. CMAJ 192(32):E901-E906. https:\/\/doi.org\/10.1503\/cmaj.200077","journal-title":"Cmaj"},{"issue":"4","key":"6855_CR5","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1001\/jama.2013.285063","volume":"311","author":"X Sun","year":"2014","unstructured":"Sun X, Ioannidis JP, Agoritsas T, Alba AC, Guyatt G (2014) How to use a subgroup analysis: users\u2019 guide to the medical literature. JAMA 311(4):405\u2013411. https:\/\/doi.org\/10.1001\/jama.2013.285063","journal-title":"Jama"},{"issue":"7","key":"6855_CR6","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.jclinepi.2012.03.013","volume":"66","author":"J Andrews","year":"2013","unstructured":"Andrews J, Guyatt G, Oxman AD et al (2013) GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol 66(7):719\u2013725. https:\/\/doi.org\/10.1016\/j.jclinepi.2012.03.013","journal-title":"J Clin Epidemiol"},{"key":"6855_CR7","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.jclinepi.2019.10.014","volume":"119","author":"N Santesso","year":"2020","unstructured":"Santesso N, Glenton C, Dahm P et al (2020) GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions. J Clin Epidemiol 119:126\u2013135. https:\/\/doi.org\/10.1016\/j.jclinepi.2019.10.014","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"6855_CR8","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12913-024-12160-z","volume":"25","author":"M Peimani","year":"2025","unstructured":"Peimani M, Stewart AL, Garmaroudi G, Nasli-Esfahani E (2025) Shared decision-making in type 2 diabetes: a systematic review of patients\u2019 preferences and healthcare providers\u2019 perspectives. BMC Health Serv Res 25(1):39. https:\/\/doi.org\/10.1186\/s12913-024-12160-z","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"6855_CR9","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2337\/cd24-0042","volume":"43","author":"S Vasistha","year":"2025","unstructured":"Vasistha S, Kanchibhatla A, Blanchette JE, Rieke J, Hughes AS (2025) The sugar-coated truth: the quality of diabetes health information on tiktok. Clin Diabetes 43(1):53\u201358. https:\/\/doi.org\/10.2337\/cd24-0042","journal-title":"Clin Diabetes"},{"issue":"4","key":"6855_CR10","doi-asserted-by":"publisher","first-page":"e14209","DOI":"10.2196\/14209","volume":"22","author":"A Elnaggar","year":"2020","unstructured":"Elnaggar A, Ta Park V, Lee SJ, Bender M, Siegmund LA, Park LG (2020) Patients\u2019 use of social media for diabetes self-care: systematic review. J Med Internet Res 22(4):e14209. https:\/\/doi.org\/10.2196\/14209","journal-title":"J Med Internet Res"},{"issue":"5","key":"6855_CR11","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/s2213-8587(26)00069-0","volume":"14","author":"C Tejera-P\u00e9rez","year":"2026","unstructured":"Tejera-P\u00e9rez C (2026) Viral medicine: social media and new expectations of obesity treatment. Lancet Diabetes Endocrinol 14(5):374. https:\/\/doi.org\/10.1016\/s2213-8587(26)00069-0","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"6855_CR12","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/s2213-8587(25)00061-0","volume":"13","author":"J Henson","year":"2025","unstructured":"Henson J, Baker LA, Watson E, Yates T, Davies MJ (2025) Type 2 diabetes and accelerated ageing in skeletal muscle. Lancet Diabetes Endocrinol 13(5):362\u2013364. https:\/\/doi.org\/10.1016\/s2213-8587(25)00061-0","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"6855_CR13","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.2337\/dci23-0035","volume":"46","author":"K Khunti","year":"2023","unstructured":"Khunti K, Chudasama YV, Gregg EW et al (2023) Diabetes and multiple long-term conditions: a review of our current global health challenge. Diabetes Care 46(12):2092\u20132101. https:\/\/doi.org\/10.2337\/dci23-0035","journal-title":"Diabetes Care"},{"issue":"1","key":"6855_CR14","doi-asserted-by":"publisher","first-page":"258","DOI":"10.2337\/dci20-0053","volume":"44","author":"F Hill-Briggs","year":"2020","unstructured":"Hill-Briggs F, Adler NE, Berkowitz SA et al (2020) Social determinants of health and diabetes: a scientific review. Diabetes Care 44(1):258\u2013279. https:\/\/doi.org\/10.2337\/dci20-0053","journal-title":"Diabetes Care"},{"issue":"10365","key":"6855_CR15","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1016\/s0140-6736(22)01655-5","volume":"400","author":"E Ahmad","year":"2022","unstructured":"Ahmad E, Lim S, Lamptey R, Webb DR, Davies MJ (2022) Type 2 diabetes. Lancet 400(10365):1803\u20131820. https:\/\/doi.org\/10.1016\/s0140-6736(22)01655-5","journal-title":"Lancet"},{"issue":"19","key":"6855_CR16","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.3390\/cells13191662","volume":"13","author":"V Pellegrini","year":"2024","unstructured":"Pellegrini V, La Grotta R, Carreras F et al (2024) Inflammatory trajectory of type 2 diabetes: novel opportunities for early and late treatment. Cells 13(19):1662. https:\/\/doi.org\/10.3390\/cells13191662","journal-title":"Cells"},{"issue":"1","key":"6855_CR17","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1093\/ehjcvp\/pvad074","volume":"10","author":"WC Zheng","year":"2024","unstructured":"Zheng WC, Chan W, Dart A, Shaw JA (2024) Novel therapeutic targets and emerging treatments for atherosclerotic cardiovascular disease. Eur Heart J Cardiovasc Pharmacother 10(1):53\u201367. https:\/\/doi.org\/10.1093\/ehjcvp\/pvad074","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"Suppl 6","key":"6855_CR18","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/dom.16402","volume":"27","author":"C Evans-Molina","year":"2025","unstructured":"Evans-Molina C, Oram RA (2025) Type 1 diabetes presenting in adults: trends, diagnostic challenges and unique features. Diabetes Obes Metab 27(Suppl 6):57\u201368. https:\/\/doi.org\/10.1111\/dom.16402","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"6855_CR19","doi-asserted-by":"publisher","first-page":"770","DOI":"10.2337\/dci23-0038","volume":"47","author":"SI Stone","year":"2024","unstructured":"Stone SI, Balasubramanyam A, Posey JE (2024) Atypical diabetes: what have we learned and what does the future hold? Diabetes Care 47(5):770\u2013781. https:\/\/doi.org\/10.2337\/dci23-0038","journal-title":"Diabetes Care"},{"issue":"12","key":"6855_CR20","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.2337\/dc24-2841","volume":"48","author":"JB Buse","year":"2025","unstructured":"Buse JB, Kahn SE, Aroda VR et al (2025) Prevalence of hypercortisolism in difficult-to-control type 2 diabetes. Diabetes Care 48(12):2012\u20132020. https:\/\/doi.org\/10.2337\/dc24-2841","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"6855_CR21","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.2337\/dc26-S002","volume":"49","author":"American Diabetes Association Professional Practice Committee","year":"2026","unstructured":"American Diabetes Association Professional Practice Committee (2026) 2. Diagnosis and classification of diabetes: standards of care in diabetes-2026. Diabetes Care 49(Suppl 1):S27-s49. https:\/\/doi.org\/10.2337\/dc26-S002","journal-title":"Diabetes Care"},{"issue":"10","key":"6855_CR22","doi-asserted-by":"publisher","first-page":"e1771","DOI":"10.1016\/s2214-109x(25)00263-3","volume":"13","author":"P Wadivkar","year":"2025","unstructured":"Wadivkar P, Jebasingh F, Thomas N et al (2025) Classifying a distinct form of diabetes in lean individuals with a history of undernutrition: an international consensus statement. Lancet Glob Health 13(10):e1771\u2013e1776. https:\/\/doi.org\/10.1016\/s2214-109x(25)00263-3","journal-title":"Lancet Glob Health"},{"issue":"1 Suppl 1","key":"6855_CR23","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.2337\/dc25-S002","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","unstructured":"American Diabetes Association Professional Practice Committee (2025) 2. Diagnosis and classification of diabetes: standards of care in diabetes-2025. Diabetes Care 48(1 Suppl 1):S27-s49. https:\/\/doi.org\/10.2337\/dc25-S002","journal-title":"Diabetes Care"},{"issue":"1 Suppl 1","key":"6855_CR24","doi-asserted-by":"publisher","first-page":"S128","DOI":"10.2337\/dc25-S006","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","unstructured":"American Diabetes Association Professional Practice Committee (2025) 6. Glycemic goals and hypoglycemia: standards of care in diabetes-2025. Diabetes Care 48(1 Suppl 1):S128-s145. https:\/\/doi.org\/10.2337\/dc25-S006","journal-title":"Diabetes Care"},{"issue":"8","key":"6855_CR25","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.2337\/dc23-0560","volume":"46","author":"TODAY Study Group","year":"2023","unstructured":"TODAY Study Group (2023) Effect of early glycemic control in youth-onset type 2 diabetes on longer-term glycemic control and \u03b2-cell function: results from the TODAY study. Diabetes Care 46(8):1507\u20131514. https:\/\/doi.org\/10.2337\/dc23-0560","journal-title":"Diabetes Care"},{"issue":"12","key":"6855_CR26","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/s2213-8587(24)00242-0","volume":"12","author":"B Lin","year":"2024","unstructured":"Lin B, Coleman RL, Bragg F, Maddaloni E, Holman RR, Adler AI (2024) Younger-onset compared with later-onset type 2 diabetes: an analysis of the UK Prospective Diabetes Study (UKPDS) with up to 30 years of follow-up (UKPDS 92). Lancet Diabetes Endocrinol 12(12):904\u2013914. https:\/\/doi.org\/10.1016\/s2213-8587(24)00242-0","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"Suppl 1","key":"6855_CR27","doi-asserted-by":"publisher","first-page":"S150","DOI":"10.2337\/dc26-S007","volume":"49","author":"American Diabetes Association Professional Practice Committee","year":"2026","unstructured":"American Diabetes Association Professional Practice Committee (2026) 7. Diabetes technology: standards of care in diabetes-2026. Diabetes Care 49(Suppl 1):S150-s165. https:\/\/doi.org\/10.2337\/dc26-S007","journal-title":"Diabetes Care"},{"issue":"5","key":"6855_CR28","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1007\/s00125-024-06107-6","volume":"67","author":"M Jancev","year":"2024","unstructured":"Jancev M, Vissers T, Visseren FLJ et al (2024) Continuous glucose monitoring in adults with type 2 diabetes: a systematic review and meta-analysis. Diabetologia 67(5):798\u2013810. https:\/\/doi.org\/10.1007\/s00125-024-06107-6","journal-title":"Diabetologia"},{"issue":"1 Suppl 1","key":"6855_CR29","doi-asserted-by":"publisher","first-page":"S207","DOI":"10.2337\/dc25-S010","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","unstructured":"American Diabetes Association Professional Practice Committee (2025) 10. Cardiovascular disease and risk management: standards of care in diabetes-2025. Diabetes Care 48(1 Suppl 1):S207-s238. https:\/\/doi.org\/10.2337\/dc25-S010","journal-title":"Diabetes Care"},{"issue":"17","key":"6855_CR30","doi-asserted-by":"publisher","first-page":"e1154","DOI":"10.1161\/cir.0000000000001423","volume":"153","author":"RS Blumenthal","year":"2026","unstructured":"Blumenthal RS, Morris PB, Gaudino M et al (2026) 2026 ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 153(17):e1154\u2013e1276. https:\/\/doi.org\/10.1161\/cir.0000000000001423","journal-title":"Circulation"},{"issue":"18","key":"6855_CR31","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1016\/j.jacc.2025.05.007","volume":"86","author":"DW Jones","year":"2025","unstructured":"Jones DW, Ferdinand KC, Taler SJ et al (2025) 2025 AHA\/ACC\/AANP\/AAPA\/ABC\/ACCP\/ACPM\/AGS\/AMA\/ASPC\/NMA\/PCNA\/SGIM guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 86(18):1567\u20131678. https:\/\/doi.org\/10.1016\/j.jacc.2025.05.007","journal-title":"J Am Coll Cardiol"},{"issue":"42","key":"6855_CR32","doi-asserted-by":"publisher","first-page":"4359","DOI":"10.1093\/eurheartj\/ehaf190","volume":"46","author":"F Mach","year":"2025","unstructured":"Mach F, Koskinas KC, Roeters van Lennep JE et al (2025) 2025 Focused Update of the 2019 ESC\/EAS Guidelines for the management of dyslipidaemias. Eur Heart J 46(42):4359\u20134378. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf190","journal-title":"Eur Heart J"},{"issue":"1 Suppl 1","key":"6855_CR33","doi-asserted-by":"publisher","first-page":"S59","DOI":"10.2337\/dc25-S004","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","unstructured":"American Diabetes Association Professional Practice Committee (2025) 4. Comprehensive medical evaluation and assessment of comorbidities: standards of care in diabetes-2025. Diabetes Care 48(1 Suppl 1):S59-s85. https:\/\/doi.org\/10.2337\/dc25-S004","journal-title":"Diabetes Care"},{"issue":"6","key":"6855_CR34","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1007\/s00125-023-05891-x","volume":"66","author":"A Kautzky-Willer","year":"2023","unstructured":"Kautzky-Willer A, Leutner M, Harreiter J (2023) Sex differences in type 2 diabetes. Diabetologia 66(6):986\u20131002. https:\/\/doi.org\/10.1007\/s00125-023-05891-x","journal-title":"Diabetologia"},{"key":"6855_CR35","doi-asserted-by":"publisher","first-page":"1279058","DOI":"10.3389\/fendo.2023.1279058","volume":"14","author":"XB Zhu","year":"2023","unstructured":"Zhu XB, Niu ZH, Fan WM, Sheng CS, Chen Q (2023) Type 2 diabetes mellitus and the risk of male infertility: a Mendelian randomization study. Front Endocrinol (Lausanne) 14:1279058. https:\/\/doi.org\/10.3389\/fendo.2023.1279058","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"6855_CR36","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.pcd.2023.05.005","volume":"17","author":"J Singh","year":"2023","unstructured":"Singh J, Sahoo AK, Swain J, Mangaraj S, Kanwar JB, Manglunia A (2023) Assessment of hypogonadism and its determinants among adult men with type 2 diabetes mellitus. Prim Care Diabetes 17(4):348\u2013353. https:\/\/doi.org\/10.1016\/j.pcd.2023.05.005","journal-title":"Prim Care Diabetes"},{"issue":"9","key":"6855_CR37","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1007\/s00125-022-05746-x","volume":"65","author":"Q Liu","year":"2022","unstructured":"Liu Q, Tang B, Zhu Z et al (2022) A genome-wide cross-trait analysis identifies shared loci and causal relationships of type 2 diabetes and glycaemic traits with polycystic ovary syndrome. Diabetologia 65(9):1483\u20131494. https:\/\/doi.org\/10.1007\/s00125-022-05746-x","journal-title":"Diabetologia"},{"issue":"3","key":"6855_CR38","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s42000-020-00225-7","volume":"19","author":"D Cre\u0163u","year":"2020","unstructured":"Cre\u0163u D, Cernea S, Onea CR, Pop RM (2020) Reproductive health in women with type 2 diabetes mellitus. Hormones (Athens) 19(3):291\u2013300. https:\/\/doi.org\/10.1007\/s42000-020-00225-7","journal-title":"Hormones (Athens)"},{"issue":"1 Suppl 1","key":"6855_CR39","doi-asserted-by":"publisher","first-page":"S239","DOI":"10.2337\/dc25-S011","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","unstructured":"American Diabetes Association Professional Practice Committee (2025) 11. Chronic kidney disease and risk management: standards of care in diabetes-2025. Diabetes Care 48(1 Suppl 1):S239-s251. https:\/\/doi.org\/10.2337\/dc25-S011","journal-title":"Diabetes Care"},{"issue":"1 Suppl 1","key":"6855_CR40","doi-asserted-by":"publisher","first-page":"S252","DOI":"10.2337\/dc25-S012","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","unstructured":"American Diabetes Association Professional Practice Committee (2025) 12. Retinopathy, neuropathy, and foot care: standards of care in diabetes-2025. Diabetes Care 48(1 Suppl 1):S252-S265. https:\/\/doi.org\/10.2337\/dc25-S012","journal-title":"Diabetes Care"},{"issue":"1 Suppl 1","key":"6855_CR41","doi-asserted-by":"publisher","first-page":"S181","DOI":"10.2337\/dc25-S009","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","unstructured":"American Diabetes Association Professional Practice Committee (2025) 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2025. Diabetes Care 48(1 Suppl 1):S181-s206. https:\/\/doi.org\/10.2337\/dc25-S009","journal-title":"Diabetes Care"},{"issue":"11","key":"6855_CR42","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/s2213-8587(24)00272-9","volume":"12","author":"CM Prado","year":"2024","unstructured":"Prado CM, Phillips SM, Gonzalez MC, Heymsfield SB (2024) Muscle matters: the effects of medically induced weight loss on skeletal muscle. Lancet Diabetes Endocrinol 12(11):785\u2013787. https:\/\/doi.org\/10.1016\/s2213-8587(24)00272-9","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"Suppl 4","key":"6855_CR43","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/dom.15728","volume":"26","author":"IJ Neeland","year":"2024","unstructured":"Neeland IJ, Linge J, Birkenfeld AL (2024) Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes Obes Metab 26(Suppl 4):16\u201327. https:\/\/doi.org\/10.1111\/dom.15728","journal-title":"Diabetes Obes Metab"},{"issue":"10267","key":"6855_CR44","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1016\/s0140-6736(20)32374-6","volume":"396","author":"JCN Chan","year":"2021","unstructured":"Chan JCN, Lim LL, Wareham NJ et al (2021) The Lancet Commission on diabetes: using data to transform diabetes care and patient lives. Lancet 396(10267):2019\u20132082. https:\/\/doi.org\/10.1016\/s0140-6736(20)32374-6","journal-title":"Lancet"},{"issue":"10173","key":"6855_CR45","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/s0140-6736(18)32822-8","volume":"393","author":"BA Swinburn","year":"2019","unstructured":"Swinburn BA, Kraak VI, Allender S et al (2019) The global syndemic of obesity, undernutrition, and climate change: the lancet commission report. Lancet 393(10173):791\u2013846. https:\/\/doi.org\/10.1016\/s0140-6736(18)32822-8","journal-title":"Lancet"},{"issue":"6","key":"6855_CR46","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1007\/s00125-023-05901-y","volume":"66","author":"JM Ratter-Rieck","year":"2023","unstructured":"Ratter-Rieck JM, Roden M, Herder C (2023) Diabetes and climate change: current evidence and implications for people with diabetes, clinicians and policy stakeholders. Diabetologia 66(6):1003\u20131015. https:\/\/doi.org\/10.1007\/s00125-023-05901-y","journal-title":"Diabetologia"},{"issue":"Supplement_1","key":"6855_CR47","doi-asserted-by":"publisher","first-page":"S89","DOI":"10.2337\/dc26-S005","volume":"49","author":"American Diabetes Association Professional Practice Committee","year":"2026","unstructured":"American Diabetes Association Professional Practice Committee (2026) 5. Facilitating positive health behaviors and well-being to improve health outcomes: standards of care in diabetes-2026. Diabetes Care 49(Supplement_1):S89-s131. https:\/\/doi.org\/10.2337\/dc26-S005","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"6855_CR48","doi-asserted-by":"publisher","first-page":"S183","DOI":"10.2337\/dc26-S009","volume":"49","author":"American Diabetes Association Professional Practice Committee","year":"2026","unstructured":"American Diabetes Association Professional Practice Committee (2026) 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2026. Diabetes Care 49(Suppl 1):S183-s215. https:\/\/doi.org\/10.2337\/dc26-S009","journal-title":"Diabetes Care"},{"issue":"5","key":"6855_CR49","doi-asserted-by":"publisher","first-page":"731","DOI":"10.2337\/dci19-0014","volume":"42","author":"AB Evert","year":"2019","unstructured":"Evert AB, Dennison M, Gardner CD et al (2019) Nutrition therapy for adults with diabetes or prediabetes: a consensus report. Diabetes Care 42(5):731\u2013754. https:\/\/doi.org\/10.2337\/dci19-0014","journal-title":"Diabetes Care"},{"issue":"12","key":"6855_CR50","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/s41574-025-01161-5","volume":"21","author":"L Barrea","year":"2025","unstructured":"Barrea L, Verde L, Colao A, Mandarino LJ, Muscogiuri G (2025) Medical nutrition therapy for the management of type 2 diabetes mellitus. Nat Rev Endocrinol 21(12):769\u2013782. https:\/\/doi.org\/10.1038\/s41574-025-01161-5","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"6855_CR51","doi-asserted-by":"publisher","first-page":"174","DOI":"10.2174\/0115734021351456250326051146","volume":"21","author":"S Dehghani","year":"2025","unstructured":"Dehghani S, Karimi P, Tarei NN et al (2025) Comparison of the effect of intermittent fasting with Mediterranean diet on glycemic, lipid, and anthropometric indices in type 2 diabetes: a review of randomized controlled trials. Curr Hypertens Rev 21(3):174\u2013185. https:\/\/doi.org\/10.2174\/0115734021351456250326051146","journal-title":"Curr Hypertens Rev"},{"issue":"5","key":"6855_CR52","doi-asserted-by":"publisher","first-page":"104433","DOI":"10.1016\/j.numecd.2025.104433","volume":"36","author":"F Lauria","year":"2026","unstructured":"Lauria F, Formisano A, Dello Russo M et al (2026) Mediterranean diet, gut microbiota, and type 2 diabetes: a systematic review and meta-analysis of intervention trials. Nutr Metab Cardiovasc Dis 36(5):104433. https:\/\/doi.org\/10.1016\/j.numecd.2025.104433","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"1","key":"6855_CR53","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41387-024-00285-3","volume":"14","author":"A Podadera-Herreros","year":"2024","unstructured":"Podadera-Herreros A, Arenas-de Larriva AP, Gutierrez-Mariscal FM et al (2024) Mediterranean diet as a strategy for preserving kidney function in patients with coronary heart disease with type 2 diabetes and obesity: a secondary analysis of CORDIOPREV randomized controlled trial. Nutr Diabetes 14(1):27. https:\/\/doi.org\/10.1038\/s41387-024-00285-3","journal-title":"Nutr Diabetes"},{"issue":"10338","key":"6855_CR54","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1016\/s0140-6736(22)00122-2","volume":"399","author":"J Delgado-Lista","year":"2022","unstructured":"Delgado-Lista J, Alcala-Diaz JF, Torres-Pe\u00f1a JD et al (2022) Long-term secondary prevention of cardiovascular disease with a Mediterranean diet and a low-fat diet (CORDIOPREV): a randomised controlled trial. Lancet 399(10338):1876\u20131885. https:\/\/doi.org\/10.1016\/s0140-6736(22)00122-2","journal-title":"Lancet"},{"issue":"34","key":"6855_CR55","doi-asserted-by":"publisher","first-page":"2870","DOI":"10.1093\/eurheartj\/ehz174","volume":"40","author":"M Mazidi","year":"2019","unstructured":"Mazidi M, Katsiki N, Mikhailidis DP, Sattar N, Banach M (2019) Lower carbohydrate diets and all-cause and cause-specific mortality: a population-based cohort study and pooling of prospective studies. Eur Heart J 40(34):2870\u20132879. https:\/\/doi.org\/10.1093\/eurheartj\/ehz174","journal-title":"Eur Heart J"},{"issue":"1","key":"6855_CR56","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12986-024-00824-w","volume":"21","author":"P Ghasemi","year":"2024","unstructured":"Ghasemi P, Jafari M, Maskouni SJ et al (2024) Impact of very low carbohydrate ketogenic diets on cardiovascular risk factors among patients with type 2 diabetes; GRADE-assessed systematic review and meta-analysis of clinical trials. Nutr Metab (Lond) 21(1):50. https:\/\/doi.org\/10.1186\/s12986-024-00824-w","journal-title":"Nutr Metab (Lond)"},{"issue":"3","key":"6855_CR57","doi-asserted-by":"publisher","first-page":"397","DOI":"10.3390\/nu18030397","volume":"18","author":"J Kilian","year":"2026","unstructured":"Kilian J, Szl\u0119zak D, Tyszka-Czochara M, Filipowicz-Popielarska E, Bronowicka-Adamska P (2026) The ketogenic diet in type 2 diabetes and obesity: a narrative review of clinical evidence. Nutrients 18(3):397. https:\/\/doi.org\/10.3390\/nu18030397","journal-title":"Nutrients"},{"issue":"7","key":"6855_CR58","doi-asserted-by":"publisher","first-page":"e1677","DOI":"10.1093\/nutrit\/nuae123","volume":"83","author":"MV Beretta","year":"2025","unstructured":"Beretta MV, Flores CAO, Colameo GF, Echabe LW, Busnello FM (2025) Low-carbohydrate dietary interventions for metabolic control in individuals with type 2 diabetes mellitus: an overview of systematic reviews. Nutr Rev 83(7):e1677\u2013e1692. https:\/\/doi.org\/10.1093\/nutrit\/nuae123","journal-title":"Nutr Rev"},{"issue":"1","key":"6855_CR59","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.ajcnut.2023.04.032","volume":"118","author":"BF Oliveira","year":"2023","unstructured":"Oliveira BF, Chang CR, Oetsch K et al (2023) Impact of a low-carbohydrate compared with low-fat breakfast on blood glucose control in type 2 diabetes: a randomized trial. Am J Clin Nutr 118(1):209\u2013217. https:\/\/doi.org\/10.1016\/j.ajcnut.2023.04.032","journal-title":"Am J Clin Nutr"},{"issue":"20","key":"6855_CR60","doi-asserted-by":"publisher","first-page":"4391","DOI":"10.3390\/nu14204391","volume":"14","author":"TA Apekey","year":"2022","unstructured":"Apekey TA, Maynard MJ, Kittana M, Kunutsor SK (2022) Comparison of the effectiveness of low carbohydrate versus low fat diets, in type 2 diabetes: systematic review and meta-analysis of randomized controlled trials. Nutrients 14(20):4391. https:\/\/doi.org\/10.3390\/nu14204391","journal-title":"Nutrients"},{"issue":"1","key":"6855_CR61","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1186\/s13098-024-01492-9","volume":"16","author":"X Zeng","year":"2024","unstructured":"Zeng X, Ji QP, Jiang ZZ, Xu Y (2024) The effect of different dietary restriction on weight management and metabolic parameters in people with type 2 diabetes mellitus: a network meta-analysis of randomized controlled trials. Diabetol Metab Syndr 16(1):254. https:\/\/doi.org\/10.1186\/s13098-024-01492-9","journal-title":"Diabetol Metab Syndr"},{"issue":"9","key":"6855_CR62","doi-asserted-by":"publisher","first-page":"3830","DOI":"10.1111\/dom.15730","volume":"26","author":"M Khalafi","year":"2024","unstructured":"Khalafi M, Habibi Maleki A, Symonds ME, Rosenkranz SK, Rohani H, Ehsanifar M (2024) The effects of intermittent fasting on body composition and cardiometabolic health in adults with prediabetes or type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab 26(9):3830\u20133841. https:\/\/doi.org\/10.1111\/dom.15730","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"6855_CR63","doi-asserted-by":"publisher","first-page":"356","DOI":"10.20960\/nh.05521","volume":"42","author":"X Huang","year":"2025","unstructured":"Huang X, Huang G, Wei G (2025) Intermittent fasting for glycemic control in patients with type 2 diabetes: a meta-analysis of randomized controlled trials. Nutr Hosp 42(2):356\u2013365. https:\/\/doi.org\/10.20960\/nh.05521","journal-title":"Nutr Hosp"},{"key":"6855_CR64","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.nutres.2025.04.008","volume":"138","author":"F Liu","year":"2025","unstructured":"Liu F, Zhang Z, Sun W, Li T (2025) The metabolic effects of intermittent fasting in patients with type 2 diabetes exist in the short term but disappear after its discontinuation: a systematic review and meta-analysis of randomized controlled trials. Nutr Res 138:135\u2013150. https:\/\/doi.org\/10.1016\/j.nutres.2025.04.008","journal-title":"Nutr Res"},{"issue":"6","key":"6855_CR65","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.2337\/dc24-0241","volume":"47","author":"M Li","year":"2024","unstructured":"Li M, Li J, Xu Y et al (2024) Effect of 5:2 regimens: energy-restricted diet or low-volume high-intensity interval training combined with resistance exercise on glycemic control and cardiometabolic health in adults with overweight\/obesity and type 2 diabetes: a three-arm randomized controlled trial. Diabetes Care 47(6):1074\u20131083. https:\/\/doi.org\/10.2337\/dc24-0241","journal-title":"Diabetes Care"},{"issue":"6","key":"6855_CR66","doi-asserted-by":"publisher","first-page":"e2416786","DOI":"10.1001\/jamanetworkopen.2024.16786","volume":"7","author":"L Guo","year":"2024","unstructured":"Guo L, Xi Y, Jin W et al (2024) A 5:2 intermittent fasting meal replacement diet and glycemic control for adults with diabetes: the EARLY randomized clinical trial. JAMA Netw Open 7(6):e2416786. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.16786","journal-title":"JAMA Netw Open"},{"issue":"10","key":"6855_CR67","doi-asserted-by":"publisher","first-page":"e2339337","DOI":"10.1001\/jamanetworkopen.2023.39337","volume":"6","author":"V Pavlou","year":"2023","unstructured":"Pavlou V, Cienfuegos S, Lin S et al (2023) Effect of time-restricted eating on weight loss in adults with type 2 diabetes: a randomized clinical trial. JAMA Netw Open 6(10):e2339337. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.39337","journal-title":"JAMA Netw Open"},{"issue":"14","key":"6855_CR68","doi-asserted-by":"publisher","first-page":"3156","DOI":"10.3390\/nu15143156","volume":"15","author":"T Jing","year":"2023","unstructured":"Jing T, Zhang S, Bai M et al (2023) Effect of dietary approaches on glycemic control in patients with type 2 diabetes: a systematic review with network meta-analysis of randomized trials. Nutrients 15(14):3156. https:\/\/doi.org\/10.3390\/nu15143156","journal-title":"Nutrients"},{"issue":"1","key":"6855_CR69","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s00125-021-05577-2","volume":"65","author":"C Churuangsuk","year":"2022","unstructured":"Churuangsuk C, Hall J, Reynolds A, Griffin SJ, Combet E, Lean MEJ (2022) Diets for weight management in adults with type 2 diabetes: an umbrella review of published meta-analyses and systematic review of trials of diets for diabetes remission. Diabetologia 65(1):14\u201336. https:\/\/doi.org\/10.1007\/s00125-021-05577-2","journal-title":"Diabetologia"},{"issue":"8","key":"6855_CR70","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.2337\/dc26-0937","volume":"49","author":"E Johnsen","year":"2026","unstructured":"Johnsen E, Bengtsson J, Halasa T et al (2026) Achieving at least 15% weight loss within 2 years of type 2 diabetes diagnosis is associated with lower risks of macrovascular and microvascular complications: a U.K. cohort study. Diabetes Care 49(8):1480\u20131489. https:\/\/doi.org\/10.2337\/dc26-0937","journal-title":"Diabetes Care"},{"issue":"10120","key":"6855_CR71","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/s0140-6736(17)33102-1","volume":"391","author":"ME Lean","year":"2018","unstructured":"Lean ME, Leslie WS, Barnes AC et al (2018) Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet 391(10120):541\u2013551. https:\/\/doi.org\/10.1016\/s0140-6736(17)33102-1","journal-title":"Lancet"},{"issue":"10","key":"6855_CR72","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.2337\/dci21-0034","volume":"44","author":"MC Riddle","year":"2021","unstructured":"Riddle MC, Cefalu WT, Evans PH et al (2021) Consensus report: definition and interpretation of remission in type 2 diabetes. Diabetes Care 44(10):2438\u20132444. https:\/\/doi.org\/10.2337\/dci21-0034","journal-title":"Diabetes Care"},{"issue":"4","key":"6855_CR73","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/s2213-8587(23)00385-6","volume":"12","author":"ME Lean","year":"2024","unstructured":"Lean ME, Leslie WS, Barnes AC et al (2024) 5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension study. Lancet Diabetes Endocrinol 12(4):233\u2013246. https:\/\/doi.org\/10.1016\/s2213-8587(23)00385-6","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"6855_CR74","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1002\/oby.23158","volume":"29","author":"RR Wing","year":"2021","unstructured":"Wing RR (2021) Does lifestyle intervention improve health of adults with overweight\/obesity and type 2 diabetes? Findings from the look AHEAD randomized trial. Obesity (Silver Spring) 29(8):1246\u20131258. https:\/\/doi.org\/10.1002\/oby.23158","journal-title":"Obesity (Silver Spring)"},{"issue":"3","key":"6855_CR75","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s00125-023-06048-6","volume":"67","author":"EW Gregg","year":"2024","unstructured":"Gregg EW, Chen H, Bancks MP et al (2024) Impact of remission from type 2 diabetes on long-term health outcomes: findings from the Look AHEAD study. Diabetologia 67(3):459\u2013469. https:\/\/doi.org\/10.1007\/s00125-023-06048-6","journal-title":"Diabetologia"},{"issue":"9","key":"6855_CR76","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1111\/dom.15073","volume":"25","author":"R Retnakaran","year":"2023","unstructured":"Retnakaran R, Pu J, Emery A, Kramer CK, Zinman B (2023) Baseline determinants of remission of type 2 diabetes in response to short-term insulin-based therapy: the pivotal role of beta-cell function. Diabetes Obes Metab 25(9):2473\u20132481. https:\/\/doi.org\/10.1111\/dom.15073","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"6855_CR77","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/s2213-8587(24)00346-2","volume":"13","author":"S Kanbour","year":"2025","unstructured":"Kanbour S, Ageeb RA, Malik RA, Abu-Raddad LJ (2025) Impact of bodyweight loss on type 2 diabetes remission: a systematic review and meta-regression analysis of randomised controlled trials. Lancet Diabetes Endocrinol 13(4):294\u2013306. https:\/\/doi.org\/10.1016\/s2213-8587(24)00346-2","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"6855_CR78","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.ajcnut.2023.03.018","volume":"117","author":"A Jayedi","year":"2023","unstructured":"Jayedi A, Zeraattalab-Motlagh S, Shahinfar H, Gregg EW, Shab-Bidar S (2023) Effect of calorie restriction in comparison to usual diet or usual care on remission of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Am J Clin Nutr 117(5):870\u2013882. https:\/\/doi.org\/10.1016\/j.ajcnut.2023.03.018","journal-title":"Am J Clin Nutr"},{"key":"6855_CR79","doi-asserted-by":"publisher","first-page":"106520","DOI":"10.1016\/j.phrs.2022.106520","volume":"185","author":"P Paul","year":"2022","unstructured":"Paul P, Kaul R, Harfouche M et al (2022) The effect of microbiome-modulating probiotics, prebiotics and synbiotics on glucose homeostasis in type 2 diabetes: a systematic review, meta-analysis, and meta-regression of clinical trials. Pharmacol Res 185:106520. https:\/\/doi.org\/10.1016\/j.phrs.2022.106520","journal-title":"Pharmacol Res"},{"issue":"2","key":"6855_CR80","doi-asserted-by":"publisher","first-page":"3181","DOI":"10.1007\/s12602-025-10644-w","volume":"18","author":"A Setayesh","year":"2026","unstructured":"Setayesh A, Karimi M, Karimi MA et al (2026) Effects of probiotic and synbiotic supplementation on glycemic indices in adult individuals with prediabetes and type 2 diabetes mellitus: a grade-assessed systematic review and dose-response meta-analysis of RCTs. Probiotics Antimicrob Proteins 18(2):3181\u20133204. https:\/\/doi.org\/10.1007\/s12602-025-10644-w","journal-title":"Probiotics Antimicrob Proteins"},{"key":"6855_CR81","doi-asserted-by":"publisher","first-page":"1015045","DOI":"10.3389\/fphar.2022.1015045","volume":"13","author":"W Xie","year":"2022","unstructured":"Xie W, Su F, Wang G et al (2022) Glucose-lowering effect of berberine on type 2 diabetes: a systematic review and meta-analysis. Front Pharmacol 13:1015045. https:\/\/doi.org\/10.3389\/fphar.2022.1015045","journal-title":"Front Pharmacol"},{"issue":"12","key":"6855_CR82","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.medcli.2021.06.028","volume":"158","author":"IA Abdelhaleem","year":"2022","unstructured":"Abdelhaleem IA, Brakat AM, Adayel HM, Asla MM, Rizk MA, Aboalfetoh AY (2022) The effects of resveratrol on glycemic control and cardiometabolic parameters in patients with T2DM: a systematic review and meta-analysis. Med Clin (Barc) 158(12):576\u2013585. https:\/\/doi.org\/10.1016\/j.medcli.2021.06.028","journal-title":"Med Clin (Barc)"},{"issue":"2","key":"6855_CR83","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1007\/s40200-025-01682-w","volume":"24","author":"M Karimi","year":"2025","unstructured":"Karimi M, Bahreini N, Pirzad S et al (2025) Propolis supplementation improves cardiometabolic health in patients with type 2 diabetes mellitus: findings from a GRADE-assessed systematic review and meta-analysis of RCTs. J Diabetes Metab Disord 24(2):164. https:\/\/doi.org\/10.1007\/s40200-025-01682-w","journal-title":"J Diabetes Metab Disord"},{"issue":"10","key":"6855_CR84","doi-asserted-by":"publisher","first-page":"4693","DOI":"10.1002\/ptr.70071","volume":"39","author":"Y Fan","year":"2025","unstructured":"Fan Y, Wu L, Zhang Y et al (2025) The impact of okra (Abelmoschus esculentus) supplementation on diabetes and obesity biomarkers in type 2 diabetes patients: a systematic review and meta-analysis of randomized controlled trials. Phytother Res 39(10):4693\u20134703. https:\/\/doi.org\/10.1002\/ptr.70071","journal-title":"Phytother Res"},{"issue":"1","key":"6855_CR85","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12902-022-01209-x","volume":"23","author":"MA Farahmand","year":"2023","unstructured":"Farahmand MA, Daneshzad E, Fung TT et al (2023) What is the impact of vitamin D supplementation on glycemic control in people with type-2 diabetes: a systematic review and meta-analysis of randomized controlled trails. BMC Endocr Disord 23(1):15. https:\/\/doi.org\/10.1186\/s12902-022-01209-x","journal-title":"BMC Endocr Disord"},{"key":"6855_CR86","doi-asserted-by":"publisher","first-page":"9960656","DOI":"10.1155\/2024\/9960656","volume":"2024","author":"M Afraie","year":"2024","unstructured":"Afraie M, Bahrami P, Kohnepoushi P et al (2024) The effect of vitamin D supplementation on glycemic control and cardiovascular risk factors in type 2 diabetes: an updated systematic review and meta-analysis of clinical trials. J Diabetes Res 2024:9960656. https:\/\/doi.org\/10.1155\/2024\/9960656","journal-title":"J Diabetes Res"},{"key":"6855_CR87","doi-asserted-by":"publisher","first-page":"1462535","DOI":"10.3389\/fnut.2024.1462535","volume":"11","author":"L Cheng","year":"2024","unstructured":"Cheng L, Lv C, Xue L et al (2024) The prevention and improvement effects of vitamin D on type 2 diabetes mellitus: evidence from an umbrella review on meta-analyses of cohort studies and randomized controlled trials. Front Nutr 11:1462535. https:\/\/doi.org\/10.3389\/fnut.2024.1462535","journal-title":"Front Nutr"},{"issue":"1","key":"6855_CR88","doi-asserted-by":"publisher","first-page":"18463","DOI":"10.1038\/s41598-023-45846-1","volume":"13","author":"G Zhao","year":"2023","unstructured":"Zhao G, Yu X, Wang L et al (2023) Serum 25-hydroxyvitamin D level is associated with short-term glycemic variability metrics derived from continuous glucose monitoring in T2DM. Sci Rep 13(1):18463. https:\/\/doi.org\/10.1038\/s41598-023-45846-1","journal-title":"Sci Rep"},{"issue":"2","key":"6855_CR89","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1249\/mss.0000000000002800","volume":"54","author":"JA Kanaley","year":"2022","unstructured":"Kanaley JA, Colberg SR, Corcoran MH et al (2022) Exercise\/physical activity in individuals with type 2 diabetes: a consensus statement from the American college of sports medicine. Med Sci Sports Exerc 54(2):353\u2013368. https:\/\/doi.org\/10.1249\/mss.0000000000002800","journal-title":"Med Sci Sports Exerc"},{"issue":"11","key":"6855_CR90","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.2337\/dc16-1728","volume":"39","author":"SR Colberg","year":"2016","unstructured":"Colberg SR, Sigal RJ, Yardley JE et al (2016) Physical activity\/exercise and diabetes: a position statement of the American diabetes association. Diabetes Care 39(11):2065\u20132079. https:\/\/doi.org\/10.2337\/dc16-1728","journal-title":"Diabetes Care"},{"issue":"17","key":"6855_CR91","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1001\/jama.2011.576","volume":"305","author":"D Umpierre","year":"2011","unstructured":"Umpierre D, Ribeiro PA, Kramer CK et al (2011) Physical activity advice only or structured exercise training and association with HbA1c levels in type 2 diabetes: a systematic review and meta-analysis. JAMA 305(17):1790\u20131799. https:\/\/doi.org\/10.1001\/jama.2011.576","journal-title":"Jama"},{"issue":"1","key":"6855_CR92","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12933-025-03048-1","volume":"25","author":"M Michielsen","year":"2025","unstructured":"Michielsen M, Yagiz J, Hanssens M et al (2025) The effect of exercise characteristics on HbA1c and other cardiovascular risk factors in adults with type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials. Cardiovasc Diabetol 25(1):30. https:\/\/doi.org\/10.1186\/s12933-025-03048-1","journal-title":"Cardiovasc Diabetol"},{"key":"6855_CR93","doi-asserted-by":"publisher","first-page":"112027","DOI":"10.1016\/j.diabres.2025.112027","volume":"221","author":"SP Garcia","year":"2025","unstructured":"Garcia SP, Cureau FV, Iorra FQ et al (2025) Effects of exercise training and physical activity advice on HbA1c in people with type 2 diabetes: a network meta-analysis of randomized controlled trials. Diabetes Res Clin Pract 221:112027. https:\/\/doi.org\/10.1016\/j.diabres.2025.112027","journal-title":"Diabetes Res Clin Pract"},{"issue":"2","key":"6855_CR94","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2337\/dc23-0800","volume":"47","author":"D Gallardo-G\u00f3mez","year":"2024","unstructured":"Gallardo-G\u00f3mez D, Salazar-Mart\u00ednez E, Alfonso-Rosa RM et al (2024) Optimal dose and type of physical activity to improve glycemic control in people diagnosed with type 2 diabetes: a systematic review and meta-analysis. Diabetes Care 47(2):295\u2013303. https:\/\/doi.org\/10.2337\/dc23-0800","journal-title":"Diabetes Care"},{"issue":"10","key":"6855_CR95","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1007\/s40279-024-02057-6","volume":"54","author":"Z Liang","year":"2024","unstructured":"Liang Z, Zhang M, Wang C et al (2024) The best exercise modality and dose to reduce glycosylated hemoglobin in patients with type 2 diabetes: a systematic review with pairwise, network, and dose-response meta-analyses. Sports Med 54(10):2557\u20132570. https:\/\/doi.org\/10.1007\/s40279-024-02057-6","journal-title":"Sports Med"},{"issue":"8","key":"6855_CR96","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1007\/s40279-022-01673-4","volume":"52","author":"A Jayedi","year":"2022","unstructured":"Jayedi A, Emadi A, Shab-Bidar S (2022) Dose-dependent effect of supervised aerobic exercise on HbA(1c) in patients with type 2 diabetes: a meta-analysis of randomized controlled trials. Sports Med 52(8):1919\u20131938. https:\/\/doi.org\/10.1007\/s40279-022-01673-4","journal-title":"Sports Med"},{"issue":"4","key":"6855_CR97","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1111\/dom.16220","volume":"27","author":"ET Poon","year":"2025","unstructured":"Poon ET, Li HY, Kong APS, Little JP (2025) Efficacy of high-intensity interval training in individuals with type 2 diabetes mellitus: an umbrella review of systematic reviews and meta-analyses. Diabetes Obes Metab 27(4):1719\u20131734. https:\/\/doi.org\/10.1111\/dom.16220","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"6855_CR98","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s12966-018-0703-3","volume":"15","author":"B Pan","year":"2018","unstructured":"Pan B, Ge L, Xun YQ et al (2018) Exercise training modalities in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis. Int J Behav Nutr Phys Act 15(1):72. https:\/\/doi.org\/10.1186\/s12966-018-0703-3","journal-title":"Int J Behav Nutr Phys Act"},{"issue":"10","key":"6855_CR99","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1136\/bjsports-2024-108947","volume":"59","author":"SB Al-Mhanna","year":"2025","unstructured":"Al-Mhanna SB, Franklin BA, Jakicic JM et al (2025) Impact of resistance training on cardiometabolic health-related indices in patients with type 2 diabetes and overweight\/obesity: a systematic review and meta-analysis of randomised controlled trials. Br J Sports Med 59(10):733\u2013746. https:\/\/doi.org\/10.1136\/bjsports-2024-108947","journal-title":"Br J Sports Med"},{"issue":"10","key":"6855_CR100","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/s41574-025-01160-6","volume":"21","author":"F Sanchis-Gomar","year":"2025","unstructured":"Sanchis-Gomar F, Neeland IJ, Lavie CJ (2025) Balancing weight and muscle loss in GLP1 receptor agonist therapy. Nat Rev Endocrinol 21(10):584\u2013585. https:\/\/doi.org\/10.1038\/s41574-025-01160-6","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"6855_CR101","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1001\/jama.2024.6586","volume":"332","author":"C Conte","year":"2024","unstructured":"Conte C, Hall KD, Klein S (2024) Is weight loss-indiced muscle mass loss clinically relevant? JAMA 332(1):9\u201310. https:\/\/doi.org\/10.1001\/jama.2024.6586","journal-title":"JAMA"},{"issue":"5","key":"6855_CR102","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1111\/dom.16275","volume":"27","author":"M Look","year":"2025","unstructured":"Look M, Dunn JP, Kushner RF et al (2025) Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab 27(5):2720\u20132729. https:\/\/doi.org\/10.1111\/dom.16275","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"6855_CR103","doi-asserted-by":"publisher","first-page":"130","DOI":"10.2337\/dc15-1240","volume":"39","author":"J Henson","year":"2016","unstructured":"Henson J, Davies MJ, Bodicoat DH et al (2016) Breaking up prolonged sitting with standing or walking attenuates the postprandial metabolic response in postmenopausal women: a randomized acute study. Diabetes Care 39(1):130\u2013138. https:\/\/doi.org\/10.2337\/dc15-1240","journal-title":"Diabetes Care"},{"issue":"6","key":"6855_CR104","doi-asserted-by":"publisher","first-page":"964","DOI":"10.2337\/dc15-2336","volume":"39","author":"PC Dempsey","year":"2016","unstructured":"Dempsey PC, Larsen RN, Sethi P et al (2016) Benefits for type 2 diabetes of interrupting prolonged sitting with brief bouts of light walking or simple resistance activities. Diabetes Care 39(6):964\u2013972. https:\/\/doi.org\/10.2337\/dc15-2336","journal-title":"Diabetes Care"},{"issue":"6","key":"6855_CR105","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.2337\/dc20-1410","volume":"44","author":"AR Homer","year":"2021","unstructured":"Homer AR, Taylor FC, Dempsey PC et al (2021) Frequency of interruptions to sitting time: benefits for postprandial metabolism in type 2 diabetes. Diabetes Care 44(6):1254\u20131263. https:\/\/doi.org\/10.2337\/dc20-1410","journal-title":"Diabetes Care"},{"issue":"4","key":"6855_CR106","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.jshs.2020.12.006","volume":"10","author":"M Quan","year":"2021","unstructured":"Quan M, Xun P, Wu H et al (2021) Effects of interrupting prolonged sitting on postprandial glycemia and insulin responses: a network meta-analysis. J Sport Health Sci 10(4):419\u2013429. https:\/\/doi.org\/10.1016\/j.jshs.2020.12.006","journal-title":"J Sport Health Sci"},{"issue":"2","key":"6855_CR107","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s40279-019-01183-w","volume":"50","author":"R Loh","year":"2020","unstructured":"Loh R, Stamatakis E, Folkerts D, Allgrove JE, Moir HJ (2020) Effects of interrupting prolonged sitting with physical activity breaks on blood glucose, insulin and triacylglycerol measures: a systematic review and meta-analysis. Sports Med 50(2):295\u2013330. https:\/\/doi.org\/10.1007\/s40279-019-01183-w","journal-title":"Sports Med"},{"issue":"8","key":"6855_CR108","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1007\/s40279-022-01649-4","volume":"52","author":"AJ Buffey","year":"2022","unstructured":"Buffey AJ, Herring MP, Langley CK, Donnelly AE, Carson BP (2022) The acute effects of interrupting prolonged sitting time in adults with standing and light-intensity walking on biomarkers of cardiometabolic health in adults: a systematic review and meta-analysis. Sports Med 52(8):1765\u20131787. https:\/\/doi.org\/10.1007\/s40279-022-01649-4","journal-title":"Sports Med"},{"issue":"18","key":"6855_CR109","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1093\/eurjpc\/zwad229","volume":"30","author":"M Banach","year":"2023","unstructured":"Banach M, Lewek J, Surma S et al (2023) The association between daily step count and all-cause and cardiovascular mortality: a meta-analysis. Eur J Prev Cardiol 30(18):1975\u20131985. https:\/\/doi.org\/10.1093\/eurjpc\/zwad229","journal-title":"Eur J Prev Cardiol"},{"issue":"3","key":"6855_CR110","doi-asserted-by":"publisher","first-page":"e219","DOI":"10.1016\/s2468-2667(21)00302-9","volume":"7","author":"AE Paluch","year":"2022","unstructured":"Paluch AE, Bajpai S, Bassett DR et al (2022) Daily steps and all-cause mortality: a meta-analysis of 15 international cohorts. Lancet Public Health 7(3):e219\u2013e228. https:\/\/doi.org\/10.1016\/s2468-2667(21)00302-9","journal-title":"Lancet Public Health"},{"issue":"8","key":"6855_CR111","doi-asserted-by":"publisher","first-page":"e668","DOI":"10.1016\/s2468-2667(25)00164-1","volume":"10","author":"D Ding","year":"2025","unstructured":"Ding D, Nguyen B, Nau T et al (2025) Daily steps and health outcomes in adults: a systematic review and dose-response meta-analysis. Lancet Public Health 10(8):e668\u2013e681. https:\/\/doi.org\/10.1016\/s2468-2667(25)00164-1","journal-title":"Lancet Public Health"},{"issue":"9","key":"6855_CR112","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.2337\/dc22-0524","volume":"45","author":"J Del Pozo-Cruz","year":"2022","unstructured":"Del Pozo-Cruz J, Alvarez-Barbosa F, Gallardo-Gomez D, Del Pozo Cruz B (2022) Optimal number of steps per day to prevent all-cause mortality in people with prediabetes and diabetes. Diabetes Care 45(9):2156\u20132158. https:\/\/doi.org\/10.2337\/dc22-0524","journal-title":"Diabetes Care"},{"issue":"3","key":"6855_CR113","doi-asserted-by":"publisher","first-page":"529","DOI":"10.2337\/dc14-2073","volume":"38","author":"Z Shan","year":"2015","unstructured":"Shan Z, Ma H, Xie M et al (2015) Sleep duration and risk of type 2 diabetes: a meta-analysis of prospective studies. Diabetes Care 38(3):529\u2013537. https:\/\/doi.org\/10.2337\/dc14-2073","journal-title":"Diabetes Care"},{"key":"6855_CR114","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.smrv.2016.02.001","volume":"31","author":"SWH Lee","year":"2017","unstructured":"Lee SWH, Ng KY, Chin WK (2017) The impact of sleep amount and sleep quality on glycemic control in type 2 diabetes: a systematic review and meta-analysis. Sleep Med Rev 31:91\u2013101. https:\/\/doi.org\/10.1016\/j.smrv.2016.02.001","journal-title":"Sleep Med Rev"},{"issue":"4","key":"6855_CR115","doi-asserted-by":"publisher","first-page":"772","DOI":"10.2337\/dc21-0089","volume":"45","author":"J Liu","year":"2022","unstructured":"Liu J, Richmond RC, Bowden J et al (2022) Assessing the causal role of sleep traits on glycated hemoglobin: a Mendelian randomization study. Diabetes Care 45(4):772\u2013781. https:\/\/doi.org\/10.2337\/dc21-0089","journal-title":"Diabetes Care"},{"issue":"3","key":"6855_CR116","doi-asserted-by":"publisher","first-page":"331","DOI":"10.2337\/dci23-0037","volume":"47","author":"J Henson","year":"2024","unstructured":"Henson J, Covenant A, Hall AP et al (2024) Waking up to the importance of sleep in type 2 diabetes management: a narrative review. Diabetes Care 47(3):331\u2013343. https:\/\/doi.org\/10.2337\/dci23-0037","journal-title":"Diabetes Care"},{"issue":"1","key":"6855_CR117","doi-asserted-by":"publisher","first-page":"235","DOI":"10.2337\/dc19-0550","volume":"43","author":"A Brouwer","year":"2020","unstructured":"Brouwer A, van Raalte DH, Rutters F et al (2020) Sleep and HbA(1c) in patients with type 2 diabetes: which sleep characteristics matter most? Diabetes Care 43(1):235\u2013243. https:\/\/doi.org\/10.2337\/dc19-0550","journal-title":"Diabetes Care"},{"issue":"9","key":"6855_CR118","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.2337\/dc12-2697","volume":"36","author":"S Reutrakul","year":"2013","unstructured":"Reutrakul S, Hood MM, Crowley SJ et al (2013) Chronotype is independently associated with glycemic control in type 2 diabetes. Diabetes Care 36(9):2523\u20132529. https:\/\/doi.org\/10.2337\/dc12-2697","journal-title":"Diabetes Care"},{"issue":"1","key":"6855_CR119","doi-asserted-by":"publisher","first-page":"147916412413073","DOI":"10.1177\/14791641241307367","volume":"22","author":"SA Mostafa","year":"2025","unstructured":"Mostafa SA, Hanif W, Crowe F et al (2025) The effect of non-pharmacological sleep interventions on glycaemic measures in adults with sleep disturbances and behaviours: a systematic review and meta-analysis. Diab Vasc Dis Res 22(1):14791641241307368. https:\/\/doi.org\/10.1177\/14791641241307367","journal-title":"Diab Vasc Dis Res"},{"issue":"6","key":"6855_CR120","doi-asserted-by":"publisher","first-page":"893","DOI":"10.3390\/biology11060893","volume":"11","author":"C Garc\u00eda-Serrano","year":"2022","unstructured":"Garc\u00eda-Serrano C, Pujol Salud J, Aran-Sol\u00e9 L et al (2022) Enhancing night and day circadian contrast through sleep education in prediabetes and type 2 diabetes mellitus: a randomized controlled trial. Biology (Basel) 11(6):893. https:\/\/doi.org\/10.3390\/biology11060893","journal-title":"Biology (Basel)"},{"issue":"Suppl 1","key":"6855_CR121","doi-asserted-by":"publisher","first-page":"S216","DOI":"10.2337\/dc26-S010","volume":"49","author":"American Diabetes Association Professional Practice Committee","year":"2026","unstructured":"American Diabetes Association Professional Practice Committee (2026) 10. Cardiovascular disease and risk management: standards of care in diabetes-2026. Diabetes Care 49(Suppl 1):S216-s245. https:\/\/doi.org\/10.2337\/dc26-S010","journal-title":"Diabetes Care"},{"issue":"3","key":"6855_CR122","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1001\/jamainternmed.2024.7357","volume":"185","author":"H Shin","year":"2025","unstructured":"Shin H, Paik JM, Everett BM et al (2025) Comparative effectiveness of individual sodium-glucose cotransporter 2 inhibitors. JAMA Intern Med 185(3):302\u2013313. https:\/\/doi.org\/10.1001\/jamainternmed.2024.7357","journal-title":"JAMA Intern Med"},{"issue":"2","key":"6855_CR123","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","volume":"6","author":"DK McGuire","year":"2021","unstructured":"McGuire DK, Shih WJ, Cosentino F et al (2021) Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. JAMA Cardiol 6(2):148\u2013158. https:\/\/doi.org\/10.1001\/jamacardio.2020.4511","journal-title":"JAMA Cardiol"},{"issue":"22","key":"6855_CR124","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373(22):2117\u20132128. https:\/\/doi.org\/10.1056\/NEJMoa1504720","journal-title":"N Engl J Med"},{"issue":"7","key":"6855_CR125","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377(7):644\u2013657. https:\/\/doi.org\/10.1056\/NEJMoa1611925","journal-title":"N Engl J Med"},{"issue":"4","key":"6855_CR126","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP et al (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380(4):347\u2013357. https:\/\/doi.org\/10.1056\/NEJMoa1812389","journal-title":"N Engl J Med"},{"issue":"15","key":"6855_CR127","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","volume":"383","author":"CP Cannon","year":"2020","unstructured":"Cannon CP, Pratley R, Dagogo-Jack S et al (2020) Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med 383(15):1425\u20131435. https:\/\/doi.org\/10.1056\/NEJMoa2004967","journal-title":"N Engl J Med"},{"issue":"2","key":"6855_CR128","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMoa2030186","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt DL, Szarek M, Pitt B et al (2021) Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med 384(2):129\u2013139. https:\/\/doi.org\/10.1056\/NEJMoa2030186","journal-title":"N Engl J Med"},{"issue":"21","key":"6855_CR129","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE et al (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381(21):1995\u20132008. https:\/\/doi.org\/10.1056\/NEJMoa1911303","journal-title":"N Engl J Med"},{"issue":"15","key":"6855_CR130","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J et al (2020) Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 383(15):1413\u20131424. https:\/\/doi.org\/10.1056\/NEJMoa2022190","journal-title":"N Engl J Med"},{"issue":"2","key":"6855_CR131","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2030183","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt DL, Szarek M, Steg PG et al (2021) Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med 384(2):117\u2013128. https:\/\/doi.org\/10.1056\/NEJMoa2030183","journal-title":"N Engl J Med"},{"issue":"16","key":"6855_CR132","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G et al (2021) Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 385(16):1451\u20131461. https:\/\/doi.org\/10.1056\/NEJMoa2107038","journal-title":"N Engl J Med"},{"issue":"24","key":"6855_CR133","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B et al (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380(24):2295\u20132306. https:\/\/doi.org\/10.1056\/NEJMoa1811744","journal-title":"N Engl J Med"},{"issue":"15","key":"6855_CR134","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R et al (2020) Dapagliflozin in patients with chronic kidney disease. N Engl J Med 383(15):1436\u20131446. https:\/\/doi.org\/10.1056\/NEJMoa2024816","journal-title":"N Engl J Med"},{"issue":"2","key":"6855_CR135","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"WG Herrington","year":"2023","unstructured":"Herrington WG, Staplin N, Wanner C et al (2023) Empagliflozin in patients with chronic kidney disease. N Engl J Med 388(2):117\u2013127. https:\/\/doi.org\/10.1056\/NEJMoa2204233","journal-title":"N Engl J Med"},{"key":"6855_CR136","unstructured":"Boehringer Ingelheim (2025) Prescribing information for JARDIANCE. Boehringer Ingelheim, Ingelheim am Rhein, Germany. Available from https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/204629s063lbl.pdf. Accessed 30 April 2026"},{"key":"6855_CR137","unstructured":"Janssen (2024) Prescribing information for INVOKANA. Janssen, Beerse, Belgium. Available from https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/204042s043lbl.pdf. Accessed 30 April 2026"},{"key":"6855_CR138","unstructured":"AstraZeneca (2024) Prescribing information for FARXIGA. AstraZeneca, Wilmington, DE, USA. Available from https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/202293s031lbl.pdf. Accessed 30 April 2026"},{"key":"6855_CR139","unstructured":"Merck (2024) Prescribing information for STEGLATRO. Merck, Readington, NJ, USA. Available from https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/209803s008lbledt.pdf. Accessed 30 April 2026"},{"issue":"1","key":"6855_CR140","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.aace.2020.11.009","volume":"7","author":"S Mistry","year":"2021","unstructured":"Mistry S, Eschler DC (2021) Euglycemic diabetic ketoacidosis caused by SGLT2 inhibitors and a ketogenic diet: a case series and review of literature. AACE Clin Case Rep 7(1):17\u201319. https:\/\/doi.org\/10.1016\/j.aace.2020.11.009","journal-title":"AACE Clin Case Rep"},{"issue":"Suppl 1","key":"6855_CR141","doi-asserted-by":"publisher","first-page":"S132","DOI":"10.2337\/dc26-S006","volume":"49","author":"American Diabetes Association Professional Practice Committee","year":"2026","unstructured":"American Diabetes Association Professional Practice Committee (2026) 6. Glycemic goals, hypoglycemia, and hyperglycemic crises: standards of care in diabetes-2026. Diabetes Care 49(Suppl 1):S132-s149. https:\/\/doi.org\/10.2337\/dc26-S006","journal-title":"Diabetes Care"},{"issue":"12","key":"6855_CR142","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1007\/s00198-020-05590-y","volume":"31","author":"BB Qian","year":"2020","unstructured":"Qian BB, Chen Q, Li L, Yan CF (2020) Association between combined treatment with SGLT2 inhibitors and metformin for type 2 diabetes mellitus on fracture risk: a meta-analysis of randomized controlled trials. Osteoporos Int 31(12):2313\u20132320. https:\/\/doi.org\/10.1007\/s00198-020-05590-y","journal-title":"Osteoporos Int"},{"issue":"3","key":"6855_CR143","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s40618-019-01103-9","volume":"43","author":"EG Dorsey-Trevi\u00f1o","year":"2020","unstructured":"Dorsey-Trevi\u00f1o EG, Gonz\u00e1lez-Gonz\u00e1lez JG, Alvarez-Villalobos N et al (2020) Sodium-glucose cotransporter 2 (SGLT-2) inhibitors and microvascular outcomes in patients with type 2 diabetes: systematic review and meta-analysis. J Endocrinol Invest 43(3):289\u2013304. https:\/\/doi.org\/10.1007\/s40618-019-01103-9","journal-title":"J Endocrinol Invest"},{"issue":"2","key":"6855_CR144","doi-asserted-by":"publisher","first-page":"glad181","DOI":"10.1093\/gerona\/glad181","volume":"79","author":"P Vart","year":"2024","unstructured":"Vart P, Butt JH, Jongs N et al (2024) Efficacy and safety of dapagliflozin in patients with chronic kidney disease across the spectrum of frailty. J Gerontol A Biol Sci Med Sci 79(2):glad181. https:\/\/doi.org\/10.1093\/gerona\/glad181","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"16","key":"6855_CR145","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1161\/circulationaha.122.061754","volume":"146","author":"JH Butt","year":"2022","unstructured":"Butt JH, Jhund PS, Belohl\u00e1vek J et al (2022) Efficacy and safety of dapagliflozin according to frailty in patients with heart failure: a prespecified analysis of the DELIVER trial. Circulation 146(16):1210\u20131224. https:\/\/doi.org\/10.1161\/circulationaha.122.061754","journal-title":"Circulation"},{"issue":"9","key":"6855_CR146","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1007\/s00125-024-06190-9","volume":"67","author":"LM G\u00fcdemann","year":"2024","unstructured":"G\u00fcdemann LM, Young KG, Thomas NJM et al (2024) Safety and effectiveness of SGLT2 inhibitors in a UK population with type 2 diabetes and aged over 70 years: an instrumental variable approach. Diabetologia 67(9):1817\u20131827. https:\/\/doi.org\/10.1007\/s00125-024-06190-9","journal-title":"Diabetologia"},{"issue":"6","key":"6855_CR147","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1111\/dom.14671","volume":"24","author":"JY Barraclough","year":"2022","unstructured":"Barraclough JY, Yu J, Figtree GA et al (2022) Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: data from the CANVAS Program and CREDENCE trial. Diabetes Obes Metab 24(6):1072\u20131083. https:\/\/doi.org\/10.1111\/dom.14671","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"6855_CR148","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1001\/jama.2025.20835","volume":"335","author":"N Staplin","year":"2026","unstructured":"Staplin N, Roddick AJ, Neuen BL et al (2026) Effects of sodium glucose cotransporter 2 inhibitors by diabetes status and level of albuminuria: a meta-analysis. JAMA 335(3):220\u2013232. https:\/\/doi.org\/10.1001\/jama.2025.20835","journal-title":"Jama"},{"key":"6855_CR149","doi-asserted-by":"publisher","first-page":"101102","DOI":"10.1016\/j.molmet.2020.101102","volume":"46","author":"MA Nauck","year":"2021","unstructured":"Nauck MA, Quast DR, Wefers J, Meier JJ (2021) GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab 46:101102. https:\/\/doi.org\/10.1016\/j.molmet.2020.101102","journal-title":"Mol Metab"},{"issue":"1","key":"6855_CR150","doi-asserted-by":"publisher","first-page":"e2555449","DOI":"10.1001\/jamanetworkopen.2025.55449","volume":"9","author":"KK S\u00f8rensen","year":"2026","unstructured":"S\u00f8rensen KK, M\u00f8ller FT, Yazdanfard PDW et al (2026) Consumer food purchases after glucagon-like peptide-1 receptor agonist initiation. JAMA Netw Open 9(1):e2555449. https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.55449","journal-title":"JAMA Netw Open"},{"issue":"15","key":"6855_CR151","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","volume":"390","author":"MN Kosiborod","year":"2024","unstructured":"Kosiborod MN, Petrie MC, Borlaug BA et al (2024) Semaglutide in patients with obesity-related heart failure and type 2 diabetes. N Engl J Med 390(15):1394\u20131407. https:\/\/doi.org\/10.1056\/NEJMoa2313917","journal-title":"N Engl J Med"},{"issue":"21","key":"6855_CR152","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","volume":"392","author":"AJ Sanyal","year":"2025","unstructured":"Sanyal AJ, Newsome PN, Kliers I et al (2025) Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med 392(21):2089\u20132099. https:\/\/doi.org\/10.1056\/NEJMoa2413258","journal-title":"N Engl J Med"},{"issue":"18","key":"6855_CR153","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1001\/jama.2026.2113","volume":"335","author":"S Anderer","year":"2026","unstructured":"Anderer S (2026) FDA approves GLP-1 obesity pill without food or water restrictions. JAMA 335(18):1564. https:\/\/doi.org\/10.1001\/jama.2026.2113","journal-title":"Jama"},{"key":"6855_CR154","unstructured":"Novo Nordisk (2019) Prescribing information for RYBELSUS. Novo Nordisk, Plainsboro, NJ, USA. Available from https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/213051s018lbl.pdf. Accessed 30 April 2026"},{"issue":"10534","key":"6855_CR155","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/s0140-6736(26)00202-3","volume":"407","author":"J Rosenstock","year":"2026","unstructured":"Rosenstock J, Yabe D, Cox D et al (2026) Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial. Lancet 407(10534):1147\u20131160. https:\/\/doi.org\/10.1016\/s0140-6736(26)00202-3","journal-title":"Lancet"},{"issue":"10403","key":"6855_CR156","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/s0140-6736(23)01127-3","volume":"402","author":"VR Aroda","year":"2023","unstructured":"Aroda VR, Aberle J, Bardtrum L et al (2023) Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial. Lancet 402(10403):693\u2013704. https:\/\/doi.org\/10.1016\/s0140-6736(23)01127-3","journal-title":"Lancet"},{"issue":"11","key":"6855_CR157","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/s2213-8587(25)00225-6","volume":"13","author":"I Lingvay","year":"2025","unstructured":"Lingvay I, Bergenheim SJ, Buse JB et al (2025) Once-weekly semaglutide 7\u00b72 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol 13(11):935\u2013948. https:\/\/doi.org\/10.1016\/s2213-8587(25)00225-6","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"6855_CR158","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1177\/10600280231199852","volume":"58","author":"A Duong","year":"2024","unstructured":"Duong A, Heacock S, Amering S, Brennan L, Venci J, Acquisto NM (2024) Real-world impact of 3 and 4.5 mg doses of dulaglutide on weight and hemoglobin A1c in patients with type 2 diabetes mellitus. Ann Pharmacother 58(6):589\u2013597. https:\/\/doi.org\/10.1177\/10600280231199852","journal-title":"Ann Pharmacother"},{"issue":"3","key":"6855_CR159","doi-asserted-by":"publisher","first-page":"765","DOI":"10.2337\/dc20-1473","volume":"44","author":"JP Frias","year":"2021","unstructured":"Frias JP, Bonora E, Nevarez Ruiz L et al (2021) Efficacy and safety of dulaglutide 3.0 mg and 4.5 mg versus dulaglutide 1.5 mg in metformin-treated patients with type 2 diabetes in a randomized controlled trial (AWARD-11). Diabetes Care 44(3):765\u2013773. https:\/\/doi.org\/10.2337\/dc20-1473","journal-title":"Diabetes Care"},{"issue":"4","key":"6855_CR160","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41574-022-00783-3","volume":"19","author":"R Hammoud","year":"2023","unstructured":"Hammoud R, Drucker DJ (2023) Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1. Nat Rev Endocrinol 19(4):201\u2013216. https:\/\/doi.org\/10.1038\/s41574-022-00783-3","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"6855_CR161","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s12933-022-01604-7","volume":"21","author":"MA Nauck","year":"2022","unstructured":"Nauck MA, D\u2019Alessio DA (2022) Tirzepatide, a dual GIP\/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. Cardiovasc Diabetol 21(1):169. https:\/\/doi.org\/10.1186\/s12933-022-01604-7","journal-title":"Cardiovasc Diabetol"},{"issue":"6","key":"6855_CR162","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/s2213-8587(22)00070-5","volume":"10","author":"A Gastaldelli","year":"2022","unstructured":"Gastaldelli A, Cusi K, Fern\u00e1ndez Land\u00f3 L, Bray R, Brouwers B, Rodr\u00edguez \u00c1 (2022) Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol 10(6):393\u2013406. https:\/\/doi.org\/10.1016\/s2213-8587(22)00070-5","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"13","key":"6855_CR163","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1056\/NEJMoa2404881","volume":"391","author":"A Malhotra","year":"2024","unstructured":"Malhotra A, Grunstein RR, Fietze I et al (2024) Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med 391(13):1193\u20131205. https:\/\/doi.org\/10.1056\/NEJMoa2404881","journal-title":"N Engl J Med"},{"issue":"5","key":"6855_CR164","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2410027","volume":"392","author":"M Packer","year":"2025","unstructured":"Packer M, Zile MR, Kramer CM et al (2025) Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med 392(5):427\u2013437. https:\/\/doi.org\/10.1056\/NEJMoa2410027","journal-title":"N Engl J Med"},{"issue":"24","key":"6855_CR165","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1056\/NEJMoa2505928","volume":"393","author":"SJ Nicholls","year":"2025","unstructured":"Nicholls SJ, Pavo I, Bhatt DL et al (2025) Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes. N Engl J Med 393(24):2409\u20132420. https:\/\/doi.org\/10.1056\/NEJMoa2505928","journal-title":"N Engl J Med"},{"key":"6855_CR166","doi-asserted-by":"publisher","unstructured":"Sattar N, Gerstein HC, D'Alessio D et al (2026) Estimating the true MACE benefits from tirzepatide in SURPASS-CVOT using an imputed placebo analysis of REWIND. Diabetes Care dc260298. https:\/\/doi.org\/10.2337\/dc26-0298","DOI":"10.2337\/dc26-0298"},{"issue":"1","key":"6855_CR167","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1080\/00325481.2021.2002616","volume":"134","author":"S Wharton","year":"2022","unstructured":"Wharton S, Davies M, Dicker D et al (2022) Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice. Postgrad Med 134(1):14\u201319. https:\/\/doi.org\/10.1080\/00325481.2021.2002616","journal-title":"Postgrad Med"},{"issue":"5","key":"6855_CR168","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s11892-016-0728-4","volume":"16","author":"H Peng","year":"2016","unstructured":"Peng H, Want LL, Aroda VR (2016) Safety and tolerability of glucagon-like peptide-1 receptor agonists utilizing data from the exenatide clinical trial development program. Curr Diab Rep 16(5):44. https:\/\/doi.org\/10.1007\/s11892-016-0728-4","journal-title":"Curr Diab Rep"},{"issue":"5","key":"6855_CR169","doi-asserted-by":"publisher","first-page":"846","DOI":"10.2337\/dc25-0241","volume":"48","author":"MMY Lee","year":"2025","unstructured":"Lee MMY, Sattar N, Pop-Busui R et al (2025) Cardiovascular and kidney outcomes and mortality with long-acting injectable and oral glucagon-like peptide 1 receptor agonists in individuals with type 2 diabetes: a systematic review and meta-analysis of randomized trials. Diabetes Care 48(5):846\u2013859. https:\/\/doi.org\/10.2337\/dc25-0241","journal-title":"Diabetes Care"},{"issue":"5","key":"6855_CR170","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1001\/jamainternmed.2022.0338","volume":"182","author":"L He","year":"2022","unstructured":"He L, Wang J, Ping F et al (2022) Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials. JAMA Intern Med 182(5):513\u2013519. https:\/\/doi.org\/10.1001\/jamainternmed.2022.0338","journal-title":"JAMA Intern Med"},{"issue":"8","key":"6855_CR171","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1001\/jamaophthalmol.2024.2296","volume":"142","author":"JT Hathaway","year":"2024","unstructured":"Hathaway JT, Shah MP, Hathaway DB et al (2024) Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide. JAMA Ophthalmol 142(8):732\u2013739. https:\/\/doi.org\/10.1001\/jamaophthalmol.2024.2296","journal-title":"JAMA Ophthalmol"},{"issue":"6","key":"6855_CR172","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.ophtha.2026.02.013","volume":"133","author":"A Abdelaal","year":"2026","unstructured":"Abdelaal A, Abu Serhan H, Alsaadi M, Yaldo L, Gaier ED, Elhusseiny AM (2026) Semaglutide and the risk of nonarteritic ischemic optic neuropathy: a systematic review and certainty of evidence meta-analysis. Ophthalmology 133(6):799\u2013810. https:\/\/doi.org\/10.1016\/j.ophtha.2026.02.013","journal-title":"Ophthalmology"},{"issue":"9","key":"6855_CR173","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.2337\/dc20-0437","volume":"43","author":"MJ Crowley","year":"2020","unstructured":"Crowley MJ, McGuire DK, Alexopoulos AS et al (2020) Effects of liraglutide on cardiovascular outcomes in type 2 diabetes patients with and without baseline metformin use: post hoc analyses of the LEADER trial. Diabetes Care 43(9):e108\u2013e110. https:\/\/doi.org\/10.2337\/dc20-0437","journal-title":"Diabetes Care"},{"issue":"2","key":"6855_CR174","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1111\/dom.14226","volume":"23","author":"BL Neuen","year":"2021","unstructured":"Neuen BL, Arnott C, Perkovic V et al (2021) Sodium-glucose co-transporter-2 inhibitors with and without metformin: a meta-analysis of cardiovascular, kidney and mortality outcomes. Diabetes Obes Metab 23(2):382\u2013390. https:\/\/doi.org\/10.1111\/dom.14226","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"6855_CR175","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1093\/eurjpc\/zwaa074","volume":"28","author":"W Masson","year":"2021","unstructured":"Masson W, Lavalle-Cobo A, Lobo M, Masson G, Molinero G (2021) Novel antidiabetic drugs and risk of cardiovascular events in patients without baseline metformin use: a meta-analysis. Eur J Prev Cardiol 28(1):69\u201375. https:\/\/doi.org\/10.1093\/eurjpc\/zwaa074","journal-title":"Eur J Prev Cardiol"},{"issue":"3","key":"6855_CR176","doi-asserted-by":"publisher","first-page":"547","DOI":"10.2337\/dc17-2231","volume":"41","author":"JD Lalau","year":"2018","unstructured":"Lalau JD, Kajbaf F, Bennis Y, Hurtel-Lemaire AS, Belpaire F, De Broe ME (2018) Metformin treatment in patients with type 2 diabetes and chronic kidney disease stages 3A, 3B, or 4. Diabetes Care 41(3):547\u2013553. https:\/\/doi.org\/10.2337\/dc17-2231","journal-title":"Diabetes Care"},{"issue":"2","key":"6855_CR177","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.jdiacomp.2017.11.001","volume":"32","author":"M Out","year":"2018","unstructured":"Out M, Kooy A, Lehert P, Schalkwijk CA, Stehouwer CDA (2018) Long-term treatment with metformin in type 2 diabetes and methylmalonic acid: post hoc analysis of a randomized controlled 4.3year trial. J Diabetes Complications 32(2):171\u2013178. https:\/\/doi.org\/10.1016\/j.jdiacomp.2017.11.001","journal-title":"J Diabetes Complications"},{"issue":"4","key":"6855_CR178","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1210\/jc.2015-3754","volume":"101","author":"VR Aroda","year":"2016","unstructured":"Aroda VR, Edelstein SL, Goldberg RB et al (2016) Long-term metformin use and vitamin B12 deficiency in the diabetes prevention program outcomes study. J Clin Endocrinol Metab 101(4):1754\u20131761. https:\/\/doi.org\/10.1210\/jc.2015-3754","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"6855_CR179","doi-asserted-by":"publisher","first-page":"618","DOI":"10.7326\/m23-1490","volume":"177","author":"T Drake","year":"2024","unstructured":"Drake T, Landsteiner A, Langsetmo L et al (2024) Newer pharmacologic treatments in adults with type 2 diabetes: a systematic review and network meta-analysis for the American College of Physicians. Ann Intern Med 177(5):618\u2013632. https:\/\/doi.org\/10.7326\/m23-1490","journal-title":"Ann Intern Med"},{"issue":"Suppl 1","key":"6855_CR180","doi-asserted-by":"publisher","first-page":"S144","DOI":"10.2337\/dc22-S010","volume":"45","author":"American Diabetes Association Professional Practice Committee","year":"2022","unstructured":"American Diabetes Association Professional Practice Committee (2022) 10. Cardiovascular disease and risk management: standards of medical care in diabetes-2022. Diabetes Care 45(Suppl 1):S144-s174. https:\/\/doi.org\/10.2337\/dc22-S010","journal-title":"Diabetes Care"},{"issue":"1","key":"6855_CR181","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12944-024-02132-x","volume":"23","author":"Y Gong","year":"2024","unstructured":"Gong Y, Bai X, Zhang D et al (2024) Effect of DPP-4i inhibitors on renal function in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Lipids Health Dis 23(1):157. https:\/\/doi.org\/10.1186\/s12944-024-02132-x","journal-title":"Lipids Health Dis"},{"issue":"1","key":"6855_CR182","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13098-022-00924-8","volume":"14","author":"M Yu","year":"2022","unstructured":"Yu M, Yang Z, Chen C et al (2022) Association of the gallbladder or biliary diseases with dipeptidyl peptidase 4 inhibitors in patients with type 2 diabetes: a meta-analysis of randomized controlled trials. Diabetol Metab Syndr 14(1):153. https:\/\/doi.org\/10.1186\/s13098-022-00924-8","journal-title":"Diabetol Metab Syndr"},{"issue":"Suppl 1","key":"6855_CR183","doi-asserted-by":"publisher","first-page":"S125","DOI":"10.2337\/dc22-S009","volume":"45","author":"American Diabetes Association Professional Practice Committee","year":"2022","unstructured":"American Diabetes Association Professional Practice Committee (2022) 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2022. Diabetes Care 45(Suppl 1):S125-s143. https:\/\/doi.org\/10.2337\/dc22-S009","journal-title":"Diabetes Care"},{"issue":"10","key":"6855_CR184","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/s2213-8587(18)30025-1","volume":"6","author":"K Khunti","year":"2018","unstructured":"Khunti K, Chatterjee S, Gerstein HC, Zoungas S, Davies MJ (2018) Do sulphonylureas still have a place in clinical practice? Lancet Diabetes Endocrinol 6(10):821\u2013832. https:\/\/doi.org\/10.1016\/s2213-8587(18)30025-1","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9131","key":"6855_CR185","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","unstructured":"UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352(9131):837\u2013853","journal-title":"Lancet"},{"issue":"5","key":"6855_CR186","doi-asserted-by":"publisher","first-page":"967","DOI":"10.2337\/dc22-1238","volume":"46","author":"H Wang","year":"2023","unstructured":"Wang H, Cordiner RLM, Huang Y et al (2023) Cardiovascular safety in type 2 diabetes with sulfonylureas as second-line drugs: a nationwide population-based comparative safety study. Diabetes Care 46(5):967\u2013977. https:\/\/doi.org\/10.2337\/dc22-1238","journal-title":"Diabetes Care"},{"issue":"12","key":"6855_CR187","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1001\/jama.2019.13772","volume":"322","author":"J Rosenstock","year":"2019","unstructured":"Rosenstock J, Kahn SE, Johansen OE et al (2019) Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial. JAMA 322(12):1155\u20131166. https:\/\/doi.org\/10.1001\/jama.2019.13772","journal-title":"Jama"},{"issue":"12","key":"6855_CR188","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1007\/s00125-018-4729-5","volume":"61","author":"MJ Davies","year":"2018","unstructured":"Davies MJ, D\u2019Alessio DA, Fradkin J et al (2018) Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 61(12):2461\u20132498. https:\/\/doi.org\/10.1007\/s00125-018-4729-5","journal-title":"Diabetologia"},{"issue":"2","key":"6855_CR189","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s00125-019-05039-w","volume":"63","author":"JB Buse","year":"2020","unstructured":"Buse JB, Wexler DJ, Tsapas A et al (2020) 2019 update to: management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 63(2):221\u2013228. https:\/\/doi.org\/10.1007\/s00125-019-05039-w","journal-title":"Diabetologia"},{"issue":"12","key":"6855_CR190","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.2337\/dci18-0033","volume":"41","author":"MJ Davies","year":"2018","unstructured":"Davies MJ, D\u2019Alessio DA, Fradkin J et al (2018) Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 41(12):2669\u20132701. https:\/\/doi.org\/10.2337\/dci18-0033","journal-title":"Diabetes Care"},{"issue":"2","key":"6855_CR191","doi-asserted-by":"publisher","first-page":"487","DOI":"10.2337\/dci19-0066","volume":"43","author":"JB Buse","year":"2020","unstructured":"Buse JB, Wexler DJ, Tsapas A et al (2020) 2019 update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 43(2):487\u2013493. https:\/\/doi.org\/10.2337\/dci19-0066","journal-title":"Diabetes Care"},{"issue":"23","key":"6855_CR192","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1056\/NEJMoa066224","volume":"355","author":"SE Kahn","year":"2006","unstructured":"Kahn SE, Haffner SM, Heise MA et al (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355(23):2427\u20132443. https:\/\/doi.org\/10.1056\/NEJMoa066224","journal-title":"N Engl J Med"},{"issue":"9493","key":"6855_CR193","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/s0140-6736(05)67528-9","volume":"366","author":"JA Dormandy","year":"2005","unstructured":"Dormandy JA, Charbonnel B, Eckland DJ et al (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366(9493):1279\u20131289. https:\/\/doi.org\/10.1016\/s0140-6736(05)67528-9","journal-title":"Lancet"},{"issue":"14","key":"6855_CR194","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1056\/NEJMoa1506930","volume":"374","author":"WN Kernan","year":"2016","unstructured":"Kernan WN, Viscoli CM, Furie KL et al (2016) Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med 374(14):1321\u20131331. https:\/\/doi.org\/10.1056\/NEJMoa1506930","journal-title":"N Engl J Med"},{"issue":"5","key":"6855_CR195","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1001\/jamaneurol.2019.0079","volume":"76","author":"JD Spence","year":"2019","unstructured":"Spence JD, Viscoli CM, Inzucchi SE et al (2019) Pioglitazone therapy in patients with stroke and prediabetes: a post hoc analysis of the IRIS randomized clinical trial. JAMA Neurol 76(5):526\u2013535. https:\/\/doi.org\/10.1001\/jamaneurol.2019.0079","journal-title":"JAMA Neurol"},{"issue":"5","key":"6855_CR196","doi-asserted-by":"publisher","first-page":"305","DOI":"10.7326\/m15-1774","volume":"165","author":"K Cusi","year":"2016","unstructured":"Cusi K, Orsak B, Bril F et al (2016) Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. Ann Intern Med 165(5):305\u2013315. https:\/\/doi.org\/10.7326\/m15-1774","journal-title":"Ann Intern Med"},{"key":"6855_CR197","doi-asserted-by":"publisher","first-page":"108984","DOI":"10.1016\/j.diabres.2021.108984","volume":"178","author":"G Della Pepa","year":"2021","unstructured":"Della Pepa G, Russo M, Vitale M et al (2021) Pioglitazone even at low dosage improves NAFLD in type 2 diabetes: clinical and pathophysiological insights from a subgroup of the TOSCA.IT randomised trial. Diabetes Res Clin Pract 178:108984. https:\/\/doi.org\/10.1016\/j.diabres.2021.108984","journal-title":"Diabetes Res Clin Pract"},{"issue":"9681","key":"6855_CR198","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1016\/s0140-6736(09)60953-3","volume":"373","author":"PD Home","year":"2009","unstructured":"Home PD, Pocock SJ, Beck-Nielsen H et al (2009) Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 373(9681):2125\u20132135. https:\/\/doi.org\/10.1016\/s0140-6736(09)60953-3","journal-title":"Lancet"},{"issue":"1","key":"6855_CR199","doi-asserted-by":"publisher","first-page":"141","DOI":"10.2337\/diacare.27.1.141","volume":"27","author":"M Hanefeld","year":"2004","unstructured":"Hanefeld M, Brunetti P, Schernthaner GH, Matthews DR, Charbonnel BH (2004) One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care 27(1):141\u2013147. https:\/\/doi.org\/10.2337\/diacare.27.1.141","journal-title":"Diabetes Care"},{"issue":"3","key":"6855_CR200","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1210\/jc.2016-3237","volume":"102","author":"CM Viscoli","year":"2017","unstructured":"Viscoli CM, Inzucchi SE, Young LH et al (2017) Pioglitazone and risk for bone fracture: safety data from a randomized clinical trial. J Clin Endocrinol Metab 102(3):914\u2013922. https:\/\/doi.org\/10.1210\/jc.2016-3237","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"6855_CR201","doi-asserted-by":"publisher","first-page":"845","DOI":"10.2337\/dc07-2270","volume":"31","author":"SE Kahn","year":"2008","unstructured":"Kahn SE, Zinman B, Lachin JM et al (2008) Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 31(5):845\u2013851. https:\/\/doi.org\/10.2337\/dc07-2270","journal-title":"Diabetes Care"},{"issue":"4","key":"6855_CR202","doi-asserted-by":"publisher","first-page":"e21200023","DOI":"10.14440\/bladder.2024.0039","volume":"11","author":"S Baddam","year":"2024","unstructured":"Baddam S, Banka AV, Divity S, Sandesara M, Vityala Y (2024) Association between pioglitazone use and bladder cancer: a systematic review. Bladder (San Franc) 11(4):e21200023. https:\/\/doi.org\/10.14440\/bladder.2024.0039","journal-title":"Bladder (San Franc)"},{"issue":"2","key":"6855_CR203","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1177\/1479164118825376","volume":"16","author":"RA DeFronzo","year":"2019","unstructured":"DeFronzo RA, Inzucchi S, Abdul-Ghani M, Nissen SE (2019) Pioglitazone: the forgotten, cost-effective cardioprotective drug for type 2 diabetes. Diab Vasc Dis Res 16(2):133\u2013143. https:\/\/doi.org\/10.1177\/1479164118825376","journal-title":"Diab Vasc Dis Res"},{"issue":"3","key":"6855_CR204","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1007\/s12020-021-02889-6","volume":"74","author":"E Mannucci","year":"2021","unstructured":"Mannucci E, Caiulo C, Naletto L, Madama G, Monami M (2021) Efficacy and safety of different basal and prandial insulin analogues for the treatment of type 2 diabetes: a network meta-analysis of randomized controlled trials. Endocrine 74(3):508\u2013517. https:\/\/doi.org\/10.1007\/s12020-021-02889-6","journal-title":"Endocrine"},{"issue":"3","key":"6855_CR205","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1097\/crd.0000000000000143","volume":"25","author":"J Chan","year":"2017","unstructured":"Chan J, Cheng-Lai A (2017) Inhaled insulin: a clinical and historical review. Cardiol Rev 25(3):140\u2013146. https:\/\/doi.org\/10.1097\/crd.0000000000000143","journal-title":"Cardiol Rev"},{"issue":"5","key":"6855_CR206","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1089\/dia.2018.0298","volume":"21","author":"RM Bergenstal","year":"2019","unstructured":"Bergenstal RM, Peyrot M, Dreon DM et al (2019) Implementation of basal-bolus therapy in type 2 diabetes: a randomized controlled trial comparing bolus insulin delivery using an insulin patch with an insulin pen. Diabetes Technol Ther 21(5):273\u2013285. https:\/\/doi.org\/10.1089\/dia.2018.0298","journal-title":"Diabetes Technol Ther"},{"key":"6855_CR207","doi-asserted-by":"publisher","first-page":"4568903","DOI":"10.1155\/2018\/4568903","volume":"2018","author":"L Heinemann","year":"2018","unstructured":"Heinemann L, Parkin CG (2018) Rethinking the viability and utility of inhaled insulin in clinical practice. J Diabetes Res 2018:4568903. https:\/\/doi.org\/10.1155\/2018\/4568903","journal-title":"J Diabetes Res"},{"issue":"4","key":"6855_CR208","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1056\/NEJMoa2303208","volume":"389","author":"J Rosenstock","year":"2023","unstructured":"Rosenstock J, Bain SC, Gowda A et al (2023) Weekly icodec versus daily glargine U100 in type 2 diabetes without previous insulin. N Engl J Med 389(4):297\u2013308. https:\/\/doi.org\/10.1056\/NEJMoa2303208","journal-title":"N Engl J Med"},{"issue":"9","key":"6855_CR209","doi-asserted-by":"publisher","first-page":"3810","DOI":"10.1111\/dom.15726","volume":"26","author":"HS Bajaj","year":"2024","unstructured":"Bajaj HS, \u00c1sbj\u00f6rnsd\u00f3ttir B, Bari TJ, Begtrup K, Vilsb\u00f8ll T, Rosenstock J (2024) Once-weekly insulin icodec compared with daily basal insulin analogues in type 2 diabetes: participant-level meta-analysis of the ONWARDS 1\u20135 trials. Diabetes Obes Metab 26(9):3810\u20133820. https:\/\/doi.org\/10.1111\/dom.15726","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"6855_CR210","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1056\/NEJMoa2502796","volume":"393","author":"J Rosenstock","year":"2025","unstructured":"Rosenstock J, Bailey T, Connery L et al (2025) Weekly fixed-dose insulin efsitora in type 2 diabetes without previous insulin therapy. N Engl J Med 393(4):325\u2013335. https:\/\/doi.org\/10.1056\/NEJMoa2502796","journal-title":"N Engl J Med"},{"issue":"23","key":"6855_CR211","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1056\/NEJMoa2403953","volume":"391","author":"C Wysham","year":"2024","unstructured":"Wysham C, Bajaj HS, Del Prato S et al (2024) Insulin efsitora versus degludec in type 2 diabetes without previous insulin treatment. N Engl J Med 391(23):2201\u20132211. https:\/\/doi.org\/10.1056\/NEJMoa2403953","journal-title":"N Engl J Med"},{"issue":"10497","key":"6855_CR212","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1016\/s0140-6736(25)01069-4","volume":"405","author":"T Blevins","year":"2025","unstructured":"Blevins T, Dahl D, P\u00e9rez Manghi FC et al (2025) Once-weekly insulin efsitora alfa versus once-daily insulin glargine U100 in adults with type 2 diabetes treated with basal and prandial insulin (QWINT-4): a phase 3, randomised, non-inferiority trial. Lancet 405(10497):2290\u20132301. https:\/\/doi.org\/10.1016\/s0140-6736(25)01069-4","journal-title":"Lancet"},{"issue":"7","key":"6855_CR213","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/s2213-8587(25)00096-8","volume":"13","author":"C Mathieu","year":"2025","unstructured":"Mathieu C, Giorgino F, Kim SG et al (2025) Once-weekly IcoSema versus once-weekly insulin icodec in type 2 diabetes management (COMBINE 1): an open-label, multicentre, treat-to-target, randomised, phase 3a trial. Lancet Diabetes Endocrinol 13(7):568\u2013579. https:\/\/doi.org\/10.1016\/s2213-8587(25)00096-8","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"6855_CR214","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s00125-024-06348-5","volume":"68","author":"I Lingvay","year":"2025","unstructured":"Lingvay I, Benamar M, Chen L et al (2025) Once-weekly IcoSema versus once-weekly semaglutide in adults with type 2 diabetes: the COMBINE 2 randomised clinical trial. Diabetologia 68(4):739\u2013751. https:\/\/doi.org\/10.1007\/s00125-024-06348-5","journal-title":"Diabetologia"},{"issue":"7","key":"6855_CR215","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/s2213-8587(25)00052-x","volume":"13","author":"LK Billings","year":"2025","unstructured":"Billings LK, Andreozzi F, Frederiksen M et al (2025) Once-weekly IcoSema versus multiple daily insulin injections in type 2 diabetes management (COMBINE 3): an open-label, multicentre, treat-to-target, non-inferiority, randomised, phase 3a trial. Lancet Diabetes Endocrinol 13(7):556\u2013567. https:\/\/doi.org\/10.1016\/s2213-8587(25)00052-x","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"6855_CR216","doi-asserted-by":"publisher","first-page":"138","DOI":"10.2337\/cd17-0065","volume":"36","author":"VR Aroda","year":"2018","unstructured":"Aroda VR, Arulandu JR, Cannon AJ (2018) Insulin\/glucagon-like peptide-1 receptor agonist combination therapy for the treatment of type 2 diabetes: are two agents better than one? Clin Diabetes 36(2):138\u2013147. https:\/\/doi.org\/10.2337\/cd17-0065","journal-title":"Clin Diabetes"},{"issue":"9","key":"6855_CR217","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1111\/dom.13343","volume":"20","author":"MI Maiorino","year":"2018","unstructured":"Maiorino MI, Chiodini P, Bellastella G et al (2018) Free and fixed-ratio combinations of basal insulin and GLP-1 receptor agonists versus basal insulin intensification in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab 20(9):2309\u20132313. https:\/\/doi.org\/10.1111\/dom.13343","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"6855_CR218","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1089\/dia.2019.0484","volume":"23","author":"S Kasthuri","year":"2021","unstructured":"Kasthuri S, Poongothai S, Anjana RM et al (2021) Comparison of glycemic excursion using flash continuous glucose monitoring in patients with type 2 diabetes mellitus before and after treatment with voglibose. Diabetes Technol Ther 23(3):213\u2013220. https:\/\/doi.org\/10.1089\/dia.2019.0484","journal-title":"Diabetes Technol Ther"},{"issue":"3","key":"6855_CR219","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1530\/eje-20-1121","volume":"184","author":"NB Dalsgaard","year":"2021","unstructured":"Dalsgaard NB, Gasbjerg LS, Hansen LS et al (2021) The role of GLP-1 in the postprandial effects of acarbose in type 2 diabetes. Eur J Endocrinol 184(3):383\u2013394. https:\/\/doi.org\/10.1530\/eje-20-1121","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"6855_CR220","doi-asserted-by":"publisher","first-page":"6852","DOI":"10.62347\/mcee4840","volume":"16","author":"Y Wu","year":"2024","unstructured":"Wu Y, Yang Z, Cao Q (2024) Efficacy and safety of GLP-1 receptor agonists combined with SGLT-2 inhibitors in elderly patients with type 2 diabetes: a meta-analysis. Am J Transl Res 16(11):6852\u20136866. https:\/\/doi.org\/10.62347\/mcee4840","journal-title":"Am J Transl Res"},{"issue":"5","key":"6855_CR221","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/s2213-8587(18)30023-8","volume":"6","author":"B Ludvik","year":"2018","unstructured":"Ludvik B, Fr\u00edas JP, Tinahones FJ et al (2018) Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 6(5):370\u2013381. https:\/\/doi.org\/10.1016\/s2213-8587(18)30023-8","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"6855_CR222","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/s2213-8587(24)00155-4","volume":"12","author":"EM Apperloo","year":"2024","unstructured":"Apperloo EM, Neuen BL, Fletcher RA et al (2024) Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol 12(8):545\u2013557. https:\/\/doi.org\/10.1016\/s2213-8587(24)00155-4","journal-title":"Lancet Diabetes Endocrinol"},{"key":"6855_CR223","doi-asserted-by":"publisher","first-page":"e078242","DOI":"10.1136\/bmj-2023-078242","volume":"385","author":"N Simms-Williams","year":"2024","unstructured":"Simms-Williams N, Treves N, Yin H et al (2024) Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study. BMJ 385:e078242. https:\/\/doi.org\/10.1136\/bmj-2023-078242","journal-title":"Bmj"},{"issue":"6","key":"6855_CR224","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.jacc.2023.05.048","volume":"82","author":"JS Neves","year":"2023","unstructured":"Neves JS, Borges-Canha M, Vasques-N\u00f3voa F et al (2023) GLP-1 receptor agonist therapy with and without SGLT2 inhibitors in patients with type 2 diabetes. J Am Coll Cardiol 82(6):517\u2013525. https:\/\/doi.org\/10.1016\/j.jacc.2023.05.048","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"6855_CR225","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s00125-025-06565-6","volume":"69","author":"JMT Colombijn","year":"2026","unstructured":"Colombijn JMT, de Leijer JF, Visseren FLJ et al (2026) Effectiveness and safety of combining SGLT2 inhibitors and GLP-1 receptor agonists in individuals with type 2 diabetes: a systematic review and meta-analysis of cohort studies. Diabetologia 69(1):36\u201349. https:\/\/doi.org\/10.1007\/s00125-025-06565-6","journal-title":"Diabetologia"},{"issue":"1","key":"6855_CR226","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1186\/s12933-025-02900-8","volume":"24","author":"A Shokravi","year":"2025","unstructured":"Shokravi A, Seth J, Mancini GBJ (2025) Cardiovascular and renal outcomes of dual combination therapies with glucagon-like peptide-1 receptor agonists and sodium-glucose transport protein 2 inhibitors: a systematic review and meta-analysis. Cardiovasc Diabetol 24(1):370. https:\/\/doi.org\/10.1186\/s12933-025-02900-8","journal-title":"Cardiovasc Diabetol"},{"issue":"12","key":"6855_CR227","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.2337\/dc25-1055","volume":"48","author":"RA DeFronzo","year":"2025","unstructured":"DeFronzo RA, Fonseca V, Aroda VR et al (2025) Inadequately controlled type 2 diabetes and hypercortisolism: improved glycemia with mifepristone treatment. Diabetes Care 48(12):2036\u20132044. https:\/\/doi.org\/10.2337\/dc25-1055","journal-title":"Diabetes Care"},{"issue":"23","key":"6855_CR228","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD et al (2020) Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 383(23):2219\u20132229. https:\/\/doi.org\/10.1056\/NEJMoa2025845","journal-title":"N Engl J Med"},{"issue":"24","key":"6855_CR229","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt B, Filippatos G, Agarwal R et al (2021) Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med 385(24):2252\u20132263. https:\/\/doi.org\/10.1056\/NEJMoa2110956","journal-title":"N Engl J Med"},{"issue":"6","key":"6855_CR230","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","volume":"43","author":"R Agarwal","year":"2022","unstructured":"Agarwal R, Filippatos G, Pitt B et al (2022) Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J 43(6):474\u2013484. https:\/\/doi.org\/10.1093\/eurheartj\/ehab777","journal-title":"Eur Heart J"},{"issue":"26","key":"6855_CR231","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1093\/eurheartj\/ehaf174","volume":"46","author":"M Samuel","year":"2025","unstructured":"Samuel M, Berry C, Dub\u00e9 MP et al (2025) Long-term trials of colchicine for secondary prevention of vascular events: a meta-analysis. Eur Heart J 46(26):2552\u20132563. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf174","journal-title":"Eur Heart J"},{"issue":"3","key":"6855_CR232","doi-asserted-by":"publisher","first-page":"467","DOI":"10.2337\/dc23-1825","volume":"47","author":"F Roubille","year":"2024","unstructured":"Roubille F, Bouabdallaoui N, Kouz S et al (2024) Low-dose colchicine in patients with type 2 diabetes and recent myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT). Diabetes Care 47(3):467\u2013470. https:\/\/doi.org\/10.2337\/dc23-1825","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"6855_CR233","doi-asserted-by":"publisher","first-page":"S113","DOI":"10.2337\/dc22-S008","volume":"45","author":"American Diabetes Association Professional Practice Committee","year":"2022","unstructured":"American Diabetes Association Professional Practice Committee (2022) 8. Obesity and weight management for the prevention and treatment of type 2 diabetes: standards of medical care in diabetes-2022. Diabetes Care 45(Suppl 1):S113-s124. https:\/\/doi.org\/10.2337\/dc22-S008","journal-title":"Diabetes Care"},{"issue":"1","key":"6855_CR234","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1056\/NEJMoa2416394","volume":"393","author":"LJ Aronne","year":"2025","unstructured":"Aronne LJ, Horn DB, le Roux CW et al (2025) Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med 393(1):26\u201336. https:\/\/doi.org\/10.1056\/NEJMoa2416394","journal-title":"N Engl J Med"},{"issue":"10522","key":"6855_CR235","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1016\/s0140-6736(25)02165-8","volume":"406","author":"DB Horn","year":"2026","unstructured":"Horn DB, Ryan DH, Kis SG et al (2026) Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial. Lancet 406(10522):2927\u20132944. https:\/\/doi.org\/10.1016\/s0140-6736(25)02165-8","journal-title":"Lancet"},{"issue":"11","key":"6855_CR236","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1056\/NEJMoa2500969","volume":"393","author":"S Wharton","year":"2025","unstructured":"Wharton S, Lingvay I, Bogdanski P et al (2025) Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. N Engl J Med 393(11):1077\u20131087. https:\/\/doi.org\/10.1056\/NEJMoa2500969","journal-title":"N Engl J Med"},{"issue":"6","key":"6855_CR237","doi-asserted-by":"publisher","first-page":"861","DOI":"10.2337\/dc16-0236","volume":"39","author":"F Rubino","year":"2016","unstructured":"Rubino F, Nathan DM, Eckel RH et al (2016) Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by international diabetes organizations. Diabetes Care 39(6):861\u2013877. https:\/\/doi.org\/10.2337\/dc16-0236","journal-title":"Diabetes Care"},{"issue":"4","key":"6855_CR238","doi-asserted-by":"publisher","first-page":"537","DOI":"10.2337\/dc24-2046","volume":"48","author":"DC Simonson","year":"2025","unstructured":"Simonson DC, Gourash WF, Arterburn DE et al (2025) Health-related quality of life and health utility after metabolic\/bariatric surgery versus medical\/lifestyle intervention in individuals with type 2 diabetes and obesity: the ARMMS-T2D study. Diabetes Care 48(4):537\u2013545. https:\/\/doi.org\/10.2337\/dc24-2046","journal-title":"Diabetes Care"},{"issue":"7","key":"6855_CR239","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.2337\/dc21-2441","volume":"45","author":"JP Kirwan","year":"2022","unstructured":"Kirwan JP, Courcoulas AP, Cummings DE et al (2022) Diabetes Remission in the Alliance of Randomized Trials of Medicine Versus Metabolic Surgery in Type 2 Diabetes (ARMMS-T2D). Diabetes Care 45(7):1574\u20131583. https:\/\/doi.org\/10.2337\/dc21-2441","journal-title":"Diabetes Care"},{"issue":"8","key":"6855_CR240","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1001\/jama.2024.0318","volume":"331","author":"AP Courcoulas","year":"2024","unstructured":"Courcoulas AP, Patti ME, Hu B et al (2024) Long-term outcomes of medical management vs bariatric surgery in type 2 diabetes. JAMA 331(8):654\u2013664. https:\/\/doi.org\/10.1001\/jama.2024.0318","journal-title":"Jama"},{"issue":"1","key":"6855_CR241","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12902-023-01283-9","volume":"23","author":"X Zhou","year":"2023","unstructured":"Zhou X, Zeng C (2023) Diabetes remission of bariatric surgery and nonsurgical treatments in type 2 diabetes patients who failure to meet the criteria for surgery: a systematic review and meta-analysis. BMC Endocr Disord 23(1):46. https:\/\/doi.org\/10.1186\/s12902-023-01283-9","journal-title":"BMC Endocr Disord"},{"issue":"1","key":"6855_CR242","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s40200-024-01526-z","volume":"24","author":"D Gul","year":"2025","unstructured":"Gul D, Khan AW, Butt MA et al (2025) Clinical outcomes of roux-en-Y gastric bypass versus medical therapy in type 2 diabetes mellitus: a systematic review and meta-analysis. J Diabetes Metab Disord 24(1):43. https:\/\/doi.org\/10.1007\/s40200-024-01526-z","journal-title":"J Diabetes Metab Disord"},{"issue":"8","key":"6855_CR243","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1007\/s11695-023-06671-7","volume":"33","author":"X Yi","year":"2023","unstructured":"Yi X, Zhu L, Zhu S (2023) Predictors of T2DM remission after bariatric surgery in patients with a BMI < 35 kg\/m(2): a meta-analysis. Obes Surg 33(8):2342\u20132355. https:\/\/doi.org\/10.1007\/s11695-023-06671-7","journal-title":"Obes Surg"},{"issue":"5","key":"6855_CR244","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/s2213-8587(24)00396-6","volume":"13","author":"J W\u00e5gen Hauge","year":"2025","unstructured":"W\u00e5gen Hauge J, Borgeraas H, Birkeland KI et al (2025) Effect of gastric bypass versus sleeve gastrectomy on the remission of type 2 diabetes, weight loss, and cardiovascular risk factors at 5 years (Oseberg): secondary outcomes of a single-centre, triple-blind, randomised controlled trial. Lancet Diabetes Endocrinol 13(5):397\u2013409. https:\/\/doi.org\/10.1016\/s2213-8587(24)00396-6","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"6855_CR245","doi-asserted-by":"publisher","first-page":"3341","DOI":"10.1038\/s41591-025-03893-3","volume":"31","author":"H Gasoyan","year":"2025","unstructured":"Gasoyan H, Alavi MH, Zajichek A et al (2025) Macrovascular and microvascular outcomes of metabolic surgery versus GLP-1 receptor agonists in patients with diabetes and obesity. Nat Med 31(10):3341\u20133349. https:\/\/doi.org\/10.1038\/s41591-025-03893-3","journal-title":"Nat Med"},{"issue":"2","key":"6855_CR246","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.soard.2023.08.016","volume":"20","author":"J Obeso-Fern\u00e1ndez","year":"2024","unstructured":"Obeso-Fern\u00e1ndez J, Millan-Alanis JM, S\u00e1enz-Flores M et al (2024) Benefits of metabolic surgery on macrovascular outcomes in adult patients with type 2 diabetes: a systematic review and meta-analysis. Surg Obes Relat Dis 20(2):202\u2013212. https:\/\/doi.org\/10.1016\/j.soard.2023.08.016","journal-title":"Surg Obes Relat Dis"},{"issue":"1","key":"6855_CR247","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s11695-024-07612-8","volume":"35","author":"N Einafshar","year":"2025","unstructured":"Einafshar N, Esparham A, Moghani MS, Radboy M, Ghamari MJ, Zandbaf T (2025) The impact of metabolic and bariatric surgery on diabetic kidney disease in patients with type 2 diabetes: a systematic review and meta-analysis. Obes Surg 35(1):329\u2013340. https:\/\/doi.org\/10.1007\/s11695-024-07612-8","journal-title":"Obes Surg"},{"issue":"10390","key":"6855_CR248","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1016\/s0140-6736(23)00634-7","volume":"401","author":"O Verrastro","year":"2023","unstructured":"Verrastro O, Panunzi S, Castagneto-Gissey L et al (2023) Bariatric-metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial. Lancet 401(10390):1786\u20131797. https:\/\/doi.org\/10.1016\/s0140-6736(23)00634-7","journal-title":"Lancet"},{"issue":"20","key":"6855_CR249","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1001\/jama.2021.19569","volume":"326","author":"A Aminian","year":"2021","unstructured":"Aminian A, Al-Kurd A, Wilson R et al (2021) Association of bariatric surgery with major adverse liver and cardiovascular outcomes in patients with biopsy-proven nonalcoholic steatohepatitis. JAMA 326(20):2031\u20132042. https:\/\/doi.org\/10.1001\/jama.2021.19569","journal-title":"Jama"},{"issue":"Suppl 1","key":"6855_CR250","doi-asserted-by":"publisher","first-page":"S166","DOI":"10.2337\/dc26-S008","volume":"49","author":"American Diabetes Association Professional Practice Committee","year":"2026","unstructured":"American Diabetes Association Professional Practice Committee (2026) 8. Obesity and weight management for the prevention and treatment of diabetes: standards of care in diabetes-2026. Diabetes Care 49(Suppl 1):S166-s182. https:\/\/doi.org\/10.2337\/dc26-S008","journal-title":"Diabetes Care"},{"issue":"1","key":"6855_CR251","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11695-022-06332-1","volume":"33","author":"D Eisenberg","year":"2023","unstructured":"Eisenberg D, Shikora SA, Aarts E et al (2023) 2022 American Society of Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) Indications for Metabolic and Bariatric Surgery. Obes Surg 33(1):3\u201314. https:\/\/doi.org\/10.1007\/s11695-022-06332-1","journal-title":"Obes Surg"},{"issue":"9","key":"6855_CR252","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1038\/s41591-024-03095-3","volume":"30","author":"L Busetto","year":"2024","unstructured":"Busetto L, Dicker D, Fr\u00fchbeck G et al (2024) A new framework for the diagnosis, staging and management of obesity in adults. Nat Med 30(9):2395\u20132399. https:\/\/doi.org\/10.1038\/s41591-024-03095-3","journal-title":"Nat Med"},{"issue":"1","key":"6855_CR253","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3390\/nu16010063","volume":"16","author":"G Lisco","year":"2023","unstructured":"Lisco G, Disoteo OE, De Tullio A et al (2023) Sarcopenia and diabetes: a detrimental liaison of advancing age. Nutrients 16(1):63. https:\/\/doi.org\/10.3390\/nu16010063","journal-title":"Nutrients"},{"issue":"3","key":"6855_CR254","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1159\/000521241","volume":"15","author":"LM Donini","year":"2022","unstructured":"Donini LM, Busetto L, Bischoff SC et al (2022) Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement. Obes Facts 15(3):321\u2013335. https:\/\/doi.org\/10.1159\/000521241","journal-title":"Obes Facts"},{"issue":"10","key":"6855_CR255","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1016\/j.ekir.2021.05.039","volume":"6","author":"L Wong","year":"2021","unstructured":"Wong L, Duque G, McMahon LP (2021) Sarcopenia and frailty: challenges in mainstream nephrology practice. Kidney Int Rep 6(10):2554\u20132564. https:\/\/doi.org\/10.1016\/j.ekir.2021.05.039","journal-title":"Kidney Int Rep"},{"issue":"6","key":"6855_CR256","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/s2213-8587(25)00027-0","volume":"13","author":"N Sattar","year":"2025","unstructured":"Sattar N, Neeland IJ, Dahlqvist Leinhard O et al (2025) Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): a post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial. Lancet Diabetes Endocrinol 13(6):482\u2013493. https:\/\/doi.org\/10.1016\/s2213-8587(25)00027-0","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"6855_CR257","doi-asserted-by":"publisher","first-page":"247","DOI":"10.3803\/EnM.2019.34.3.247","volume":"34","author":"JA Sargeant","year":"2019","unstructured":"Sargeant JA, Henson J, King JA, Yates T, Khunti K, Davies MJ (2019) A review of the effects of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors on lean body mass in humans. Endocrinol Metab (Seoul) 34(3):247\u2013262. https:\/\/doi.org\/10.3803\/EnM.2019.34.3.247","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"3","key":"6855_CR258","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s00125-019-05065-8","volume":"63","author":"RJ McCrimmon","year":"2020","unstructured":"McCrimmon RJ, Catarig AM, Frias JP et al (2020) Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial. Diabetologia 63(3):473\u2013485. https:\/\/doi.org\/10.1007\/s00125-019-05065-8","journal-title":"Diabetologia"},{"issue":"12","key":"6855_CR259","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1111\/j.1463-1326.2009.01158.x","volume":"11","author":"J Jendle","year":"2009","unstructured":"Jendle J, Nauck MA, Matthews DR et al (2009) Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes Metab 11(12):1163\u20131172. https:\/\/doi.org\/10.1111\/j.1463-1326.2009.01158.x","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"6855_CR260","doi-asserted-by":"publisher","first-page":"e13916","DOI":"10.1111\/obr.13916","volume":"26","author":"O Anyiam","year":"2025","unstructured":"Anyiam O, Ardavani A, Rashid RSA, Panesar A, Idris I (2025) How do glucagon-like peptide-1 receptor agonists affect measures of muscle mass in individuals with, and without, type 2 diabetes: a systematic review and meta-analysis. Obes Rev 26(7):e13916. https:\/\/doi.org\/10.1111\/obr.13916","journal-title":"Obes Rev"},{"issue":"6","key":"6855_CR261","doi-asserted-by":"publisher","first-page":"e15083","DOI":"10.1111\/dme.15083","volume":"40","author":"E Ahmad","year":"2023","unstructured":"Ahmad E, Arsenyadis F, Almaqhawi A et al (2023) Impact of novel glucose-lowering therapies on physical function in people with type 2 diabetes: a systematic review and meta-analysis of randomised placebo-controlled trials. Diabet Med 40(6):e15083. https:\/\/doi.org\/10.1111\/dme.15083","journal-title":"Diabet Med"},{"issue":"4","key":"6855_CR262","doi-asserted-by":"publisher","first-page":"3335","DOI":"10.1111\/dom.70529","volume":"28","author":"PHS Schmidt","year":"2026","unstructured":"Schmidt PHS, de Souza VSN, Machado LG et al (2026) Tirzepatide on physical function in adults with overweight or obesity: a systematic review and meta-analysis. Diabetes Obes Metab 28(4):3335\u20133343. https:\/\/doi.org\/10.1111\/dom.70529","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"6855_CR263","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1002\/jcsm.13445","volume":"15","author":"A Pandey","year":"2024","unstructured":"Pandey A, Patel KV, Segar MW et al (2024) Effect of liraglutide on thigh muscle fat and muscle composition in adults with overweight or obesity: results from a randomized clinical trial. J Cachexia Sarcopenia Muscle 15(3):1072\u20131083. https:\/\/doi.org\/10.1002\/jcsm.13445","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"5","key":"6855_CR264","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1007\/s11695-024-07173-w","volume":"34","author":"G Boppre","year":"2024","unstructured":"Boppre G, Diniz-Sousa F, Veras L et al (2024) Impact of a multicomponent exercise training program on muscle strength after bariatric surgery: a randomized controlled trial. Obes Surg 34(5):1704\u20131716. https:\/\/doi.org\/10.1007\/s11695-024-07173-w","journal-title":"Obes Surg"},{"issue":"4","key":"6855_CR265","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1007\/s11695-020-05144-5","volume":"31","author":"G In","year":"2021","unstructured":"In G, Taskin HE, Al M et al (2021) Comparison of 12-week fitness protocols following bariatric surgery: aerobic exercise versus aerobic exercise and progressive resistance. Obes Surg 31(4):1475\u20131484. https:\/\/doi.org\/10.1007\/s11695-020-05144-5","journal-title":"Obes Surg"},{"issue":"6","key":"6855_CR266","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/ijo.2017.60","volume":"41","author":"LY Herring","year":"2017","unstructured":"Herring LY, Stevinson C, Carter P et al (2017) The effects of supervised exercise training 12\u201324 months after bariatric surgery on physical function and body composition: a randomised controlled trial. Int J Obes (Lond) 41(6):909\u2013916. https:\/\/doi.org\/10.1038\/ijo.2017.60","journal-title":"Int J Obes (Lond)"},{"issue":"7","key":"6855_CR267","doi-asserted-by":"publisher","first-page":"e0271561","DOI":"10.1371\/journal.pone.0271561","volume":"17","author":"A Bellicha","year":"2022","unstructured":"Bellicha A, Ciangura C, Roda C et al (2022) Effect of exercise training after bariatric surgery: a 5-year follow-up study of a randomized controlled trial. PLoS One 17(7):e0271561. https:\/\/doi.org\/10.1371\/journal.pone.0271561","journal-title":"PLoS One"},{"issue":"1","key":"6855_CR268","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1172\/jci78016","volume":"125","author":"PM Coen","year":"2015","unstructured":"Coen PM, Tanner CJ, Helbling NL et al (2015) Clinical trial demonstrates exercise following bariatric surgery improves insulin sensitivity. J Clin Invest 125(1):248\u2013257. https:\/\/doi.org\/10.1172\/jci78016","journal-title":"J Clin Invest"},{"issue":"7","key":"6855_CR269","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1002\/oby.21864","volume":"25","author":"EA Carnero","year":"2017","unstructured":"Carnero EA, Dubis GS, Hames KC et al (2017) Randomized trial reveals that physical activity and energy expenditure are associated with weight and body composition after RYGB. Obesity (Silver Spring) 25(7):1206\u20131216. https:\/\/doi.org\/10.1002\/oby.21864","journal-title":"Obesity (Silver Spring)"},{"issue":"11","key":"6855_CR270","doi-asserted-by":"publisher","first-page":"2798","DOI":"10.1210\/clinem\/dgad326","volume":"108","author":"A Ingersen","year":"2023","unstructured":"Ingersen A, Schm\u00fccker M, Alexandersen C et al (2023) Effects of aerobic training and semaglutide treatment on pancreatic \u03b2-cell secretory function in patients with type 2 diabetes. J Clin Endocrinol Metab 108(11):2798\u20132811. https:\/\/doi.org\/10.1210\/clinem\/dgad326","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"6855_CR271","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1002\/oby.23715","volume":"31","author":"SBK Jensen","year":"2023","unstructured":"Jensen SBK, Juhl CR, Janus C et al (2023) Weight loss maintenance with exercise and liraglutide improves glucose tolerance, glucagon response, and beta cell function. Obesity (Silver Spring) 31(4):977\u2013989. https:\/\/doi.org\/10.1002\/oby.23715","journal-title":"Obesity (Silver Spring)"},{"issue":"1","key":"6855_CR272","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12933-023-01765-z","volume":"22","author":"RM Sandsdal","year":"2023","unstructured":"Sandsdal RM, Juhl CR, Jensen SBK et al (2023) Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial. Cardiovasc Diabetol 22(1):41. https:\/\/doi.org\/10.1186\/s12933-023-01765-z","journal-title":"Cardiovasc Diabetol"},{"issue":"18","key":"6855_CR273","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1056\/NEJMoa2028198","volume":"384","author":"JR Lundgren","year":"2021","unstructured":"Lundgren JR, Janus C, Jensen SBK et al (2021) Healthy weight loss maintenance with exercise, liraglutide, or both combined. N Engl J Med 384(18):1719\u20131730. https:\/\/doi.org\/10.1056\/NEJMoa2028198","journal-title":"N Engl J Med"},{"issue":"2","key":"6855_CR274","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1093\/ndt\/gfae150","volume":"40","author":"EM Apperloo","year":"2025","unstructured":"Apperloo EM, Cherney DZI, Kuhlman AB et al (2025) Effect of semaglutide on kidney function across different levels of baseline HbA1c, blood pressure, body weight and albuminuria in SUSTAIN 6 and PIONEER 6. Nephrol Dial Transplant 40(2):352\u2013359. https:\/\/doi.org\/10.1093\/ndt\/gfae150","journal-title":"Nephrol Dial Transplant"},{"issue":"12","key":"6855_CR275","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/s2213-8587(22)00308-4","volume":"10","author":"SE Inzucchi","year":"2022","unstructured":"Inzucchi SE, Claggett BL, Vaduganathan M et al (2022) Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international, multicentre, double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 10(12):869\u2013881. https:\/\/doi.org\/10.1016\/s2213-8587(22)00308-4","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"6855_CR276","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/s2213-8587(24)00304-8","volume":"13","author":"MJ Davies","year":"2025","unstructured":"Davies MJ, van der Meer P, Verma S et al (2025) Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA(1c) levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 13(3):196\u2013209. https:\/\/doi.org\/10.1016\/s2213-8587(24)00304-8","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"6855_CR277","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1111\/dom.14999","volume":"25","author":"JB McGill","year":"2023","unstructured":"McGill JB, Agarwal R, Anker SD et al (2023) Effects of finerenone in people with chronic kidney disease and type 2 diabetes are independent of HbA1c at baseline, HbA1c variability, diabetes duration and insulin use at baseline. Diabetes Obes Metab 25(6):1512\u20131522. https:\/\/doi.org\/10.1111\/dom.14999","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"6855_CR278","doi-asserted-by":"publisher","first-page":"531","DOI":"10.2337\/dci23-0041","volume":"47","author":"N Sattar","year":"2024","unstructured":"Sattar N, Presslie C, Rutter MK, McGuire DK (2024) Cardiovascular and kidney risks in individuals with type 2 diabetes: contemporary understanding with greater emphasis on excess adiposity. Diabetes Care 47(4):531\u2013543. https:\/\/doi.org\/10.2337\/dci23-0041","journal-title":"Diabetes Care"},{"issue":"7","key":"6855_CR279","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.2215\/cjn.02980322","volume":"17","author":"KR Tuttle","year":"2022","unstructured":"Tuttle KR, Wong L, St Peter W et al (2022) Moving from evidence to implementation of breakthrough therapies for diabetic kidney disease. Clin J Am Soc Nephrol 17(7):1092\u20131103. https:\/\/doi.org\/10.2215\/cjn.02980322","journal-title":"Clin J Am Soc Nephrol"},{"issue":"20","key":"6855_CR280","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa2501006","volume":"392","author":"DK McGuire","year":"2025","unstructured":"McGuire DK, Marx N, Mulvagh SL et al (2025) Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes. N Engl J Med 392(20):2001\u20132012. https:\/\/doi.org\/10.1056\/NEJMoa2501006","journal-title":"N Engl J Med"},{"issue":"23","key":"6855_CR281","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1161\/circulationaha.125.074545","volume":"151","author":"N Marx","year":"2025","unstructured":"Marx N, Deanfield JE, Mann JFE et al (2025) Oral semaglutide and cardiovascular outcomes in people with type 2 diabetes, according to SGLT2i use: prespecified analyses of the SOUL randomized trial. Circulation 151(23):1639\u20131650. https:\/\/doi.org\/10.1161\/circulationaha.125.074545","journal-title":"Circulation"},{"issue":"19","key":"6855_CR282","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A et al (2016) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375(19):1834\u20131844. https:\/\/doi.org\/10.1056\/NEJMoa1607141","journal-title":"N Engl J Med"},{"issue":"10","key":"6855_CR283","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMoa2108269","volume":"385","author":"HC Gerstein","year":"2021","unstructured":"Gerstein HC, Sattar N, Rosenstock J et al (2021) Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N Engl J Med 385(10):896\u2013907. https:\/\/doi.org\/10.1056\/NEJMoa2108269","journal-title":"N Engl J Med"},{"issue":"22","key":"6855_CR284","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1161\/circulationaha.124.071689","volume":"150","author":"BL Neuen","year":"2024","unstructured":"Neuen BL, Fletcher RA, Heath L et al (2024) Cardiovascular, kidney, and safety outcomes with GLP-1 receptor agonists alone and in combination with SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis. Circulation 150(22):1781\u20131790. https:\/\/doi.org\/10.1161\/circulationaha.124.071689","journal-title":"Circulation"},{"issue":"10489","key":"6855_CR285","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/s0140-6736(25)00509-4","volume":"405","author":"MP Bonaca","year":"2025","unstructured":"Bonaca MP, Catarig AM, Houlind K et al (2025) Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial. Lancet 405(10489):1580\u20131593. https:\/\/doi.org\/10.1016\/s0140-6736(25)00509-4","journal-title":"Lancet"},{"issue":"5","key":"6855_CR286","doi-asserted-by":"publisher","first-page":"501562","DOI":"10.1016\/j.endien.2025.501562","volume":"72","author":"F Garagoli","year":"2025","unstructured":"Garagoli F, Masson W, Barbagelata L, Lobo M (2025) Effect of glucagon-like peptide-1 receptor agonists on the risk of major adverse limb events in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized clinical trials. Endocrinol Diabetes Nutr (Engl Ed) 72(5):501562. https:\/\/doi.org\/10.1016\/j.endien.2025.501562","journal-title":"Endocrinol Diabetes Nutr (Engl Ed)"},{"issue":"3","key":"6855_CR287","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1111\/dom.70391","volume":"28","author":"D Dutta","year":"2026","unstructured":"Dutta D, Mahajan K, Kamrul-Hasan ABM, Mahajan N, Sharma M, Vohra S (2026) Impact of glucagon-like peptide-1 receptor agonism-based therapies on limb outcomes in peripheral artery disease and type 2 diabetes: an updated systematic review and meta-analysis. Diabetes Obes Metab 28(3):2075\u20132084. https:\/\/doi.org\/10.1111\/dom.70391","journal-title":"Diabetes Obes Metab"},{"key":"6855_CR288","doi-asserted-by":"publisher","unstructured":"Cesaro A, Acerbo V, Longo M et al (2026) Impact of semaglutide on limb events: a meta-analysis of randomized controlled trials. Eur J Prev Cardiol zwag077. https:\/\/doi.org\/10.1093\/eurjpc\/zwag077","DOI":"10.1093\/eurjpc\/zwag077"},{"issue":"1","key":"6855_CR289","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s12933-023-01877-6","volume":"22","author":"M Sohn","year":"2023","unstructured":"Sohn M, Dietrich JW, Nauck MA, Lim S (2023) Characteristics predicting the efficacy of SGLT-2 inhibitors versus GLP-1 receptor agonists on major adverse cardiovascular events in type 2 diabetes mellitus: a meta-analysis study. Cardiovasc Diabetol 22(1):153. https:\/\/doi.org\/10.1186\/s12933-023-01877-6","journal-title":"Cardiovasc Diabetol"},{"key":"6855_CR290","doi-asserted-by":"publisher","first-page":"108921","DOI":"10.1016\/j.diabres.2021.108921","volume":"177","author":"A Tsapas","year":"2021","unstructured":"Tsapas A, Karagiannis T, Avgerinos I, Liakos A, Bekiari E (2021) GLP-1 receptor agonists for cardiovascular outcomes with and without metformin. A systematic review and meta-analysis of cardiovascular outcomes trials. Diabetes Res Clin Pract 177:108921. https:\/\/doi.org\/10.1016\/j.diabres.2021.108921","journal-title":"Diabetes Res Clin Pract"},{"issue":"6","key":"6855_CR291","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s40292-021-00479-1","volume":"28","author":"A Lavalle-Cobo","year":"2021","unstructured":"Lavalle-Cobo A, Masson W, Lobo M, Masson G, Molinero G (2021) Glucagon-like peptide-1 receptor agonists and cardioprotective benefit in patients with type 2 diabetes without baseline metformin: a systematic review and update meta-analysis. High Blood Press Cardiovasc Prev 28(6):605\u2013612. https:\/\/doi.org\/10.1007\/s40292-021-00479-1","journal-title":"High Blood Press Cardiovasc Prev"},{"issue":"1","key":"6855_CR292","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12933-022-01489-6","volume":"21","author":"M Husain","year":"2022","unstructured":"Husain M, Consoli A, De Remigis A, Pettersson Meyer AS, Rasmussen S, Bain S (2022) Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6. Cardiovasc Diabetol 21(1):64. https:\/\/doi.org\/10.1186\/s12933-022-01489-6","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"6855_CR293","doi-asserted-by":"publisher","first-page":"109236","DOI":"10.1016\/j.jdiacomp.2025.109236","volume":"40","author":"Q Fan","year":"2026","unstructured":"Fan Q, Qin G, Du B et al (2026) Evidence-based validation of cardiovascular benefits from novel MRAs in type 2 diabetes: a meta-analysis of over 30,000 patients. J Diabetes Complications 40(1):109236. https:\/\/doi.org\/10.1016\/j.jdiacomp.2025.109236","journal-title":"J Diabetes Complications"},{"issue":"10354","key":"6855_CR294","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/s0140-6736(22)01429-5","volume":"400","author":"M Vaduganathan","year":"2022","unstructured":"Vaduganathan M, Docherty KF, Claggett BL et al (2022) SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet 400(10354):757\u2013767. https:\/\/doi.org\/10.1016\/s0140-6736(22)01429-5","journal-title":"Lancet"},{"issue":"25","key":"6855_CR295","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1016\/j.jacc.2023.04.034","volume":"81","author":"MS Usman","year":"2023","unstructured":"Usman MS, Siddiqi TJ, Anker SD et al (2023) Effect of SGLT2 inhibitors on cardiovascular outcomes across various patient populations. J Am Coll Cardiol 81(25):2377\u20132387. https:\/\/doi.org\/10.1016\/j.jacc.2023.04.034","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"6855_CR296","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/s2213-8587(24)00102-5","volume":"12","author":"MS Usman","year":"2024","unstructured":"Usman MS, Bhatt DL, Hameed I et al (2024) Effect of SGLT2 inhibitors on heart failure outcomes and cardiovascular death across the cardiometabolic disease spectrum: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 12(7):447\u2013461. https:\/\/doi.org\/10.1016\/s2213-8587(24)00102-5","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"6855_CR297","doi-asserted-by":"publisher","first-page":"afad254","DOI":"10.1093\/ageing\/afad254","volume":"53","author":"R Aldafas","year":"2024","unstructured":"Aldafas R, Crabtree T, Alkharaiji M, Vinogradova Y, Idris I (2024) Sodium-glucose cotransporter-2 inhibitors (SGLT2) in frail or older people with type 2 diabetes and heart failure: a systematic review and meta-analysis. Age Ageing 53(1):afad254. https:\/\/doi.org\/10.1093\/ageing\/afad254","journal-title":"Age Ageing"},{"issue":"11","key":"6855_CR298","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1016\/j.jchf.2024.07.017","volume":"12","author":"JH Butt","year":"2024","unstructured":"Butt JH, Shen L, Inzucchi SE et al (2024) Dapagliflozin in heart failure, type 2 diabetes, and neuropathy: a meta-analysis of DAPA-HF and DELIVER. JACC Heart Fail 12(11):1946\u20131948. https:\/\/doi.org\/10.1016\/j.jchf.2024.07.017","journal-title":"JACC Heart Fail"},{"issue":"10437","key":"6855_CR299","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1016\/s0140-6736(24)00469-0","volume":"403","author":"J Butler","year":"2024","unstructured":"Butler J, Shah SJ, Petrie MC et al (2024) Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials. Lancet 403(10437):1635\u20131648. https:\/\/doi.org\/10.1016\/s0140-6736(24)00469-0","journal-title":"Lancet"},{"issue":"17","key":"6855_CR300","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1016\/j.jacc.2024.08.004","volume":"84","author":"RE Pratley","year":"2024","unstructured":"Pratley RE, Tuttle KR, Rossing P et al (2024) Effects of semaglutide on heart failure outcomes in diabetes and chronic kidney disease in the FLOW trial. J Am Coll Cardiol 84(17):1615\u20131628. https:\/\/doi.org\/10.1016\/j.jacc.2024.08.004","journal-title":"J Am Coll Cardiol"},{"issue":"10456","key":"6855_CR301","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/s0140-6736(24)01643-x","volume":"404","author":"MN Kosiborod","year":"2024","unstructured":"Kosiborod MN, Deanfield J, Pratley R et al (2024) Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials. Lancet 404(10456):949\u2013961. https:\/\/doi.org\/10.1016\/s0140-6736(24)01643-x","journal-title":"Lancet"},{"issue":"10","key":"6855_CR302","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.jacc.2025.06.058","volume":"86","author":"M Packer","year":"2025","unstructured":"Packer M, Zile MR, Kramer CM et al (2025) Influence of type 2 diabetes on the effects of tirzepatide in patients with heart failure and a preserved ejection fraction with obesity: a prespecified stratification-based analysis. J Am Coll Cardiol 86(10):696\u2013707. https:\/\/doi.org\/10.1016\/j.jacc.2025.06.058","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"6855_CR303","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s10557-023-07432-5","volume":"38","author":"M Banerjee","year":"2024","unstructured":"Banerjee M, Maisnam I, Mukhopadhyay S (2024) Impact of heart failure history at baseline on cardiovascular effects of GLP-1 receptor agonists in type 2 diabetes: a meta-analysis. Cardiovasc Drugs Ther 38(4):739\u2013746. https:\/\/doi.org\/10.1007\/s10557-023-07432-5","journal-title":"Cardiovasc Drugs Ther"},{"issue":"4","key":"6855_CR304","doi-asserted-by":"publisher","first-page":"e70043","DOI":"10.1111\/obr.70043","volume":"27","author":"JS Neves","year":"2026","unstructured":"Neves JS, Lobato CB, Leite AR et al (2026) GLP-1 receptor agonists for the prevention of new-onset heart failure: a systematic review and meta-analysis of placebo-controlled randomized clinical trials. Obes Rev 27(4):e70043. https:\/\/doi.org\/10.1111\/obr.70043","journal-title":"Obes Rev"},{"issue":"16","key":"6855_CR305","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","volume":"391","author":"SD Solomon","year":"2024","unstructured":"Solomon SD, McMurray JJV, Vaduganathan M et al (2024) Finerenone in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 391(16):1475\u20131485. https:\/\/doi.org\/10.1056\/NEJMoa2407107","journal-title":"N Engl J Med"},{"issue":"7","key":"6855_CR306","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1002\/ejhf.3649","volume":"27","author":"JH Butt","year":"2025","unstructured":"Butt JH, Jhund PS, Henderson AD et al (2025) Finerenone, glycaemic status, and heart failure with mildly reduced or preserved ejection fraction: a prespecified analysis of the FINEARTS-HF trial. Eur J Heart Fail 27(7):1326\u20131341. https:\/\/doi.org\/10.1002\/ejhf.3649","journal-title":"Eur J Heart Fail"},{"issue":"12","key":"6855_CR307","doi-asserted-by":"publisher","first-page":"3758","DOI":"10.1038\/s41591-024-03264-4","volume":"30","author":"M Vaduganathan","year":"2024","unstructured":"Vaduganathan M, Filippatos G, Claggett BL et al (2024) Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes. Nat Med 30(12):3758\u20133764. https:\/\/doi.org\/10.1038\/s41591-024-03264-4","journal-title":"Nat Med"},{"issue":"6","key":"6855_CR308","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1002\/ejhf.2469","volume":"24","author":"G Filippatos","year":"2022","unstructured":"Filippatos G, Pitt B, Agarwal R et al (2022) Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO-DKD trial. Eur J Heart Fail 24(6):996\u20131005. https:\/\/doi.org\/10.1002\/ejhf.2469","journal-title":"Eur J Heart Fail"},{"key":"6855_CR309","doi-asserted-by":"publisher","first-page":"m4573","DOI":"10.1136\/bmj.m4573","volume":"372","author":"SC Palmer","year":"2021","unstructured":"Palmer SC, Tendal B, Mustafa RA et al (2021) Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ 372:m4573. https:\/\/doi.org\/10.1136\/bmj.m4573","journal-title":"Bmj"},{"key":"6855_CR310","doi-asserted-by":"publisher","first-page":"1019120","DOI":"10.3389\/fcvm.2022.1019120","volume":"9","author":"Z Liu","year":"2022","unstructured":"Liu Z, Bian N, Wu S et al (2022) A meta-analysis evaluating indirectly GLP-1 receptor agonists and arrhythmias in patients with type 2 diabetes and myocardial infarction. Front Cardiovasc Med 9:1019120. https:\/\/doi.org\/10.3389\/fcvm.2022.1019120","journal-title":"Front Cardiovasc Med"},{"issue":"17","key":"6855_CR311","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1016\/j.jacc.2024.08.023","volume":"84","author":"S Verma","year":"2024","unstructured":"Verma S, Butler J, Borlaug BA et al (2024) Atrial fibrillation and semaglutide effects in obesity-related heart failure with preserved ejection fraction: STEP-HFpEF program. J Am Coll Cardiol 84(17):1603\u20131614. https:\/\/doi.org\/10.1016\/j.jacc.2024.08.023","journal-title":"J Am Coll Cardiol"},{"key":"6855_CR312","doi-asserted-by":"publisher","first-page":"1554795","DOI":"10.3389\/fendo.2025.1554795","volume":"16","author":"R Wu","year":"2025","unstructured":"Wu R, Xing B, Huang Y et al (2025) Effect of semaglutide on arrhythmic, major cardiovascular, and microvascular outcomes in patients with type 2 diabetes: a systematic review and meta-analysis. Front Endocrinol (Lausanne) 16:1554795. https:\/\/doi.org\/10.3389\/fendo.2025.1554795","journal-title":"Front Endocrinol (Lausanne)"},{"key":"6855_CR313","doi-asserted-by":"publisher","first-page":"112279","DOI":"10.1016\/j.diabres.2025.112279","volume":"225","author":"JY Wu","year":"2025","unstructured":"Wu JY, Tseng KJ, Kao CL, Hung KC, Yu T, Lin YM (2025) Clinical effectiveness of tirzepatide for patients with atrial fibrillation and type 2 diabetes: a retrospective cohort study. Diabetes Res Clin Pract 225:112279. https:\/\/doi.org\/10.1016\/j.diabres.2025.112279","journal-title":"Diabetes Res Clin Pract"},{"issue":"3","key":"6855_CR314","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1111\/jce.16544","volume":"36","author":"NA Abdelhadi","year":"2025","unstructured":"Abdelhadi NA, Ragab KM, Elkholy M, Koneru J, Ellenbogen KA, Pillai A (2025) Impact of sodium-glucose co-transporter 2 inhibitors on atrial fibrillation recurrence post-catheter ablation among patients with type 2 diabetes mellitus: a systematic review and meta-analysis. J Cardiovasc Electrophysiol 36(3):673\u2013682. https:\/\/doi.org\/10.1111\/jce.16544","journal-title":"J Cardiovasc Electrophysiol"},{"key":"6855_CR315","doi-asserted-by":"publisher","first-page":"1710123","DOI":"10.3389\/fcvm.2025.1710123","volume":"12","author":"J Li","year":"2025","unstructured":"Li J, Zhang F, Fan S et al (2025) Association of SGLT2 inhibitors with post-ablation atrial fibrillation recurrence in individuals with heart failure or type 2 diabetes mellitus: a systematic review and meta-analysis. Front Cardiovasc Med 12:1710123. https:\/\/doi.org\/10.3389\/fcvm.2025.1710123","journal-title":"Front Cardiovasc Med"},{"key":"6855_CR316","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.amjcard.2025.03.002","volume":"246","author":"GG Kidess","year":"2025","unstructured":"Kidess GG, Hamza M, Goru R, Basit J, Alraiyes M, Alraies MC (2025) The impact of sodium-glucose cotransporter-2 inhibitors on atrial fibrillation burden in diabetic patients. Am J Cardiol 246:65\u201370. https:\/\/doi.org\/10.1016\/j.amjcard.2025.03.002","journal-title":"Am J Cardiol"},{"key":"6855_CR317","doi-asserted-by":"publisher","first-page":"902923","DOI":"10.3389\/fcvm.2022.902923","volume":"9","author":"Z Yin","year":"2022","unstructured":"Yin Z, Zheng H, Guo Z (2022) Effect of sodium-glucose co-transporter protein 2 inhibitors on arrhythmia in heart failure patients with or without type 2 diabetes: a meta-analysis of randomized controlled trials. Front Cardiovasc Med 9:902923. https:\/\/doi.org\/10.3389\/fcvm.2022.902923","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"6855_CR318","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12872-024-04442-5","volume":"25","author":"X Liang","year":"2025","unstructured":"Liang X, Dai J, Wang F (2025) Sodium glucose co-transporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP-4) inhibitors and the risk of atrial fibrillation in patients with type 2 diabetes mellitus: a meta-analysis. BMC Cardiovasc Disord 25(1):59. https:\/\/doi.org\/10.1186\/s12872-024-04442-5","journal-title":"BMC Cardiovasc Disord"},{"issue":"3","key":"6855_CR319","doi-asserted-by":"publisher","first-page":"e004079","DOI":"10.1136\/bmjdrc-2024-004079","volume":"12","author":"WC Knowler","year":"2024","unstructured":"Knowler WC, Chen H, Bahnson JL et al (2024) Within and post-trial effects of an intensive lifestyle intervention on kidney disease in adults with overweight or obesity and type 2 diabetes mellitus: a secondary analysis of the Look AHEAD clinical trial. BMJ Open Diabetes Res Care 12(3):e004079. https:\/\/doi.org\/10.1136\/bmjdrc-2024-004079","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"8","key":"6855_CR320","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/j.soard.2023.02.024","volume":"19","author":"J Obeso-Fern\u00e1ndez","year":"2023","unstructured":"Obeso-Fern\u00e1ndez J, Millan-Alanis JM, Rodr\u00edguez-Bautista M et al (2023) Benefits of bariatric surgery on microvascular outcomes in adult patients with type 2 diabetes: a systematic review and meta-analysis. Surg Obes Relat Dis 19(8):916\u2013927. https:\/\/doi.org\/10.1016\/j.soard.2023.02.024","journal-title":"Surg Obes Relat Dis"},{"issue":"1","key":"6855_CR321","doi-asserted-by":"publisher","first-page":"15922","DOI":"10.1038\/s41598-023-42989-z","volume":"13","author":"TA Mavrakanas","year":"2023","unstructured":"Mavrakanas TA, Tsoukas MA, Brophy JM, Sharma A, Gariani K (2023) SGLT-2 inhibitors improve cardiovascular and renal outcomes in patients with CKD: a systematic review and meta-analysis. Sci Rep 13(1):15922. https:\/\/doi.org\/10.1038\/s41598-023-42989-z","journal-title":"Sci Rep"},{"issue":"6","key":"6855_CR322","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1111\/dom.15009","volume":"25","author":"BN Nguyen","year":"2023","unstructured":"Nguyen BN, Nguyen L, Mital S, Bugden S, Nguyen HV (2023) Comparative efficacy of sodium-glucose co-transporter-2 inhibitors, glucagon-like peptide-1 receptor agonists and non-steroidal mineralocorticoid receptor antagonists in chronic kidney disease and type 2 diabetes: a systematic review and network meta-analysis. Diabetes Obes Metab 25(6):1614\u20131623. https:\/\/doi.org\/10.1111\/dom.15009","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"6855_CR323","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s13300-022-01359-0","volume":"14","author":"S Ghosal","year":"2023","unstructured":"Ghosal S, Sinha B (2023) Assessing the effects of modern renoprotective agents in preventing progression of renal composite outcomes in patients with type 2 diabetes: a network meta-analysis. Diabetes Ther 14(2):415\u2013424. https:\/\/doi.org\/10.1007\/s13300-022-01359-0","journal-title":"Diabetes Ther"},{"issue":"6","key":"6855_CR324","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.jnma.2025.08.110","volume":"117","author":"Z Dong","year":"2025","unstructured":"Dong Z, Mo W, Ling Z, Hou L, Deng T (2025) Efficacy of SGLT2 inhibitors on acute kidney injury in patients with chronic kidney disease, cardiovascular disease, and type 2 diabetes: a meta-analysis. J Natl Med Assoc 117(6):458\u2013469. https:\/\/doi.org\/10.1016\/j.jnma.2025.08.110","journal-title":"J Natl Med Assoc"},{"issue":"2","key":"6855_CR325","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1681\/asn.0000000000000491","volume":"36","author":"TJ Siddiqi","year":"2025","unstructured":"Siddiqi TJ, Cherney D, Siddiqui HF et al (2025) Effects of sodium-glucose cotransporter-2 inhibitors on kidney outcomes across baseline cardiovascular-kidney-metabolic conditions: a systematic review and meta-analyses. J Am Soc Nephrol 36(2):242\u2013255. https:\/\/doi.org\/10.1681\/asn.0000000000000491","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"6855_CR326","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1016\/j.ekir.2022.05.007","volume":"7","author":"DZI Cherney","year":"2022","unstructured":"Cherney DZI, Dagogo-Jack S, Cosentino F et al (2022) Heart and kidney outcomes with ertugliflozin in people with non-albuminuric diabetic kidney disease: a post hoc analysis from the randomized VERTIS CV trial. Kidney Int Rep 7(8):1782\u20131792. https:\/\/doi.org\/10.1016\/j.ekir.2022.05.007","journal-title":"Kidney Int Rep"},{"issue":"10","key":"6855_CR327","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.2337\/dc22-0382","volume":"45","author":"O Mosenzon","year":"2022","unstructured":"Mosenzon O, Raz I, Wiviott SD et al (2022) Dapagliflozin and prevention of kidney disease among patients with type 2 diabetes: post hoc analyses from the DECLARE-TIMI 58 trial. Diabetes Care 45(10):2350\u20132359. https:\/\/doi.org\/10.2337\/dc22-0382","journal-title":"Diabetes Care"},{"issue":"1","key":"6855_CR328","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1159\/000543162","volume":"11","author":"DZI Cherney","year":"2025","unstructured":"Cherney DZI, Frederich R, Pratley RE et al (2025) Cardiovascular and renal outcomes with ertugliflozin by baseline use of renin-angiotensin-aldosterone system inhibitors or diuretics, including mineralocorticoid receptor antagonist: analyses from the VERTIS CV trial. Kidney Dis (Basel) 11(1):63\u201374. https:\/\/doi.org\/10.1159\/000543162","journal-title":"Kidney Dis (Basel)"},{"issue":"2","key":"6855_CR329","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic V, Tuttle KR, Rossing P et al (2024) Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med 391(2):109\u2013121. https:\/\/doi.org\/10.1056\/NEJMoa2403347","journal-title":"N Engl J Med"},{"issue":"12","key":"6855_CR330","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1093\/eurheartj\/ehae613","volume":"46","author":"KW Mahaffey","year":"2025","unstructured":"Mahaffey KW, Tuttle KR, Arici M et al (2025) Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial. Eur Heart J 46(12):1096\u20131108. https:\/\/doi.org\/10.1093\/eurheartj\/ehae613","journal-title":"Eur Heart J"},{"issue":"11","key":"6855_CR331","doi-asserted-by":"publisher","first-page":"5157","DOI":"10.1111\/dom.15860","volume":"26","author":"J Wang","year":"2024","unstructured":"Wang J, Yang J, Jiang W et al (2024) Effect of semaglutide on primary prevention of diabetic kidney disease in people with type 2 diabetes: a post hoc analysis of the SUSTAIN 6 randomized controlled trial. Diabetes Obes Metab 26(11):5157\u20135166. https:\/\/doi.org\/10.1111\/dom.15860","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"6855_CR332","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1016\/j.ekir.2024.04.028","volume":"9","author":"KR Tuttle","year":"2024","unstructured":"Tuttle KR, Bain SC, Bosch-Traberg H et al (2024) Effects of once-weekly semaglutide on kidney disease outcomes by KDIGO risk category in the SUSTAIN 6 trial. Kidney Int Rep 9(7):2006\u20132015. https:\/\/doi.org\/10.1016\/j.ekir.2024.04.028","journal-title":"Kidney Int Rep"},{"issue":"6","key":"6855_CR333","doi-asserted-by":"publisher","first-page":"e70136","DOI":"10.1002\/edm2.70136","volume":"8","author":"A Abdullah","year":"2025","unstructured":"Abdullah A, Sagreeka FNU, Aniket GA et al (2025) Safety and efficacy of semaglutide in patients with chronic kidney disease, with or without type 2 diabetes: a systematic review and meta-analysis. Endocrinol Diabetes Metab 8(6):e70136. https:\/\/doi.org\/10.1002\/edm2.70136","journal-title":"Endocrinol Diabetes Metab"},{"issue":"2","key":"6855_CR334","doi-asserted-by":"publisher","first-page":"257","DOI":"10.2337\/dc25-1080","volume":"49","author":"JFE Mann","year":"2026","unstructured":"Mann JFE, Marx N, Deanfield JE et al (2026) Impact of oral semaglutide on kidney outcomes in people with type 2 diabetes: results from the SOUL randomized trial. Diabetes Care 49(2):257\u2013265. https:\/\/doi.org\/10.2337\/dc25-1080","journal-title":"Diabetes Care"},{"issue":"8","key":"6855_CR335","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.2337\/dc23-0231","volume":"46","author":"FT Botros","year":"2023","unstructured":"Botros FT, Gerstein HC, Malik R et al (2023) Dulaglutide and kidney function-related outcomes in type 2 diabetes: a REWIND post hoc analysis. Diabetes Care 46(8):1524\u20131530. https:\/\/doi.org\/10.2337\/dc23-0231","journal-title":"Diabetes Care"},{"issue":"7","key":"6855_CR336","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/s2213-8587(26)00032-x","volume":"14","author":"S Zoungas","year":"2026","unstructured":"Zoungas S, D\u2019Alessio D, Pavo I et al (2026) A comparison of the effects of tirzepatide and dulaglutide on major kidney events in people with type 2 diabetes: pre-specified exploratory analyses of the SURPASS-CVOT trial. Lancet Diabetes Endocrinol 14(7):544\u2013557. https:\/\/doi.org\/10.1016\/s2213-8587(26)00032-x","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"6855_CR337","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/s2213-8587(24)00271-7","volume":"13","author":"SV Badve","year":"2025","unstructured":"Badve SV, Bilal A, Lee MMY et al (2025) Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol 13(1):15\u201328. https:\/\/doi.org\/10.1016\/s2213-8587(24)00271-7","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"6855_CR338","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1111\/dom.70298","volume":"28","author":"D Yeo","year":"2026","unstructured":"Yeo D, Jo Y, Jeong J et al (2026) Efficacy and safety of glucagon-like peptide 1 receptor agonists across all health outcomes in type 2 diabetes: an umbrella review and evidence map of randomised controlled trials. Diabetes Obes Metab 28(2):1136\u20131149. https:\/\/doi.org\/10.1111\/dom.70298","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"6855_CR339","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/s2213-8587(24)00371-1","volume":"13","author":"BJ Orandi","year":"2025","unstructured":"Orandi BJ, Chen Y, Li Y et al (2025) GLP-1 receptor agonists in kidney transplant recipients with pre-existing diabetes: a retrospective cohort study. Lancet Diabetes Endocrinol 13(5):374\u2013383. https:\/\/doi.org\/10.1016\/s2213-8587(24)00371-1","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"6855_CR340","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.2337\/dc25-0472","volume":"48","author":"P Rossing","year":"2025","unstructured":"Rossing P, Bakris G, Perkovic V et al (2025) Effects of semaglutide with or without concomitant mineralocorticoid receptor antagonist use in participants with type 2 diabetes and chronic kidney disease: a FLOW trial prespecified secondary analysis. Diabetes Care 48(11):1878\u20131887. https:\/\/doi.org\/10.2337\/dc25-0472","journal-title":"Diabetes Care"},{"issue":"10","key":"6855_CR341","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1038\/s41591-024-03133-0","volume":"30","author":"JFE Mann","year":"2024","unstructured":"Mann JFE, Rossing P, Bakris G et al (2024) Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial. Nat Med 30(10):2849\u20132856. https:\/\/doi.org\/10.1038\/s41591-024-03133-0","journal-title":"Nat Med"},{"issue":"8","key":"6855_CR342","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1001\/jamacardio.2023.1505","volume":"8","author":"R Agarwal","year":"2023","unstructured":"Agarwal R, Pitt B, Rossing P et al (2023) Modifiability of composite cardiovascular risk associated with chronic kidney disease in type 2 diabetes with finerenone. JAMA Cardiol 8(8):732\u2013741. https:\/\/doi.org\/10.1001\/jamacardio.2023.1505","journal-title":"JAMA Cardiol"},{"issue":"11","key":"6855_CR343","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.jchf.2022.07.013","volume":"10","author":"G Filippatos","year":"2022","unstructured":"Filippatos G, Anker SD, Pitt B et al (2022) Finerenone and heart failure outcomes by kidney function\/albuminuria in chronic kidney disease and diabetes. JACC Heart Fail 10(11):860\u2013870. https:\/\/doi.org\/10.1016\/j.jchf.2022.07.013","journal-title":"JACC Heart Fail"},{"issue":"2","key":"6855_CR344","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1093\/ehjcvp\/pvad001","volume":"9","author":"G Filippatos","year":"2023","unstructured":"Filippatos G, Anker SD, August P et al (2023) Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis. Eur Heart J Cardiovasc Pharmacother 9(2):183\u2013191. https:\/\/doi.org\/10.1093\/ehjcvp\/pvad001","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"12","key":"6855_CR345","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.2337\/dc22-0294","volume":"45","author":"P Rossing","year":"2022","unstructured":"Rossing P, Anker SD, Filippatos G et al (2022) Finerenone in patients with chronic kidney disease and type 2 diabetes by sodium-glucose cotransporter 2 inhibitor treatment: the FIDELITY analysis. Diabetes Care 45(12):2991\u20132998. https:\/\/doi.org\/10.2337\/dc22-0294","journal-title":"Diabetes Care"},{"issue":"12","key":"6855_CR346","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.7326\/m23-1023","volume":"176","author":"R Agarwal","year":"2023","unstructured":"Agarwal R, Tu W, Farjat AE et al (2023) Impact of finerenone-induced albuminuria reduction on chronic kidney disease outcomes in type 2 diabetes: a mediation analysis. Ann Intern Med 176(12):1606\u20131616. https:\/\/doi.org\/10.7326\/m23-1023","journal-title":"Ann Intern Med"},{"issue":"6","key":"6855_CR347","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1056\/NEJMoa2410659","volume":"393","author":"R Agarwal","year":"2025","unstructured":"Agarwal R, Green JB, Heerspink HJL et al (2025) Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes. N Engl J Med 393(6):533\u2013543. https:\/\/doi.org\/10.1056\/NEJMoa2410659","journal-title":"N Engl J Med"},{"issue":"11","key":"6855_CR348","doi-asserted-by":"publisher","first-page":"3327","DOI":"10.1111\/dom.15232","volume":"25","author":"HJL Heerspink","year":"2023","unstructured":"Heerspink HJL, Vart P, Jongs N et al (2023) Estimated lifetime benefit of novel pharmacological therapies in patients with type 2 diabetes and chronic kidney disease: a joint analysis of randomized controlled clinical trials. Diabetes Obes Metab 25(11):3327\u20133336. https:\/\/doi.org\/10.1111\/dom.15232","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"6855_CR349","doi-asserted-by":"publisher","first-page":"437","DOI":"10.2215\/cjn.0000000902","volume":"21","author":"MF Blum","year":"2026","unstructured":"Blum MF, Mehta S, Surapaneni A et al (2026) A target trial emulation study of SGLT2 inhibitors, GLP-1 receptor agonists, and combination therapy in preventing kidney failure in type 2 diabetes. Clin J Am Soc Nephrol 21(3):437\u2013445. https:\/\/doi.org\/10.2215\/cjn.0000000902","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"6855_CR350","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1007\/s00125-025-06577-2","volume":"69","author":"TT Jansz","year":"2026","unstructured":"Jansz TT, Young KG, Hopkins R et al (2026) Precision medicine in type 2 diabetes: targeting SGLT2 inhibitor treatment for kidney protection. Diabetologia 69(2):374\u2013385. https:\/\/doi.org\/10.1007\/s00125-025-06577-2","journal-title":"Diabetologia"},{"issue":"4","key":"6855_CR351","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/s2213-8587(23)00025-6","volume":"11","author":"LE Wagenknecht","year":"2023","unstructured":"Wagenknecht LE, Lawrence JM, Isom S et al (2023) Trends in incidence of youth-onset type 1 and type 2 diabetes in the USA, 2002\u201318: results from the population-based SEARCH for Diabetes in Youth study. Lancet Diabetes Endocrinol 11(4):242\u2013250. https:\/\/doi.org\/10.1016\/s2213-8587(23)00025-6","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"14","key":"6855_CR352","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMc2507615","volume":"394","author":"M Fang","year":"2026","unstructured":"Fang M, Xu Y, Selvin E, Shin JI (2026) Trends in youth-onset type 2 diabetes, 2013\u20132024. N Engl J Med 394(14):1451\u20131453. https:\/\/doi.org\/10.1056\/NEJMc2507615","journal-title":"N Engl J Med"},{"issue":"8","key":"6855_CR353","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1007\/s00125-020-05169-6","volume":"63","author":"AK Wright","year":"2020","unstructured":"Wright AK, Welsh P, Gill JMR et al (2020) Age-, sex- and ethnicity-related differences in body weight, blood pressure, HbA(1c) and lipid levels at the diagnosis of type 2 diabetes relative to people without diabetes. Diabetologia 63(8):1542\u20131553. https:\/\/doi.org\/10.1007\/s00125-020-05169-6","journal-title":"Diabetologia"},{"issue":"7","key":"6855_CR354","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.2337\/dc25-0001","volume":"48","author":"KJ Nadeau","year":"2025","unstructured":"Nadeau KJ, Mayer-Davis EJ, Gubitosi-Klug R, Zeitler PS, Kahn SE, Dabelea D (2025) Youth-onset type 2 diabetes: what we\u2019ve learned from key youth-onset type 2 diabetes studies, what we still don\u2019t know, and why it is important. Diabetes Care 48(7):1136\u20131149. https:\/\/doi.org\/10.2337\/dc25-0001","journal-title":"Diabetes Care"},{"issue":"10","key":"6855_CR355","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/s2213-8587(23)00223-1","volume":"11","author":"Emerging Risk Factors Collaboration","year":"2023","unstructured":"Emerging Risk Factors Collaboration (2023) Life expectancy associated with different ages at diagnosis of type 2 diabetes in high-income countries: 23 million person-years of observation. Lancet Diabetes Endocrinol 11(10):731\u2013742. https:\/\/doi.org\/10.1016\/s2213-8587(23)00223-1","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"6855_CR356","doi-asserted-by":"publisher","first-page":"e194498","DOI":"10.1001\/jamapediatrics.2019.4498","volume":"174","author":"LJ Andes","year":"2020","unstructured":"Andes LJ, Cheng YJ, Rolka DB, Gregg EW, Imperatore G (2020) Prevalence of prediabetes among adolescents and young adults in the United States, 2005\u20132016. JAMA Pediatr 174(2):e194498. https:\/\/doi.org\/10.1001\/jamapediatrics.2019.4498","journal-title":"JAMA Pediatr"},{"issue":"5","key":"6855_CR357","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1056\/NEJMoa2100165","volume":"385","author":"P Bjornstad","year":"2021","unstructured":"Bjornstad P, Drews KL, Caprio S et al (2021) Long-term complications in youth-onset type 2 diabetes. N Engl J Med 385(5):416\u2013426. https:\/\/doi.org\/10.1056\/NEJMoa2100165","journal-title":"N Engl J Med"},{"issue":"8","key":"6855_CR358","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1007\/s00125-020-05174-9","volume":"63","author":"JA Sargeant","year":"2020","unstructured":"Sargeant JA, Brady EM, Zaccardi F et al (2020) Adults with early-onset type 2 diabetes (aged 18\u201339 years) are severely underrepresented in diabetes clinical research trials. Diabetologia 63(8):1516\u20131520. https:\/\/doi.org\/10.1007\/s00125-020-05174-9","journal-title":"Diabetologia"},{"issue":"5","key":"6855_CR359","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/s2213-8587(22)00052-3","volume":"10","author":"WV Tamborlane","year":"2022","unstructured":"Tamborlane WV, Laffel LM, Shehadeh N et al (2022) Efficacy and safety of dapagliflozin in children and young adults with type 2 diabetes: a prospective, multicentre, randomised, parallel group, phase 3 study. Lancet Diabetes Endocrinol 10(5):341\u2013350. https:\/\/doi.org\/10.1016\/s2213-8587(22)00052-3","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"6855_CR360","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.7326\/annals-24-04017","volume":"178","author":"U Nadgir","year":"2025","unstructured":"Nadgir U, Ali SR, Gogate J, Shaw W, Antunes J, Fonseca S (2025) Treatment with canagliflozin versus placebo in children and adolescents with type 2 diabetes: a randomized clinical trial. Ann Intern Med 178(9):1217\u20131226. https:\/\/doi.org\/10.7326\/annals-24-04017","journal-title":"Ann Intern Med"},{"issue":"3","key":"6855_CR361","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/s2213-8587(22)00387-4","volume":"11","author":"LM Laffel","year":"2023","unstructured":"Laffel LM, Danne T, Klingensmith GJ et al (2023) Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial. Lancet Diabetes Endocrinol 11(3):169\u2013181. https:\/\/doi.org\/10.1016\/s2213-8587(22)00387-4","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"6855_CR362","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.2337\/dc21-2275","volume":"45","author":"WV Tamborlane","year":"2022","unstructured":"Tamborlane WV, Bishai R, Geller D et al (2022) Once-weekly exenatide in youth with type 2 diabetes. Diabetes Care 45(8):1833\u20131840. https:\/\/doi.org\/10.2337\/dc21-2275","journal-title":"Diabetes Care"},{"issue":"5","key":"6855_CR363","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1056\/NEJMoa2204601","volume":"387","author":"SA Arslanian","year":"2022","unstructured":"Arslanian SA, Hannon T, Zeitler P et al (2022) Once-weekly dulaglutide for the treatment of youths with type 2 diabetes. N Engl J Med 387(5):433\u2013443. https:\/\/doi.org\/10.1056\/NEJMoa2204601","journal-title":"N Engl J Med"},{"issue":"1","key":"6855_CR364","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13098-024-01337-5","volume":"16","author":"LBT Yugar","year":"2024","unstructured":"Yugar LBT, Sedenho-Prado LG, da Silva Ferreira IMC, Silva CAM, Sposito AC, Cercato C (2024) The efficacy and safety of GLP-1 receptor agonists in youth with type 2 diabetes: a meta-analysis. Diabetol Metab Syndr 16(1):92. https:\/\/doi.org\/10.1186\/s13098-024-01337-5","journal-title":"Diabetol Metab Syndr"},{"issue":"12","key":"6855_CR365","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1001\/jamapediatrics.2025.3243","volume":"179","author":"P Kotecha","year":"2025","unstructured":"Kotecha P, Huang W, Yeh YY et al (2025) Efficacy and safety of GLP-1 RAs in children and adolescents with obesity or type 2 diabetes: a systematic review and meta-analysis. JAMA Pediatr 179(12):1308\u20131317. https:\/\/doi.org\/10.1001\/jamapediatrics.2025.3243","journal-title":"JAMA Pediatr"},{"issue":"10511","key":"6855_CR366","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1016\/s0140-6736(25)01774-x","volume":"406","author":"TS Hannon","year":"2025","unstructured":"Hannon TS, Chao LC, Barrientos-P\u00e9rez M et al (2025) Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 406(10511):1484\u20131496. https:\/\/doi.org\/10.1016\/s0140-6736(25)01774-x","journal-title":"Lancet"},{"issue":"1","key":"6855_CR367","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/dom.14192","volume":"23","author":"JCN Chan","year":"2021","unstructured":"Chan JCN, Pald\u00e1nius PM, Mathieu C, Stumvoll M, Matthews DR, Del Prato S (2021) Early combination therapy delayed treatment escalation in newly diagnosed young-onset type 2 diabetes: a subanalysis of the VERIFY study. Diabetes Obes Metab 23(1):245\u2013251. https:\/\/doi.org\/10.1111\/dom.14192","journal-title":"Diabetes Obes Metab"},{"key":"6855_CR368","doi-asserted-by":"publisher","first-page":"897776","DOI":"10.3389\/fendo.2022.897776","volume":"13","author":"S Wu","year":"2022","unstructured":"Wu S, He Y, Wu Y et al (2022) Comparative efficacy and safety of glucose-lowering drugs in children and adolescents with type 2 diabetes: a systematic review and network meta-analysis. Front Endocrinol (Lausanne) 13:897776. https:\/\/doi.org\/10.3389\/fendo.2022.897776","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"9","key":"6855_CR369","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.2337\/dc24-0322","volume":"47","author":"P Bjornstad","year":"2024","unstructured":"Bjornstad P, Arslanian SA, Hannon TS et al (2024) Dulaglutide and glomerular hyperfiltration, proteinuria, and albuminuria in youth with type 2 diabetes: post hoc analysis of the AWARD-PEDS study. Diabetes Care 47(9):1617\u20131621. https:\/\/doi.org\/10.2337\/dc24-0322","journal-title":"Diabetes Care"},{"issue":"2","key":"6855_CR370","doi-asserted-by":"publisher","first-page":"273","DOI":"10.2215\/cjn.0000000889","volume":"21","author":"P Bjornstad","year":"2026","unstructured":"Bjornstad P, Danne T, Klingensmith GJ et al (2026) Impact of empagliflozin on glomerular hyperfiltration and albuminuria in youth with type 2 diabetes: post hoc analysis of DINAMO. Clin J Am Soc Nephrol 21(2):273\u2013282. https:\/\/doi.org\/10.2215\/cjn.0000000889","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10","key":"6855_CR371","doi-asserted-by":"publisher","first-page":"4302","DOI":"10.1111\/dom.15777","volume":"26","author":"MA Shamim","year":"2024","unstructured":"Shamim MA, Patil AN, Amin U et al (2024) Glucagon-like peptide-1 receptor agonists in adolescents with overweight or obesity with or without type 2 diabetes multimorbidity-a systematic review and network meta-analysis. Diabetes Obes Metab 26(10):4302\u20134317. https:\/\/doi.org\/10.1111\/dom.15777","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"6855_CR372","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/s2666-7568(23)00032-6","volume":"4","author":"RE Pratley","year":"2023","unstructured":"Pratley RE, Cannon CP, Cherney DZI et al (2023) Cardiorenal outcomes, kidney function, and other safety outcomes with ertugliflozin in older adults with type 2 diabetes (VERTIS CV): secondary analyses from a randomised, double-blind trial. Lancet Healthy Longev 4(4):e143\u2013e154. https:\/\/doi.org\/10.1016\/s2666-7568(23)00032-6","journal-title":"Lancet Healthy Longev"},{"issue":"12","key":"6855_CR373","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1001\/jama.2024.27402","volume":"333","author":"P Hanlon","year":"2025","unstructured":"Hanlon P, Butterly E, Wei L et al (2025) Age and sex differences in efficacy of treatments for type 2 diabetes: a network meta-analysis. JAMA 333(12):1062\u20131073. https:\/\/doi.org\/10.1001\/jama.2024.27402","journal-title":"Jama"},{"issue":"1","key":"6855_CR374","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s13300-024-01659-7","volume":"16","author":"SC Bain","year":"2025","unstructured":"Bain SC, Belmar N, Hoff ST et al (2025) Cardiovascular, metabolic, and safety outcomes with semaglutide by baseline age: post hoc analysis of SUSTAIN 6 and PIONEER 6. Diabetes Ther 16(1):15\u201328. https:\/\/doi.org\/10.1007\/s13300-024-01659-7","journal-title":"Diabetes Ther"},{"issue":"4","key":"6855_CR375","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1007\/s13300-025-01711-0","volume":"16","author":"N Rasouli","year":"2025","unstructured":"Rasouli N, Wilding JPH, Kwan AYM, Paik JS, Sharma P, Peleshok J (2025) Tirzepatide for older adults with type 2 diabetes and without obesity: a post hoc analysis of the SURPASS clinical trials. Diabetes Ther 16(4):701\u2013715. https:\/\/doi.org\/10.1007\/s13300-025-01711-0","journal-title":"Diabetes Ther"},{"issue":"3","key":"6855_CR376","doi-asserted-by":"publisher","first-page":"e076444","DOI":"10.1136\/bmjopen-2023-076444","volume":"14","author":"S Bansal","year":"2024","unstructured":"Bansal S, Canziani MEF, Birne R et al (2024) Finerenone cardiovascular and kidney outcomes by age and sex: FIDELITY post hoc analysis of two phase 3, multicentre, double-blind trials. BMJ Open 14(3):e076444. https:\/\/doi.org\/10.1136\/bmjopen-2023-076444","journal-title":"BMJ Open"},{"issue":"8","key":"6855_CR377","doi-asserted-by":"publisher","first-page":"afae175","DOI":"10.1093\/ageing\/afae175","volume":"53","author":"SY Pan","year":"2024","unstructured":"Pan SY, Su EL, Huang CJ et al (2024) Evaluation of glucose-lowering medications in older people: a comprehensive systematic review and network meta-analysis of randomized controlled trials. Age Ageing 53(8):afae175. https:\/\/doi.org\/10.1093\/ageing\/afae175","journal-title":"Age Ageing"},{"issue":"1","key":"6855_CR378","doi-asserted-by":"publisher","first-page":"2217287","DOI":"10.1080\/0886022x.2023.2217287","volume":"45","author":"Y Liu","year":"2023","unstructured":"Liu Y, An C, Liu P, Yang F, Zhao Q (2023) Comparative safety of sodium-glucose co-transporter 2 inhibitors in elderly patients with type 2 diabetes mellitus and diabetic kidney disease: a systematic review and meta-analysis. Ren Fail 45(1):2217287. https:\/\/doi.org\/10.1080\/0886022x.2023.2217287","journal-title":"Ren Fail"},{"issue":"6","key":"6855_CR379","doi-asserted-by":"publisher","first-page":"e14393","DOI":"10.1111\/dme.14393","volume":"38","author":"M Mickute","year":"2021","unstructured":"Mickute M, Henson J, Rowlands AV et al (2021) Device-measured physical activity and its association with physical function in adults with type 2 diabetes mellitus. Diabet Med 38(6):e14393. https:\/\/doi.org\/10.1111\/dme.14393","journal-title":"Diabet Med"},{"issue":"7","key":"6855_CR380","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.2337\/dc20-2664","volume":"44","author":"TN Nguyen","year":"2021","unstructured":"Nguyen TN, Harris K, Woodward M et al (2021) The impact of frailty on the effectiveness and safety of intensive glucose control and blood pressure-lowering therapy for people with type 2 diabetes: results from the ADVANCE trial. Diabetes Care 44(7):1622\u20131629. https:\/\/doi.org\/10.2337\/dc20-2664","journal-title":"Diabetes Care"},{"issue":"4","key":"6855_CR381","doi-asserted-by":"publisher","first-page":"e1004553","DOI":"10.1371\/journal.pmed.1004553","volume":"22","author":"H Wightman","year":"2025","unstructured":"Wightman H, Butterly E, Wei L et al (2025) Frailty in randomized controlled trials of glucose-lowering therapies for type 2 diabetes: an individual participant data meta-analysis of frailty prevalence, treatment efficacy, and adverse events. PLoS Med 22(4):e1004553. https:\/\/doi.org\/10.1371\/journal.pmed.1004553","journal-title":"PLoS Med"},{"issue":"7","key":"6855_CR382","doi-asserted-by":"publisher","first-page":"968","DOI":"10.2215\/cjn.0000000700","volume":"20","author":"P Rossing","year":"2025","unstructured":"Rossing P, Birkenfeld AL, Fioretto P et al (2025) Finerenone and clinical outcomes in CKD and type 2 diabetes by frailty index: FIDELITY post hoc analysis. Clin J Am Soc Nephrol 20(7):968\u2013977. https:\/\/doi.org\/10.2215\/cjn.0000000700","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"6855_CR383","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1111\/jgs.19444","volume":"73","author":"TN Nguyen","year":"2025","unstructured":"Nguyen TN, Yu J, Perkovic V et al (2025) The efficacy and safety of canagliflozin by frailty status in participants of the CANVAS and CREDENCE trials. J Am Geriatr Soc 73(6):1787\u20131796. https:\/\/doi.org\/10.1111\/jgs.19444","journal-title":"J Am Geriatr Soc"},{"issue":"1","key":"6855_CR384","doi-asserted-by":"publisher","first-page":"e2142078","DOI":"10.1001\/jamanetworkopen.2021.42078","volume":"5","author":"M Bhattarai","year":"2022","unstructured":"Bhattarai M, Salih M, Regmi M et al (2022) Association of sodium-glucose cotransporter 2 inhibitors with cardiovascular outcomes in patients with type 2 diabetes and other risk factors for cardiovascular disease: a meta-analysis. JAMA Netw Open 5(1):e2142078. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.42078","journal-title":"JAMA Netw Open"},{"issue":"9","key":"6855_CR385","doi-asserted-by":"publisher","first-page":"3530","DOI":"10.1111\/dom.15685","volume":"26","author":"K Cardoza","year":"2024","unstructured":"Cardoza K, Kang A, Smyth B et al (2024) Geographic and racial variability in kidney, cardiovascular and safety outcomes with canagliflozin: a secondary analysis of the CREDENCE randomized trial. Diabetes Obes Metab 26(9):3530\u20133540. https:\/\/doi.org\/10.1111\/dom.15685","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"6855_CR386","doi-asserted-by":"publisher","first-page":"102804","DOI":"10.1016\/j.dsx.2023.102804","volume":"17","author":"J Zhang","year":"2023","unstructured":"Zhang J, Van Spall HG, Li L et al (2023) Effects of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on cardiovascular and kidney outcomes in Asian versus White patients with type 2 diabetes mellitus. Diabetes Metab Syndr 17(7):102804. https:\/\/doi.org\/10.1016\/j.dsx.2023.102804","journal-title":"Diabetes Metab Syndr"},{"issue":"9\u201310","key":"6855_CR387","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1159\/000532102","volume":"54","author":"D Koya","year":"2023","unstructured":"Koya D, Anker SD, Ruilope LM et al (2023) Cardiorenal outcomes with finerenone in Asian patients with chronic kidney disease and type 2 diabetes: a FIDELIO-DKD post hoc analysis. Am J Nephrol 54(9\u201310):370\u2013378. https:\/\/doi.org\/10.1159\/000532102","journal-title":"Am J Nephrol"},{"issue":"1","key":"6855_CR388","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1159\/000545415","volume":"11","author":"T Wada","year":"2025","unstructured":"Wada T, Anker SD, Liu Z et al (2025) Efficacy and safety of finerenone in Asian patients with type 2 diabetes and chronic kidney disease: a FIDELITY analysis. Kidney Dis (Basel) 11(1):402\u2013415. https:\/\/doi.org\/10.1159\/000545415","journal-title":"Kidney Dis (Basel)"},{"issue":"12","key":"6855_CR389","doi-asserted-by":"publisher","first-page":"100730","DOI":"10.1016\/j.xkme.2023.100730","volume":"5","author":"JM Flack","year":"2023","unstructured":"Flack JM, Agarwal R, Anker SD et al (2023) Finerenone in black patients with type 2 diabetes and CKD: a post hoc analysis of the pooled FIDELIO-DKD and FIGARO-DKD trials. Kidney Med 5(12):100730. https:\/\/doi.org\/10.1016\/j.xkme.2023.100730","journal-title":"Kidney Med"},{"issue":"10","key":"6855_CR390","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1111\/dom.13805","volume":"21","author":"BM Mishriky","year":"2019","unstructured":"Mishriky BM, Powell JR, Wittwer JA et al (2019) Do GLP-1RAs and SGLT-2is reduce cardiovascular events in black patients with type 2 diabetes? A systematic review and meta-analysis. Diabetes Obes Metab 21(10):2274\u20132283. https:\/\/doi.org\/10.1111\/dom.13805","journal-title":"Diabetes Obes Metab"},{"key":"6855_CR391","unstructured":"US Food & Drug Administration (2024) Diversity action plans to improve enrollment of participants from underrepresented populations in clinical studies: draft guidance for industry. Available from https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/diversity-action-plans-improve-enrollment-participants-underrepresented-populations-clinical-studies. Accessed 30 April 2026"},{"issue":"Suppl 2","key":"6855_CR392","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1007\/pl00002934","volume":"44","author":"NJ Morrish","year":"2001","unstructured":"Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H (2001) Mortality and causes of death in the WHO multinational study of vascular disease in diabetes. Diabetologia 44(Suppl 2):S14-21. https:\/\/doi.org\/10.1007\/pl00002934","journal-title":"Diabetologia"},{"issue":"25","key":"6855_CR393","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1161\/cir.0000000000000343","volume":"132","author":"JG Regensteiner","year":"2015","unstructured":"Regensteiner JG, Golden S, Huebschmann AG et al (2015) Sex differences in the cardiovascular consequences of diabetes mellitus: a scientific statement from the American Heart Association. Circulation 132(25):2424\u20132447. https:\/\/doi.org\/10.1161\/cir.0000000000000343","journal-title":"Circulation"},{"issue":"1","key":"6855_CR394","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1001\/archinte.1995.00430010063008","volume":"155","author":"WB Kannel","year":"1995","unstructured":"Kannel WB, Wilson PW (1995) Risk factors that attenuate the female coronary disease advantage. Arch Intern Med 155(1):57\u201361","journal-title":"Arch Intern Med"},{"issue":"5","key":"6855_CR395","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1007\/s00125-005-1730-6","volume":"48","author":"G Hu","year":"2005","unstructured":"Hu G, Jousilahti P, Qiao Q, Katoh S, Tuomilehto J (2005) Sex differences in cardiovascular and total mortality among diabetic and non-diabetic individuals with or without history of myocardial infarction. Diabetologia 48(5):856\u2013861. https:\/\/doi.org\/10.1007\/s00125-005-1730-6","journal-title":"Diabetologia"},{"issue":"9933","key":"6855_CR396","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1016\/s0140-6736(14)60040-4","volume":"383","author":"SA Peters","year":"2014","unstructured":"Peters SA, Huxley RR, Woodward M (2014) Diabetes as a risk factor for stroke in women compared with men: a systematic review and meta-analysis of 64 cohorts, including 775,385 individuals and 12,539 strokes. Lancet 383(9933):1973\u20131980. https:\/\/doi.org\/10.1016\/s0140-6736(14)60040-4","journal-title":"Lancet"},{"issue":"8","key":"6855_CR397","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1007\/s00125-014-3260-6","volume":"57","author":"SA Peters","year":"2014","unstructured":"Peters SA, Huxley RR, Woodward M (2014) Diabetes as risk factor for incident coronary heart disease in women compared with men: a systematic review and meta-analysis of 64 cohorts including 858,507 individuals and 28,203 coronary events. Diabetologia 57(8):1542\u20131551. https:\/\/doi.org\/10.1007\/s00125-014-3260-6","journal-title":"Diabetologia"},{"issue":"6","key":"6855_CR398","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11892-018-1005-5","volume":"18","author":"SAE Peters","year":"2018","unstructured":"Peters SAE, Woodward M (2018) Sex differences in the burden and complications of diabetes. Curr Diab Rep 18(6):33. https:\/\/doi.org\/10.1007\/s11892-018-1005-5","journal-title":"Curr Diab Rep"},{"issue":"5","key":"6855_CR399","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.2337\/dc19-2257","volume":"43","author":"KK Clemens","year":"2020","unstructured":"Clemens KK, Woodward M, Neal B, Zinman B (2020) Sex disparities in cardiovascular outcome trials of populations with diabetes: a systematic review and meta-analysis. Diabetes Care 43(5):1157\u20131163. https:\/\/doi.org\/10.2337\/dc19-2257","journal-title":"Diabetes Care"},{"issue":"6","key":"6855_CR400","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1111\/dom.14993","volume":"25","author":"JB Green","year":"2023","unstructured":"Green JB, Merrill P, Lokhnygina Y, Mentz RJ, Alfredsson J, Holman RR (2023) Sex differences in the complications, care and clinical outcomes of patients with type 2 diabetes in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). Diabetes Obes Metab 25(6):1473\u20131484. https:\/\/doi.org\/10.1111\/dom.14993","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"6855_CR401","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.dsx.2020.02.012","volume":"14","author":"AK Singh","year":"2020","unstructured":"Singh AK, Singh R (2020) Gender difference in cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 receptor agonist in type 2 diabetes: a systematic review and meta-analysis of cardio-vascular outcome trials. Diabetes Metab Syndr 14(3):181\u2013187. https:\/\/doi.org\/10.1016\/j.dsx.2020.02.012","journal-title":"Diabetes Metab Syndr"},{"issue":"2","key":"6855_CR402","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1111\/dom.13876","volume":"22","author":"K R\u00e5dholm","year":"2020","unstructured":"R\u00e5dholm K, Zhou Z, Clemens K, Neal B, Woodward M (2020) Effects of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes in women versus men. Diabetes Obes Metab 22(2):263\u2013266. https:\/\/doi.org\/10.1111\/dom.13876","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"6855_CR403","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.2337\/dci24-0094","volume":"48","author":"K Cusi","year":"2025","unstructured":"Cusi K, Abdelmalek MF, Apovian CM et al (2025) Metabolic dysfunction-associated steatotic liver disease (MASLD) in people with diabetes: the need for screening and early intervention a consensus report of the American Diabetes Association. Diabetes Care 48(7):1057\u20131082. https:\/\/doi.org\/10.2337\/dci24-0094","journal-title":"Diabetes Care"},{"issue":"3","key":"6855_CR404","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","volume":"81","author":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO)","year":"2024","unstructured":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO) (2024) EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol 81(3):492\u2013542. https:\/\/doi.org\/10.1016\/j.jhep.2024.04.031","journal-title":"J Hepatol"},{"key":"6855_CR405","doi-asserted-by":"publisher","first-page":"154455","DOI":"10.1016\/j.metabol.2020.154455","volume":"115","author":"DA Koutoukidis","year":"2021","unstructured":"Koutoukidis DA, Koshiaris C, Henry JA et al (2021) The effect of the magnitude of weight loss on non-alcoholic fatty liver disease: a systematic review and meta-analysis. Metabolism 115:154455. https:\/\/doi.org\/10.1016\/j.metabol.2020.154455","journal-title":"Metabolism"},{"issue":"1","key":"6855_CR406","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1186\/s12916-025-04320-7","volume":"23","author":"VA Arita","year":"2025","unstructured":"Arita VA, Cabezas MC, Hern\u00e1ndez Vargas JA et al (2025) Effects of Mediterranean diet, exercise, and their combination on body composition and liver outcomes in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis of randomized controlled trials. BMC Med 23(1):502. https:\/\/doi.org\/10.1186\/s12916-025-04320-7","journal-title":"BMC Med"},{"issue":"1","key":"6855_CR407","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jhep.2016.08.023","volume":"66","author":"R Hashida","year":"2017","unstructured":"Hashida R, Kawaguchi T, Bekki M et al (2017) Aerobic vs resistance exercise in non-alcoholic fatty liver disease: a systematic review. J Hepatol 66(1):142\u2013152. https:\/\/doi.org\/10.1016\/j.jhep.2016.08.023","journal-title":"J Hepatol"},{"issue":"3","key":"6855_CR408","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1210\/clinem\/dgab795","volume":"107","author":"A Sabag","year":"2022","unstructured":"Sabag A, Barr L, Armour M et al (2022) The effect of high-intensity interval training vs moderate-intensity continuous training on liver fat: a systematic review and meta-analysis. J Clin Endocrinol Metab 107(3):862\u2013881. https:\/\/doi.org\/10.1210\/clinem\/dgab795","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"6855_CR409","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/meg.0000000000002662","volume":"36","author":"Y Zeng","year":"2024","unstructured":"Zeng Y, Zhang X, Luo W, Sheng Y (2024) Effect of exercise intervention on clinical parameters in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. Eur J Gastroenterol Hepatol 36(1):1\u201312. https:\/\/doi.org\/10.1097\/meg.0000000000002662","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"9","key":"6855_CR410","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1038\/s41591-025-03799-0","volume":"31","author":"M Jara","year":"2025","unstructured":"Jara M, Norlin J, Kj\u00e6r MS et al (2025) Modulation of metabolic, inflammatory and fibrotic pathways by semaglutide in metabolic dysfunction-associated steatohepatitis. Nat Med 31(9):3128\u20133140. https:\/\/doi.org\/10.1038\/s41591-025-03799-0","journal-title":"Nat Med"},{"issue":"6","key":"6855_CR411","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/s2468-1253(23)00068-7","volume":"8","author":"R Loomba","year":"2023","unstructured":"Loomba R, Abdelmalek MF, Armstrong MJ et al (2023) Semaglutide 2\u00b74 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol Hepatol 8(6):511\u2013522. https:\/\/doi.org\/10.1016\/s2468-1253(23)00068-7","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10019","key":"6855_CR412","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/s0140-6736(15)00803-x","volume":"387","author":"MJ Armstrong","year":"2016","unstructured":"Armstrong MJ, Gaunt P, Aithal GP et al (2016) Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 387(10019):679\u2013690. https:\/\/doi.org\/10.1016\/s0140-6736(15)00803-x","journal-title":"Lancet"},{"issue":"11","key":"6855_CR413","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1007\/s00125-020-05265-7","volume":"63","author":"MS Kuchay","year":"2020","unstructured":"Kuchay MS, Krishan S, Mishra SK et al (2020) Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial). Diabetologia 63(11):2434\u20132445. https:\/\/doi.org\/10.1007\/s00125-020-05265-7","journal-title":"Diabetologia"},{"issue":"9","key":"6855_CR414","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1111\/dom.12680","volume":"18","author":"A Dutour","year":"2016","unstructured":"Dutour A, Abdesselam I, Ancel P et al (2016) Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy. Diabetes Obes Metab 18(9):882\u2013891. https:\/\/doi.org\/10.1111\/dom.12680","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"6855_CR415","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMoa2401943","volume":"391","author":"R Loomba","year":"2024","unstructured":"Loomba R, Hartman ML, Lawitz EJ et al (2024) Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N Engl J Med 391(4):299\u2013310. https:\/\/doi.org\/10.1056\/NEJMoa2401943","journal-title":"N Engl J Med"},{"issue":"22","key":"6855_CR416","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1056\/NEJMoa060326","volume":"355","author":"R Belfort","year":"2006","unstructured":"Belfort R, Harrison SA, Brown K et al (2006) A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 355(22):2297\u20132307. https:\/\/doi.org\/10.1056\/NEJMoa060326","journal-title":"N Engl J Med"},{"issue":"5","key":"6855_CR417","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1001\/jamainternmed.2016.9607","volume":"177","author":"G Musso","year":"2017","unstructured":"Musso G, Cassader M, Paschetta E, Gambino R (2017) Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis. JAMA Intern Med 177(5):633\u2013640. https:\/\/doi.org\/10.1001\/jamainternmed.2016.9607","journal-title":"JAMA Intern Med"},{"key":"6855_CR418","doi-asserted-by":"publisher","first-page":"1111430","DOI":"10.3389\/fendo.2023.1111430","volume":"14","author":"Z Wang","year":"2023","unstructured":"Wang Z, Du H, Zhao Y et al (2023) Response to pioglitazone in non-alcoholic fatty liver disease patients with vs without type 2 diabetes: a meta-analysis of randomized controlled trials. Front Endocrinol (Lausanne) 14:1111430. https:\/\/doi.org\/10.3389\/fendo.2023.1111430","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"7","key":"6855_CR419","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1111\/apt.16583","volume":"54","author":"AM Majzoub","year":"2021","unstructured":"Majzoub AM, Nayfeh T, Barnard A et al (2021) Systematic review with network meta-analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH. Aliment Pharmacol Ther 54(7):880\u2013889. https:\/\/doi.org\/10.1111\/apt.16583","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"6855_CR420","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1097\/hep.0000000000001254","volume":"82","author":"M Souza","year":"2025","unstructured":"Souza M, Al-Sharif L, Antunes VLJ, Huang DQ, Loomba R (2025) Comparison of pharmacological therapies in metabolic dysfunction-associated steatohepatitis for fibrosis regression and MASH resolution: systematic review and network meta-analysis. Hepatology 82(6):1523\u20131533. https:\/\/doi.org\/10.1097\/hep.0000000000001254","journal-title":"Hepatology"},{"issue":"4","key":"6855_CR421","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s42000-023-00493-z","volume":"22","author":"K Malandris","year":"2023","unstructured":"Malandris K, Papandreou S, Avgerinos I et al (2023) Comparative efficacy of glucose-lowering drugs on liver steatosis as assessed by means of magnetic resonance imaging in patients with type 2 diabetes mellitus: systematic review and network meta-analysis. Hormones (Athens) 22(4):655\u2013664. https:\/\/doi.org\/10.1007\/s42000-023-00493-z","journal-title":"Hormones (Athens)"},{"issue":"12","key":"6855_CR422","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1038\/oby.2011.152","volume":"19","author":"P Sathyanarayana","year":"2011","unstructured":"Sathyanarayana P, Jogi M, Muthupillai R, Krishnamurthy R, Samson SL, Bajaj M (2011) Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes. Obesity (Silver Spring) 19(12):2310\u20132315. https:\/\/doi.org\/10.1038\/oby.2011.152","journal-title":"Obesity (Silver Spring)"},{"issue":"5","key":"6855_CR423","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1111\/dom.14650","volume":"24","author":"O Lavynenko","year":"2022","unstructured":"Lavynenko O, Abdul-Ghani M, Alatrach M et al (2022) Combination therapy with pioglitazone\/exenatide\/metformin reduces the prevalence of hepatic fibrosis and steatosis: the efficacy and durability of initial combination therapy for type 2 diabetes (EDICT). Diabetes Obes Metab 24(5):899\u2013907. https:\/\/doi.org\/10.1111\/dom.14650","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"6855_CR424","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1002\/hep4.1993","volume":"6","author":"M Yoneda","year":"2022","unstructured":"Yoneda M, Kobayashi T, Honda Y et al (2022) Combination of tofogliflozin and pioglitazone for NAFLD: extension to the ToPiND randomized controlled trial. Hepatol Commun 6(9):2273\u20132285. https:\/\/doi.org\/10.1002\/hep4.1993","journal-title":"Hepatol Commun"},{"issue":"2","key":"6855_CR425","doi-asserted-by":"publisher","first-page":"298","DOI":"10.2337\/dc19-0641","volume":"43","author":"S Kahl","year":"2020","unstructured":"Kahl S, Gancheva S, Stra\u00dfburger K et al (2020) Empagliflozin effectively lowers liver fat content in well-controlled type 2 diabetes: a randomized, double-blind, phase 4, placebo-controlled trial. Diabetes Care 43(2):298\u2013305. https:\/\/doi.org\/10.2337\/dc19-0641","journal-title":"Diabetes Care"},{"issue":"9","key":"6855_CR426","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.2337\/dc21-2049","volume":"45","author":"Y Takeshita","year":"2022","unstructured":"Takeshita Y, Honda M, Harada K et al (2022) Comparison of tofogliflozin and glimepiride effects on nonalcoholic fatty liver disease in participants with type 2 diabetes: a randomized, 48-week, open-label, active-controlled trial. Diabetes Care 45(9):2064\u20132075. https:\/\/doi.org\/10.2337\/dc21-2049","journal-title":"Diabetes Care"},{"issue":"1","key":"6855_CR427","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1002\/hep4.1696","volume":"6","author":"H Takahashi","year":"2022","unstructured":"Takahashi H, Kessoku T, Kawanaka M et al (2022) Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD. Hepatol Commun 6(1):120\u2013132. https:\/\/doi.org\/10.1002\/hep4.1696","journal-title":"Hepatol Commun"},{"key":"6855_CR428","doi-asserted-by":"publisher","first-page":"e083735","DOI":"10.1136\/bmj-2024-083735","volume":"389","author":"J Lin","year":"2025","unstructured":"Lin J, Huang Y, Xu B et al (2025) Effect of dapagliflozin on metabolic dysfunction-associated steatohepatitis: multicentre, double blind, randomised, placebo controlled trial. BMJ 389:e083735. https:\/\/doi.org\/10.1136\/bmj-2024-083735","journal-title":"Bmj"},{"issue":"1","key":"6855_CR429","doi-asserted-by":"publisher","first-page":"141","DOI":"10.3748\/wjg.v23.i1.141","volume":"23","author":"TR Joy","year":"2017","unstructured":"Joy TR, McKenzie CA, Tirona RG et al (2017) Sitagliptin in patients with non-alcoholic steatohepatitis: a randomized, placebo-controlled trial. World J Gastroenterol 23(1):141\u2013150. https:\/\/doi.org\/10.3748\/wjg.v23.i1.141","journal-title":"World J Gastroenterol"},{"issue":"6","key":"6855_CR430","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","volume":"390","author":"SA Harrison","year":"2024","unstructured":"Harrison SA, Bedossa P, Guy CD et al (2024) A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med 390(6):497\u2013509. https:\/\/doi.org\/10.1056\/NEJMoa2309000","journal-title":"N Engl J Med"},{"issue":"8","key":"6855_CR431","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1038\/ijo.2016.52","volume":"40","author":"A Blackman","year":"2016","unstructured":"Blackman A, Foster GD, Zammit G et al (2016) Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial. Int J Obes (Lond) 40(8):1310\u20131319. https:\/\/doi.org\/10.1038\/ijo.2016.52","journal-title":"Int J Obes (Lond)"},{"issue":"5","key":"6855_CR432","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1007\/s11325-022-02768-y","volume":"27","author":"W Jiang","year":"2023","unstructured":"Jiang W, Li W, Cheng J, Li W, Cheng F (2023) Efficacy and safety of liraglutide in patients with type 2 diabetes mellitus and severe obstructive sleep apnea. Sleep Breath 27(5):1687\u20131694. https:\/\/doi.org\/10.1007\/s11325-022-02768-y","journal-title":"Sleep Breath"},{"issue":"1","key":"6855_CR433","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1186\/s12967-025-06302-y","volume":"23","author":"R Yang","year":"2025","unstructured":"Yang R, Zhang L, Guo J et al (2025) Glucagon-like peptide-1 receptor agonists for obstructive sleep apnea in patients with obesity and type 2 diabetes mellitus: a systematic review and meta-analysis. J Transl Med 23(1):389. https:\/\/doi.org\/10.1186\/s12967-025-06302-y","journal-title":"J Transl Med"},{"issue":"5","key":"6855_CR434","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s00228-024-03643-3","volume":"80","author":"L Xie","year":"2024","unstructured":"Xie L, Li S, Yu X, Wei Q, Yu F, Tong J (2024) DAHOS study: efficacy of dapagliflozin in treating heart failure with reduced ejection fraction and obstructive sleep apnea syndrome - a 3-month, multicenter, randomized controlled clinical trial. Eur J Clin Pharmacol 80(5):771\u2013780. https:\/\/doi.org\/10.1007\/s00228-024-03643-3","journal-title":"Eur J Clin Pharmacol"},{"issue":"12","key":"6855_CR435","doi-asserted-by":"publisher","first-page":"3007","DOI":"10.2337\/dc20-1096","volume":"43","author":"IJ Neeland","year":"2020","unstructured":"Neeland IJ, Eliasson B, Kasai T et al (2020) The impact of empagliflozin on obstructive sleep apnea and cardiovascular and renal outcomes: an exploratory analysis of the EMPA-REG OUTCOME trial. Diabetes Care 43(12):3007\u20133015. https:\/\/doi.org\/10.2337\/dc20-1096","journal-title":"Diabetes Care"},{"issue":"2","key":"6855_CR436","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s11325-022-02594-2","volume":"27","author":"BS Wojeck","year":"2023","unstructured":"Wojeck BS, Inzucchi SE, Neeland IJ et al (2023) Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trial. Sleep Breath 27(2):669\u2013672. https:\/\/doi.org\/10.1007\/s11325-022-02594-2","journal-title":"Sleep Breath"},{"issue":"20","key":"6855_CR437","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1001\/jama.2025.3471","volume":"333","author":"F Pan","year":"2025","unstructured":"Pan F, Wang Y, Lim YZ et al (2025) Metformin for knee osteoarthritis in patients with overweight or obesity: a randomized clinical trial. JAMA 333(20):1804\u20131812. https:\/\/doi.org\/10.1001\/jama.2025.3471","journal-title":"Jama"},{"issue":"1","key":"6855_CR438","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1007\/s40520-025-03017-4","volume":"37","author":"G Jiang","year":"2025","unstructured":"Jiang G, Yang X, Zhu G, Liu T (2025) Comparative efficacy and safety of antidiabetic drugs for obese patients with knee osteoarthritis: a network meta-analysis of randomized controlled trials. Aging Clin Exp Res 37(1):142. https:\/\/doi.org\/10.1007\/s40520-025-03017-4","journal-title":"Aging Clin Exp Res"},{"issue":"2","key":"6855_CR439","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1093\/ajcn\/nqaa328","volume":"113","author":"H Gudbergsen","year":"2021","unstructured":"Gudbergsen H, Overgaard A, Henriksen M et al (2021) Liraglutide after diet-induced weight loss for pain and weight control in knee osteoarthritis: a randomized controlled trial. Am J Clin Nutr 113(2):314\u2013323. https:\/\/doi.org\/10.1093\/ajcn\/nqaa328","journal-title":"Am J Clin Nutr"},{"issue":"17","key":"6855_CR440","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1056\/NEJMoa2403664","volume":"391","author":"H Bliddal","year":"2024","unstructured":"Bliddal H, Bays H, Czernichow S et al (2024) Once-weekly semaglutide in persons with obesity and knee osteoarthritis. N Engl J Med 391(17):1573\u20131583. https:\/\/doi.org\/10.1056\/NEJMoa2403664","journal-title":"N Engl J Med"},{"issue":"7","key":"6855_CR441","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1001\/jamainternmed.2025.1189","volume":"185","author":"JA Luchsinger","year":"2025","unstructured":"Luchsinger JA, Rosin SP, Kazemi EJ et al (2025) Glucose-lowering medications, glycemia, and cognitive outcomes: the GRADE randomized clinical trial. JAMA Intern Med 185(7):778\u2013787. https:\/\/doi.org\/10.1001\/jamainternmed.2025.1189","journal-title":"JAMA Intern Med"},{"issue":"5","key":"6855_CR442","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1001\/jamaneurol.2025.0360","volume":"82","author":"A Seminer","year":"2025","unstructured":"Seminer A, Mulihano A, O\u2019Brien C et al (2025) Cardioprotective glucose-lowering agents and dementia risk: a systematic review and meta-analysis. JAMA Neurol 82(5):450\u2013460. https:\/\/doi.org\/10.1001\/jamaneurol.2025.0360","journal-title":"JAMA Neurol"},{"issue":"7","key":"6855_CR443","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1001\/jamapsychiatry.2025.0679","volume":"82","author":"ACS Pierret","year":"2025","unstructured":"Pierret ACS, Mizuno Y, Saunders P et al (2025) Glucagon-like peptide 1 receptor agonists and mental health: a systematic review and meta-analysis. JAMA Psychiatry 82(7):643\u2013653. https:\/\/doi.org\/10.1001\/jamapsychiatry.2025.0679","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"6855_CR444","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41591-025-04106-7","volume":"32","author":"P Edison","year":"2026","unstructured":"Edison P, Femminella GD, Ritchie C et al (2026) Liraglutide in mild to moderate Alzheimer\u2019s disease: a phase 2b clinical trial. Nat Med 32(1):353\u2013361. https:\/\/doi.org\/10.1038\/s41591-025-04106-7","journal-title":"Nat Med"},{"issue":"10544","key":"6855_CR445","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1016\/s0140-6736(26)00459-9","volume":"407","author":"JL Cummings","year":"2026","unstructured":"Cummings JL, Atri A, Sano M et al (2026) Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer\u2019s disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials. Lancet 407(10544):2167\u20132179. https:\/\/doi.org\/10.1016\/s0140-6736(26)00459-9","journal-title":"Lancet"},{"issue":"1","key":"6855_CR446","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1186\/s12877-024-05352-z","volume":"24","author":"HH Lu","year":"2024","unstructured":"Lu HH, Zhou Y, Chen C, Gu ZJ (2024) Meta-analysis of the effect of exercise intervention on cognitive function in elderly patients with type 2 diabetes mellitus. BMC Geriatr 24(1):770. https:\/\/doi.org\/10.1186\/s12877-024-05352-z","journal-title":"BMC Geriatr"},{"issue":"8","key":"6855_CR447","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1016\/j.apmr.2023.10.005","volume":"105","author":"J Zhang","year":"2024","unstructured":"Zhang J, Tam WWS, Hounsri K, Kusuyama J, Wu VX (2024) Effectiveness of combined aerobic and resistance exercise on cognition, metabolic health, physical function, and health-related quality of life in middle-aged and older adults with type 2 diabetes mellitus: a systematic review and meta-analysis. Arch Phys Med Rehabil 105(8):1585\u20131599. https:\/\/doi.org\/10.1016\/j.apmr.2023.10.005","journal-title":"Arch Phys Med Rehabil"},{"key":"6855_CR448","doi-asserted-by":"publisher","first-page":"1655768","DOI":"10.3389\/fendo.2025.1655768","volume":"16","author":"X Chen","year":"2025","unstructured":"Chen X, Huang Y, Xiong X (2025) Mechanisms underlying cognitive impairment and management strategies in type 2 diabetes. Front Endocrinol (Lausanne) 16:1655768. https:\/\/doi.org\/10.3389\/fendo.2025.1655768","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"10497","key":"6855_CR449","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1016\/s0140-6736(25)01012-8","volume":"405","author":"LL Lim","year":"2025","unstructured":"Lim LL, Jones S, Cikomola JC, Hivert MF, Misra S (2025) Understanding the drivers and consequences of early-onset type 2 diabetes. Lancet 405(10497):2327\u20132340. https:\/\/doi.org\/10.1016\/s0140-6736(25)01012-8","journal-title":"Lancet"},{"key":"6855_CR450","doi-asserted-by":"publisher","first-page":"112014","DOI":"10.1016\/j.diabres.2025.112014","volume":"221","author":"K Wojujutari Ajele","year":"2025","unstructured":"Wojujutari Ajele K, Sunday Idemudia E (2025) The role of depression and diabetes distress in glycemic control: a meta-analysis. Diabetes Res Clin Pract 221:112014. https:\/\/doi.org\/10.1016\/j.diabres.2025.112014","journal-title":"Diabetes Res Clin Pract"},{"issue":"12","key":"6855_CR451","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.2337\/dci17-0041","volume":"40","author":"JK Dickinson","year":"2017","unstructured":"Dickinson JK, Guzman SJ, Maryniuk MD et al (2017) The use of language in diabetes care and education. Diabetes Care 40(12):1790\u20131799. https:\/\/doi.org\/10.2337\/dci17-0041","journal-title":"Diabetes Care"},{"issue":"12","key":"6855_CR452","doi-asserted-by":"publisher","first-page":"e15424","DOI":"10.1111\/dme.15424","volume":"41","author":"E Litterbach","year":"2024","unstructured":"Litterbach E, Holmes-Truscott E, Gray S et al (2024) \u201cI feel like I\u2019m being talked to like an equal\u201d: diabetes language matters to adults with diabetes, a mixed-methods study. Diabet Med 41(12):e15424. https:\/\/doi.org\/10.1111\/dme.15424","journal-title":"Diabet Med"},{"key":"6855_CR453","doi-asserted-by":"publisher","first-page":"e70079","DOI":"10.1111\/obr.70079","volume":"27","author":"M Spreckley","year":"2026","unstructured":"Spreckley M, Ruggiero CF, Brown A (2026) Nutrition strategies for next-generation incretin therapies: a systematic scoping review of the current evidence. Obes Rev 27:e70079. https:\/\/doi.org\/10.1111\/obr.70079","journal-title":"Obes Rev"},{"key":"6855_CR454","unstructured":"US Department of Health and Human Services, Centers for Disease Control and Prevention (2018) Writing SMART Objectives. Available from https:\/\/www.cdc.gov\/healthy-youth\/funded-programs\/pdf\/brief3b.pdf. Accessed 30 April 2026"},{"issue":"2","key":"6855_CR455","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1056\/NEJMoa1212914","volume":"369","author":"RR Wing","year":"2013","unstructured":"Wing RR, Bolin P, Brancati FL et al (2013) Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 369(2):145\u2013154. https:\/\/doi.org\/10.1056\/NEJMoa1212914","journal-title":"N Engl J Med"},{"issue":"4","key":"6855_CR456","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s13668-014-0099-x","volume":"3","author":"X Pi-Sunyer","year":"2014","unstructured":"Pi-Sunyer X (2014) The look AHEAD trial: a review and discussion of its outcomes. Curr Nutr Rep 3(4):387\u2013391. https:\/\/doi.org\/10.1007\/s13668-014-0099-x","journal-title":"Curr Nutr Rep"},{"issue":"6","key":"6855_CR457","doi-asserted-by":"publisher","first-page":"e3840","DOI":"10.1002\/dmrr.3840","volume":"40","author":"DS Romadlon","year":"2024","unstructured":"Romadlon DS, Tu YK, Chen YC, Hasan F, Kurniawan R, Chiu HY (2024) Comparative effects of diabetes self-management programs on type 2 diabetes clinical outcomes: a systematic review and network meta-analysis. Diabetes Metab Res Rev 40(6):e3840. https:\/\/doi.org\/10.1002\/dmrr.3840","journal-title":"Diabetes Metab Res Rev"},{"issue":"7","key":"6855_CR458","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.2337\/dc15-0730","volume":"38","author":"MA Powers","year":"2015","unstructured":"Powers MA, Bardsley J, Cypress M et al (2015) Diabetes self-management education and support in type 2 diabetes: a joint position statement of the American Diabetes Association, the American Association of Diabetes Educators, and the Academy of Nutrition and Dietetics. Diabetes Care 38(7):1372\u20131382. https:\/\/doi.org\/10.2337\/dc15-0730","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"6855_CR459","doi-asserted-by":"publisher","first-page":"S60","DOI":"10.2337\/dc22-S005","volume":"45","author":"American Diabetes Association Professional Practice Committee","year":"2022","unstructured":"American Diabetes Association Professional Practice Committee (2022) 5. Facilitating behavior change and well-being to improve health outcomes: standards of medical care in diabetes-2022. Diabetes Care 45(Suppl 1):S60-S82. https:\/\/doi.org\/10.2337\/dc22-S005","journal-title":"Diabetes Care"},{"issue":"6","key":"6855_CR460","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.pec.2015.11.003","volume":"99","author":"CA Chrvala","year":"2016","unstructured":"Chrvala CA, Sherr D, Lipman RD (2016) Diabetes self-management education for adults with type 2 diabetes mellitus: a systematic review of the effect on glycemic control. Patient Educ Couns 99(6):926\u2013943. https:\/\/doi.org\/10.1016\/j.pec.2015.11.003","journal-title":"Patient Educ Couns"},{"issue":"11","key":"6855_CR461","doi-asserted-by":"publisher","first-page":"848","DOI":"10.7326\/m15-1400","volume":"163","author":"J Pillay","year":"2015","unstructured":"Pillay J, Armstrong MJ, Butalia S et al (2015) Behavioral programs for type 2 diabetes mellitus: a systematic review and network meta-analysis. Ann Intern Med 163(11):848\u2013860. https:\/\/doi.org\/10.7326\/m15-1400","journal-title":"Ann Intern Med"},{"issue":"4","key":"6855_CR462","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1111\/jan.13163","volume":"73","author":"FF Zhao","year":"2017","unstructured":"Zhao FF, Suhonen R, Koskinen S, Leino-Kilpi H (2017) Theory-based self-management educational interventions on patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. J Adv Nurs 73(4):812\u2013833. https:\/\/doi.org\/10.1111\/jan.13163","journal-title":"J Adv Nurs"},{"issue":"8","key":"6855_CR463","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1111\/dme.13340","volume":"34","author":"K Odgers-Jewell","year":"2017","unstructured":"Odgers-Jewell K, Ball LE, Kelly JT, Isenring EA, Reidlinger DP, Thomas R (2017) Effectiveness of group-based self-management education for individuals with type 2 diabetes: a systematic review with meta-analyses and meta-regression. Diabet Med 34(8):1027\u20131039. https:\/\/doi.org\/10.1111\/dme.13340","journal-title":"Diabet Med"},{"issue":"3","key":"6855_CR464","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1007\/s12020-016-1168-2","volume":"55","author":"X He","year":"2017","unstructured":"He X, Li J, Wang B et al (2017) Diabetes self-management education reduces risk of all-cause mortality in type 2 diabetes patients: a systematic review and meta-analysis. Endocrine 55(3):712\u2013731. https:\/\/doi.org\/10.1007\/s12020-016-1168-2","journal-title":"Endocrine"},{"issue":"2","key":"6855_CR465","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/s2213-8587(17)30239-5","volume":"6","author":"S Chatterjee","year":"2018","unstructured":"Chatterjee S, Davies MJ, Heller S, Speight J, Snoek FJ, Khunti K (2018) Diabetes structured self-management education programmes: a narrative review and current innovations. Lancet Diabetes Endocrinol 6(2):130\u2013142. https:\/\/doi.org\/10.1016\/s2213-8587(17)30239-5","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"6855_CR466","doi-asserted-by":"publisher","first-page":"3880","DOI":"10.1186\/s12889-025-25014-y","volume":"25","author":"O Atac","year":"2025","unstructured":"Atac O, Bryant GC, Burrows WB et al (2025) Referrals and utilization of diabetes self-management education and support (DSMES) among patients with type 1 and type 2 diabetes at a regional medical center in Kentucky. BMC Public Health 25(1):3880. https:\/\/doi.org\/10.1186\/s12889-025-25014-y","journal-title":"BMC Public Health"},{"issue":"4","key":"6855_CR467","doi-asserted-by":"publisher","first-page":"505","DOI":"10.2337\/cd23-0082","volume":"42","author":"L Arena","year":"2024","unstructured":"Arena L, Austin R, Esquivel N, Vigil T, Kaelin-Kee J, Millstein S (2024) Understanding barriers and facilitators to participating in diabetes self-management education and support services from multiple perspectives: results of a mixed-methods study of medicaid members, medicaid managed care organizations, and providers in New York State. Clin Diabetes 42(4):505\u2013514. https:\/\/doi.org\/10.2337\/cd23-0082","journal-title":"Clin Diabetes"},{"issue":"8","key":"6855_CR468","doi-asserted-by":"publisher","first-page":"qxae097","DOI":"10.1093\/haschl\/qxae097","volume":"2","author":"A Tharakan","year":"2024","unstructured":"Tharakan A, McPeek Hinz E, Zhu E et al (2024) Accessibility of diabetes education in the United States: barriers, policy implications, and the road ahead. Health Aff Sch 2(8):qxae097. https:\/\/doi.org\/10.1093\/haschl\/qxae097","journal-title":"Health Aff Sch"},{"issue":"3","key":"6855_CR469","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1007\/s00125-021-05609-x","volume":"65","author":"N Lindekilde","year":"2022","unstructured":"Lindekilde N, Scheuer SH, Rutters F et al (2022) Prevalence of type 2 diabetes in psychiatric disorders: an umbrella review with meta-analysis of 245 observational studies from 32 systematic reviews. Diabetologia 65(3):440\u2013456. https:\/\/doi.org\/10.1007\/s00125-021-05609-x","journal-title":"Diabetologia"},{"issue":"5","key":"6855_CR470","doi-asserted-by":"publisher","first-page":"e70002","DOI":"10.1111\/dme.70002","volume":"42","author":"A Versluis","year":"2025","unstructured":"Versluis A, Boels AM, Huijden MCG, Mijnsbergen MD, Rutten G, Vos RC (2025) Diabetes self-management education and support delivered by mobile health (mHealth) interventions for adults with type 2 diabetes-A systematic review and meta-analysis. Diabet Med 42(5):e70002. https:\/\/doi.org\/10.1111\/dme.70002","journal-title":"Diabet Med"},{"issue":"7","key":"6855_CR471","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1007\/s13300-024-01595-6","volume":"15","author":"N Alonso-Carril","year":"2024","unstructured":"Alonso-Carril N, Rodriguez-Rodr\u00edguez S, Quir\u00f3s C et al (2024) Could online education replace face-to-face education in diabetes? A systematic review. Diabetes Ther 15(7):1513\u20131524. https:\/\/doi.org\/10.1007\/s13300-024-01595-6","journal-title":"Diabetes Ther"},{"issue":"8","key":"6855_CR472","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s41574-023-00857-w","volume":"19","author":"K Khunti","year":"2023","unstructured":"Khunti K, Cheng AYY (2023) Therapeutic inertia in type 2 diabetes mellitus: a fine line between advancing and de-intensifying. Nat Rev Endocrinol 19(8):437\u2013438. https:\/\/doi.org\/10.1038\/s41574-023-00857-w","journal-title":"Nat Rev Endocrinol"},{"issue":"2","key":"6855_CR473","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.pcd.2017.01.007","volume":"11","author":"K Khunti","year":"2017","unstructured":"Khunti K, Davies MJ (2017) Clinical inertia-time to reappraise the terminology? Prim Care Diabetes 11(2):105\u2013106. https:\/\/doi.org\/10.1016\/j.pcd.2017.01.007","journal-title":"Prim Care Diabetes"},{"issue":"3","key":"6855_CR474","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/dom.14603","volume":"24","author":"M Evans","year":"2022","unstructured":"Evans M, Engberg S, Faurby M, Fernandes J, Hudson P, Polonsky W (2022) Adherence to and persistence with antidiabetic medications and associations with clinical and economic outcomes in people with type 2 diabetes mellitus: a systematic literature review. Diabetes Obes Metab 24(3):377\u2013390. https:\/\/doi.org\/10.1111\/dom.14603","journal-title":"Diabetes Obes Metab"},{"key":"6855_CR475","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.2147\/ppa.S106821","volume":"10","author":"WH Polonsky","year":"2016","unstructured":"Polonsky WH, Henry RR (2016) Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors. Patient Prefer Adherence 10:1299\u20131307. https:\/\/doi.org\/10.2147\/ppa.S106821","journal-title":"Patient Prefer Adherence"},{"issue":"6","key":"6855_CR476","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1093\/tbm\/ibaa118","volume":"10","author":"P Konstantinou","year":"2020","unstructured":"Konstantinou P, Kassianos AP, Georgiou G et al (2020) Barriers, facilitators, and interventions for medication adherence across chronic conditions with the highest non-adherence rates: a scoping review with recommendations for intervention development. Transl Behav Med 10(6):1390\u20131398. https:\/\/doi.org\/10.1093\/tbm\/ibaa118","journal-title":"Transl Behav Med"},{"issue":"4","key":"6855_CR477","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1177\/1932296816633721","volume":"10","author":"P Lasalvia","year":"2016","unstructured":"Lasalvia P, Barahona-Correa JE, Romero-Alvernia DM et al (2016) Pen devices for insulin self-administration compared with needle and vial: systematic review of the literature and meta-analysis. J Diabetes Sci Technol 10(4):959\u2013966. https:\/\/doi.org\/10.1177\/1932296816633721","journal-title":"J Diabetes Sci Technol"},{"issue":"10278","key":"6855_CR478","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/s0140-6736(21)00213-0","volume":"397","author":"M Davies","year":"2021","unstructured":"Davies M, F\u00e6rch L, Jeppesen OK et al (2021) Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet 397(10278):971\u2013984. https:\/\/doi.org\/10.1016\/s0140-6736(21)00213-0","journal-title":"Lancet"},{"issue":"5","key":"6855_CR479","doi-asserted-by":"publisher","first-page":"790","DOI":"10.2337\/dc24-2790","volume":"48","author":"F Giorgino","year":"2025","unstructured":"Giorgino F, Lingvay I, Van Gaal LF et al (2025) Early fasting serum glucose or weight reduction with tirzepatide and metabolic outcomes in people with type 2 diabetes: a post hoc analysis of the SURPASS trials. Diabetes Care 48(5):790\u2013798. https:\/\/doi.org\/10.2337\/dc24-2790","journal-title":"Diabetes Care"},{"issue":"11","key":"6855_CR480","doi-asserted-by":"publisher","first-page":"3791","DOI":"10.3390\/jcm14113791","volume":"14","author":"M Quarenghi","year":"2025","unstructured":"Quarenghi M, Capelli S, Galligani G, Giana A, Preatoni G, Turri Quarenghi R (2025) Weight regain after liraglutide, semaglutide or tirzepatide interruption: a narrative review of randomized studies. J Clin Med 14(11):3791. https:\/\/doi.org\/10.3390\/jcm14113791","journal-title":"J Clin Med"},{"issue":"3","key":"6855_CR481","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1111\/dom.15400","volume":"26","author":"T Yates","year":"2024","unstructured":"Yates T, Biddle GJH, Henson J et al (2024) Impact of weight loss and weight gain trajectories on body composition in a population at high risk of type 2 diabetes: a prospective cohort analysis. Diabetes Obes Metab 26(3):1008\u20131015. https:\/\/doi.org\/10.1111\/dom.15400","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"6855_CR482","doi-asserted-by":"publisher","first-page":"e3752","DOI":"10.1002\/dmrr.3752","volume":"40","author":"R Wang","year":"2024","unstructured":"Wang R, Luo S, Xiao Z, Zhou Z (2024) Efficacy and safety of fixed-ratio combination insulin degludec\/liraglutide in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials. Diabetes Metab Res Rev 40(3):e3752. https:\/\/doi.org\/10.1002\/dmrr.3752","journal-title":"Diabetes Metab Res Rev"},{"issue":"5","key":"6855_CR483","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1007\/s00125-025-06633-x","volume":"69","author":"VC Bertuol Jr","year":"2026","unstructured":"Bertuol VC Jr, Iorra F, Vieceli T et al (2026) Effects of insulin regimens for type 2 diabetes mellitus: a systematic review and network meta-analysis. Diabetologia 69(5):1150\u20131163. https:\/\/doi.org\/10.1007\/s00125-025-06633-x","journal-title":"Diabetologia"},{"issue":"3","key":"6855_CR484","doi-asserted-by":"publisher","first-page":"152","DOI":"10.2337\/diaspect.29.3.152","volume":"29","author":"SL Anderson","year":"2016","unstructured":"Anderson SL, Trujillo JM (2016) Basal insulin use with GLP-1 receptor agonists. Diabetes Spectr 29(3):152\u2013160. https:\/\/doi.org\/10.2337\/diaspect.29.3.152","journal-title":"Diabetes Spectr"},{"issue":"17","key":"6855_CR485","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1001\/jama.2023.20294","volume":"330","author":"J Rosenstock","year":"2023","unstructured":"Rosenstock J, Fr\u00edas JP, Rodbard HW et al (2023) Tirzepatide vs insulin lispro added to basal insulin in type 2 diabetes: the SURPASS-6 randomized clinical trial. JAMA 330(17):1631\u20131640. https:\/\/doi.org\/10.1001\/jama.2023.20294","journal-title":"Jama"},{"issue":"5","key":"6855_CR486","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1089\/dia.2021.0489","volume":"24","author":"G Davis","year":"2022","unstructured":"Davis G, Bailey R, Calhoun P, Price D, Beck RW (2022) Magnitude of glycemic improvement in patients with type 2 diabetes treated with basal insulin: subgroup analyses from the MOBILE study. Diabetes Technol Ther 24(5):324\u2013331. https:\/\/doi.org\/10.1089\/dia.2021.0489","journal-title":"Diabetes Technol Ther"},{"issue":"6","key":"6855_CR487","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/s2213-8587(26)00076-8","volume":"14","author":"EG Wilmot","year":"2026","unstructured":"Wilmot EG, Moore P, Sathyapalan T et al (2026) Continuous glucose monitoring versus self-monitoring of blood glucose in individuals with type 2 diabetes: a randomised, multicentre, open-label, superiority trial. Lancet Diabetes Endocrinol 14(6):463\u2013474. https:\/\/doi.org\/10.1016\/s2213-8587(26)00076-8","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"6855_CR488","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1210\/clinem\/dgad652","volume":"109","author":"S Uhl","year":"2024","unstructured":"Uhl S, Choure A, Rouse B, Loblack A, Reaven P (2024) Effectiveness of continuous glucose monitoring on metrics of glycemic control in type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. J Clin Endocrinol Metab 109(4):1119\u20131131. https:\/\/doi.org\/10.1210\/clinem\/dgad652","journal-title":"J Clin Endocrinol Metab"},{"issue":"18","key":"6855_CR489","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1056\/NEJMoa2415948","volume":"392","author":"YC Kudva","year":"2025","unstructured":"Kudva YC, Raghinaru D, Lum JW et al (2025) A randomized trial of automated insulin delivery in type 2 diabetes. N Engl J Med 392(18):1801\u20131812. https:\/\/doi.org\/10.1056\/NEJMoa2415948","journal-title":"N Engl J Med"},{"issue":"6","key":"6855_CR490","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.2337\/dc25-2435","volume":"49","author":"LC Hespanhol","year":"2026","unstructured":"Hespanhol LC, Agarwal S, Carvalhal G et al (2026) Automated insulin delivery systems in type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Care 49(6):1134\u20131143. https:\/\/doi.org\/10.2337\/dc25-2435","journal-title":"Diabetes Care"},{"issue":"6","key":"6855_CR491","doi-asserted-by":"publisher","first-page":"5091","DOI":"10.1111\/dom.70708","volume":"28","author":"S Di Molfetta","year":"2026","unstructured":"Di Molfetta S, Di Gioia L, Caruso I et al (2026) Efficacy and safety of automated insulin delivery in people with type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab 28(6):5091\u20135100. https:\/\/doi.org\/10.1111\/dom.70708","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"6855_CR492","doi-asserted-by":"publisher","first-page":"e15196","DOI":"10.1111\/dme.15196","volume":"41","author":"BE Amer","year":"2024","unstructured":"Amer BE, Yaqout YE, Abozaid AM, Afifi E, Aboelkhier MM (2024) Does fully closed-loop automated insulin delivery improve glycaemic control in patients with type 2 diabetes? A meta-analysis of randomized controlled trials. Diabet Med 41(1):e15196. https:\/\/doi.org\/10.1111\/dme.15196","journal-title":"Diabet Med"},{"issue":"2","key":"6855_CR493","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1111\/dom.14893","volume":"25","author":"W Hinton","year":"2023","unstructured":"Hinton W, Ansari AS, Whyte MB et al (2023) Sodium-glucose co-transporter-2 inhibitors in type 2 diabetes: are clinical trial benefits for heart failure reflected in real-world clinical practice? A systematic review and meta-analysis of observational studies. Diabetes Obes Metab 25(2):501\u2013515. https:\/\/doi.org\/10.1111\/dom.14893","journal-title":"Diabetes Obes Metab"},{"key":"6855_CR494","doi-asserted-by":"publisher","first-page":"465","DOI":"10.2147\/ceor.S361886","volume":"14","author":"S Glover","year":"2022","unstructured":"Glover S, Borrego ME, Ray GM, Roberts MH (2022) Sodium-glucose cotransporter 2 inhibitor use among individuals age <65 with type 2 diabetes and heart failure with reduced ejection fraction: a cost-benefit analysis. Clinicoecon Outcomes Res 14:465\u2013477. https:\/\/doi.org\/10.2147\/ceor.S361886","journal-title":"Clinicoecon Outcomes Res"},{"issue":"5","key":"6855_CR495","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1007\/s13300-025-01715-w","volume":"16","author":"D Connolly","year":"2025","unstructured":"Connolly D, Collins E, Ren H, Wan Yau Ming S, Davidson J, Bain S (2025) Real-world comparisons between glucagon-like peptide-1 receptor agonists and other glucose-lowering agents in type 2 diabetes: retrospective analyses of cardiovascular and economic outcomes in England. Diabetes Ther 16(5):955\u2013975. https:\/\/doi.org\/10.1007\/s13300-025-01715-w","journal-title":"Diabetes Ther"},{"issue":"2","key":"6855_CR496","doi-asserted-by":"publisher","first-page":"117","DOI":"10.18553\/jmcp.2025.24251","volume":"31","author":"TJ Dunn","year":"2025","unstructured":"Dunn TJ, Cao Y, Xie L, Guevarra M, Mitri J (2025) Comparing demographic\/clinical characteristics, health care resource utilization, and costs among patients with type 2 diabetes and established atherosclerotic cardiovascular disease with and without the use of cardioprotective medications. J Manag Care Spec Pharm 31(2):117\u2013126. https:\/\/doi.org\/10.18553\/jmcp.2025.24251","journal-title":"J Manag Care Spec Pharm"},{"issue":"2","key":"6855_CR497","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1002\/oby.23622","volume":"31","author":"GE White","year":"2023","unstructured":"White GE, Shu I, Rometo D, Arnold J, Korytkowski M, Luo J (2023) Real-world weight-loss effectiveness of glucagon-like peptide-1 agonists among patients with type 2 diabetes: a retrospective cohort study. Obesity (Silver Spring) 31(2):537\u2013544. https:\/\/doi.org\/10.1002\/oby.23622","journal-title":"Obesity (Silver Spring)"},{"issue":"11","key":"6855_CR498","doi-asserted-by":"publisher","first-page":"4989","DOI":"10.1111\/dom.15911","volume":"26","author":"CS Mayer","year":"2024","unstructured":"Mayer CS, Fontelo P (2024) Semaglutide use in people with obesity and type 2 diabetes from real-world utilization data: an analysis of the All of US program. Diabetes Obes Metab 26(11):4989\u20134995. https:\/\/doi.org\/10.1111\/dom.15911","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"6855_CR499","doi-asserted-by":"publisher","first-page":"e2536100","DOI":"10.1001\/jamanetworkopen.2025.36100","volume":"8","author":"R Neugebauer","year":"2025","unstructured":"Neugebauer R, An J, Dombrowski SK et al (2025) Glucose-lowering medication classes and cardiovascular outcomes in patients with type 2 diabetes. JAMA Netw Open 8(10):e2536100. https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.36100","journal-title":"JAMA Netw Open"},{"key":"6855_CR500","doi-asserted-by":"publisher","first-page":"100617","DOI":"10.1016\/j.lanepe.2023.100617","volume":"29","author":"ME Malik","year":"2023","unstructured":"Malik ME, Falkentoft AC, Jensen J et al (2023) Discontinuation and reinitiation of SGLT-2 inhibitors and GLP-1R agonists in patients with type 2 diabetes: a nationwide study from 2013 to 2021. Lancet Reg Health Eur 29:100617. https:\/\/doi.org\/10.1016\/j.lanepe.2023.100617","journal-title":"Lancet Reg Health Eur"},{"issue":"11","key":"6855_CR501","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1111\/jdi.14285","volume":"15","author":"K Boonpattharatthiti","year":"2024","unstructured":"Boonpattharatthiti K, Songkla PN, Chantara J et al (2024) Prevalence of adherence to oral antidiabetic drugs in patients with type 2 diabetes: a systematic review and meta-analysis. J Diabetes Investig 15(11):1614\u20131625. https:\/\/doi.org\/10.1111\/jdi.14285","journal-title":"J Diabetes Investig"},{"issue":"3","key":"6855_CR502","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s13300-024-01530-9","volume":"15","author":"P Rodriguez","year":"2024","unstructured":"Rodriguez P, San Martin VT, Pantalone KM (2024) Therapeutic inertia in the management of type 2 diabetes: a narrative review. Diabetes Ther 15(3):567\u2013583. https:\/\/doi.org\/10.1007\/s13300-024-01530-9","journal-title":"Diabetes Ther"},{"issue":"9","key":"6855_CR503","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1111\/dom.14455","volume":"23","author":"RE Powell","year":"2021","unstructured":"Powell RE, Zaccardi F, Beebe C et al (2021) Strategies for overcoming therapeutic inertia in type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab 23(9):2137\u20132154. https:\/\/doi.org\/10.1111\/dom.14455","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"6855_CR504","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1186\/s12912-025-02782-x","volume":"24","author":"Y Chen","year":"2025","unstructured":"Chen Y, Zhou T, Su L, Guo Y, Ke X (2025) Effects of nurse-led telephone interventions on HbA1c levels in patients with type 2 diabetes: a meta-analysis-based evaluation of follow-up protocols. BMC Nurs 24(1):284. https:\/\/doi.org\/10.1186\/s12912-025-02782-x","journal-title":"BMC Nurs"},{"issue":"1","key":"6855_CR505","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1016\/j.amepre.2019.02.005","volume":"57","author":"TW Levengood","year":"2019","unstructured":"Levengood TW, Peng Y, Xiong KZ et al (2019) Team-based care to improve diabetes management: a community guide meta-analysis. Am J Prev Med 57(1):e17\u2013e26. https:\/\/doi.org\/10.1016\/j.amepre.2019.02.005","journal-title":"Am J Prev Med"},{"issue":"5","key":"6855_CR506","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.pcd.2019.12.007","volume":"14","author":"S Abdulrhim","year":"2020","unstructured":"Abdulrhim S, Sankaralingam S, Ibrahim MIM, Awaisu A (2020) The impact of pharmacist care on diabetes outcomes in primary care settings: an umbrella review of published systematic reviews. Prim Care Diabetes 14(5):393\u2013400. https:\/\/doi.org\/10.1016\/j.pcd.2019.12.007","journal-title":"Prim Care Diabetes"},{"issue":"3","key":"6855_CR507","doi-asserted-by":"publisher","first-page":"e125","DOI":"10.1016\/s2589-7500(22)00233-3","volume":"5","author":"G Moschonis","year":"2023","unstructured":"Moschonis G, Siopis G, Jung J et al (2023) Effectiveness, reach, uptake, and feasibility of digital health interventions for adults with type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials. Lancet Digit Health 5(3):e125\u2013e143. https:\/\/doi.org\/10.1016\/s2589-7500(22)00233-3","journal-title":"Lancet Digit Health"},{"issue":"3","key":"6855_CR508","doi-asserted-by":"publisher","first-page":"292","DOI":"10.3390\/jfmk10030292","volume":"10","author":"C Gomez-Garcia","year":"2025","unstructured":"Gomez-Garcia C, Maher CA, Sa\u00f1udo B, Jurado-Castro JM (2025) Mobile health interventions for individuals with type 2 diabetes and overweight or obesity-a systematic review and meta-analysis. J Funct Morphol Kinesiol 10(3):292. https:\/\/doi.org\/10.3390\/jfmk10030292","journal-title":"J Funct Morphol Kinesiol"},{"issue":"1","key":"6855_CR509","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13098-022-00846-5","volume":"14","author":"DS Santos","year":"2022","unstructured":"Santos DS, Batistelli CRS, Lara M, Ferreira ES, Moreira TR, Cotta RMM (2022) The effectiveness of the use of telehealth programs in the care of individuals with hypertension and or diabetes mellitus: systematic review and meta-analysis. Diabetol Metab Syndr 14(1):76. https:\/\/doi.org\/10.1186\/s13098-022-00846-5","journal-title":"Diabetol Metab Syndr"},{"issue":"4","key":"6855_CR510","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1038\/s41591-025-03498-w","volume":"31","author":"S Mueller","year":"2025","unstructured":"Mueller S, Dinges SMT, Gass F et al (2025) Telemedicine-supported lifestyle intervention for glycemic control in patients with CHD and T2DM: multicenter, randomized controlled trial. Nat Med 31(4):1203\u20131213. https:\/\/doi.org\/10.1038\/s41591-025-03498-w","journal-title":"Nat Med"},{"key":"6855_CR511","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2147\/jmdh.S494584","volume":"18","author":"A Christy","year":"2025","unstructured":"Christy A, Fernanda F, Insani WN, Abdulah R (2025) Pharmacist-led digital health interventions for patients with diabetes: a systematic review. J Multidiscip Healthc 18:101\u2013112. https:\/\/doi.org\/10.2147\/jmdh.S494584","journal-title":"J Multidiscip Healthc"},{"issue":"3","key":"6855_CR512","doi-asserted-by":"publisher","first-page":"e70041","DOI":"10.1111\/wvn.70041","volume":"22","author":"L Wang","year":"2025","unstructured":"Wang L, Li J, Zhang M, Chan MMK, Ho MH (2025) Effectiveness of transtheoretical model-based motivational interviewing on glycemic control among adults with type 2 diabetes: a systematic review and meta-analysis of randomized control trials. Worldviews Evid Based Nurs 22(3):e70041. https:\/\/doi.org\/10.1111\/wvn.70041","journal-title":"Worldviews Evid Based Nurs"},{"issue":"2","key":"6855_CR513","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1111\/dom.16067","volume":"27","author":"EA Finkelstein","year":"2025","unstructured":"Finkelstein EA, Gardner DS, Tham KW et al (2025) Effectiveness and cost-effectiveness of an app and rewards-based intervention in type 2 diabetes: a randomised controlled trial. Diabetes Obes Metab 27(2):729\u2013739. https:\/\/doi.org\/10.1111\/dom.16067","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"6855_CR514","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1186\/s13643-022-02117-w","volume":"11","author":"LH Goh","year":"2022","unstructured":"Goh LH, Siah CJR, Tam WWS, Tai ES, Young DYL (2022) Effectiveness of the chronic care model for adults with type 2 diabetes in primary care: a systematic review and meta-analysis. Syst Rev 11(1):273. https:\/\/doi.org\/10.1186\/s13643-022-02117-w","journal-title":"Syst Rev"},{"issue":"8","key":"6855_CR515","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1001\/jamainternmed.2025.2015","volume":"185","author":"RW Grant","year":"2025","unstructured":"Grant RW, Peterson I, McCloskey JM et al (2025) Diabetes deprescribing in older adults: a randomized clinical trial. JAMA Intern Med 185(8):926\u2013935. https:\/\/doi.org\/10.1001\/jamainternmed.2025.2015","journal-title":"JAMA Intern Med"},{"issue":"6","key":"6855_CR516","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1177\/26350106241285827","volume":"50","author":"M Rezaeiahari","year":"2024","unstructured":"Rezaeiahari M, Acharya M, Henske J, Owsley K, Bodenhamer J (2024) Utilization of diabetes self-management education and support among medicare beneficiaries newly diagnosed with diabetes in Arkansas, 12 months postdiagnosis (2015\u20132018). Sci Diabetes Self Manag Care 50(6):510\u2013519. https:\/\/doi.org\/10.1177\/26350106241285827","journal-title":"Sci Diabetes Self Manag Care"},{"key":"6855_CR517","doi-asserted-by":"publisher","first-page":"100759","DOI":"10.1016\/j.lana.2024.100759","volume":"34","author":"LA Rodriguez","year":"2024","unstructured":"Rodriguez LA, Finertie H, Neugebauer RS et al (2024) Race and ethnicity and pharmacy dispensing of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Lancet Reg Health Am 34:100759. https:\/\/doi.org\/10.1016\/j.lana.2024.100759","journal-title":"Lancet Reg Health Am"},{"issue":"11","key":"6855_CR518","doi-asserted-by":"publisher","first-page":"e2445316","DOI":"10.1001\/jamanetworkopen.2024.45316","volume":"7","author":"A Wallia","year":"2024","unstructured":"Wallia A, Agarwal S, Owen AL et al (2024) Disparities in continuous glucose monitoring among patients receiving care in federally qualified health centers. JAMA Netw Open 7(11):e2445316. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.45316","journal-title":"JAMA Netw Open"},{"issue":"10480","key":"6855_CR519","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/s0140-6736(24)02617-5","volume":"405","author":"JM Dennis","year":"2025","unstructured":"Dennis JM, Young KG, Cardoso P et al (2025) A five-drug class model using routinely available clinical features to optimise prescribing in type 2 diabetes: a prediction model development and validation study. Lancet 405(10480):701\u2013714. https:\/\/doi.org\/10.1016\/s0140-6736(24)02617-5","journal-title":"Lancet"},{"issue":"4","key":"6855_CR520","doi-asserted-by":"publisher","first-page":"278","DOI":"10.7326\/m20-0864","volume":"173","author":"A Tsapas","year":"2020","unstructured":"Tsapas A, Avgerinos I, Karagiannis T et al (2020) Comparative effectiveness of glucose-lowering drugs for type 2 diabetes: a systematic review and network meta-analysis. Ann Intern Med 173(4):278\u2013286. https:\/\/doi.org\/10.7326\/m20-0864","journal-title":"Ann Intern Med"},{"issue":"9","key":"6855_CR521","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1111\/dom.14451","volume":"23","author":"A Tsapas","year":"2021","unstructured":"Tsapas A, Karagiannis T, Kakotrichi P et al (2021) Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetes Obes Metab 23(9):2116\u20132124. https:\/\/doi.org\/10.1111\/dom.14451","journal-title":"Diabetes Obes Metab"}],"updated-by":[{"DOI":"10.1007\/s00125-026-06911-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:00:00Z","timestamp":1793145600000}}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-026-06855-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00125-026-06855-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-026-06855-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T11:35:50Z","timestamp":1793273750000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00125-026-06855-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,2]]},"references-count":521,"alternative-id":["6855"],"URL":"https:\/\/doi.org\/10.1007\/s00125-026-06855-7","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,2]]},"assertion":[{"value":"3 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: The sample size for the prespecified interim analysis of the phase III ESSENCE trial at week 72 was corrected to 800.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00125-026-06911-2","URL":"https:\/\/doi.org\/10.1007\/s00125-026-06911-2","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M. Bonar and C. Franklin (both Leicester Diabetes Centre, University of Leicester and the University Hospitals of Leicester NHS Trust, UK) assisted with the conception and execution of figures and tables; T. Yates and J. Henson (both Leicester Diabetes Centre, University of Leicester and the University Hospitals of Leicester NHS Trust, UK) and Z. I. Saeed and J. W. Ostrominski (both Brigham and Women's Hospital, Harvard Medical School, MA, USA) supported the production and content of Fig.\n                      \n                      . We acknowledge the support of C. Stendall and M. Spencer (both Leicester Diabetes Centre, University of Leicester and the University Hospitals of Leicester NHS Trust, UK), R. R. Bannuru, A. Bennett and J. Neumiller (all ADA, Arlington, VA, USA), P. Niemann, M. Sch\u00f6nke and L. Rother (all EASD, Dusseldorf, Germany), the Committee for Clinical Affairs of the EASD and the Professional Practice Committee of the ADA.","order":1,"name":"Ethics","label":"Acknowledgements","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Details of the search strategy and list of identified articles can be found at\n                      \n                      .","order":2,"name":"Ethics","label":"Data availability","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"This activity was funded by the American Diabetes Association and the European Association for the Study of Diabetes.","order":3,"name":"Ethics","label":"Funding","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"MJD has acted as a consultant\/advisor and speaker for Eli Lilly, Novo Nordisk and Sanofi, as a consultant\/advisor for Kailera, has attended advisory boards for AbbVie, Amgen, AstraZeneca, Biomea Fusion, Carmot\/Roche, Daewoong Pharmaceutical, Sanofi, Zealand Pharma, Regeneron, GSK, Innovent Bio and EktaH, and as a speaker for AstraZeneca, Boehringer Ingelheim, Obesity Alliance and Zuellig Pharma. She has received grants from AstraZeneca, Boehringer Ingelheim and Novo Nordisk. VRA has institutional contracts with Amgen, AstraZeneca, Applied Therapeutics, Biomea, Corcept, Eli Lilly, Fractyl, Kailera, Novo Nordisk, Pfizer, Recordati, Rhythm and Servier and is a consultant for Baim, Mediflix, Roche and Sanofi. MB is a member of the ADA Board of Directors and has received research funding (to institution) from the ADA. He is Editor-in-Chief of BMJ Open Diabetes Research and Care. NAE has served on the advisory board for Novo Nordisk. FG has received research support from Eli Lilly and Roche Diabetes Care, consulting fees from Eli Lilly, Novo Nordisk, and Kayothera, and serves or has served on advisory boards for AstraZeneca, Biomea, Boehringer Ingelheim, Eli Lilly, Kayothera, Lifescan, Merck, Sharp & Dohme, Medtronic, Novo Nordisk, Roche Diabetes Care and Sanofi. FG serves or has served on boards for EASD\/European Foundation for the Study of Diabetes (EFSD), and European Diabetes Forum (EUDF). He has given lectures, presentations or educational events for AstraZeneca, Boehringer Ingelheim, Eli Lilly, Lifescan, Merck Sharp & Dohme, Medtronic, Novo Nordisk, Roche Diabetes Care, Sanofi and has received support for medical writing and statistical analysis from Eli Lilly, Novo Nordisk, Roche Diabetes Care and Sanofi. JG is or has acted as a consultant for Aqua, AstraZeneca, Bayer, Boehringer Ingelheim, Fractyl, vTv, Lilly, Novo Nordisk, Roche, Sparrow Pharmaceuticals, Vertex and Zealand. She has received research support from Boehringer Ingelheim, Cour, GentiBio, Merck and Metsera. RRK currently serves as Chief Scientific and Medical Officer of the ADA. NMM is an author of modules for Up To Date on Medical Nutrition Therapy for type 2 diabetes and prevention of type 2 diabetes. She is entitled to royalties for this authorship. CM serves or has served on the advisory panel for Novo Nordisk, Sanofi, Eli Lilly and Company, Novartis, Dexcom, Boehringer Ingelheim, Bayer, Roche, Abbott, Medtronic, Insulet, Biomea Fusion, SAB Bio, vTv Therapeutics and Vertex. Financial compensation for these activities has been received by KU Leuven; KU Leuven has received research support for CM from Dexcom, Novo Nordisk and Sanofi. CM serves or has served on the speakers bureau for Novo Nordisk, Sanofi, Eli Lilly and Company, Medtronic, Dexcom, Insulet, Abbott, Vertex and Boehringer Ingelheim. Financial compensation for these activities has been received by KU Leuven. CM is president of EUDF. All external support of EUDF can be found on\n                      \n                      . SER has received research funding (to institution) from Bayer and NIDDK. She is on the Steering Committee for FineOne and has participated on the scientific advisory board for Bayer, Novo Nordisk and Travere. PR has received grants or contracts (to institution) from AstraZeneca, Bayer and Novo Nordisk, and honoraria (to institution) from Astra Zeneca, Abbott, Bayer, Boehringer Ingelheim, Eli Lilly and Novo Nordisk. He has received consulting fees from AstraZeneca, Abbott, Amgen, Bayer, Boehringer Ingelheim, Novo Nordisk, Lexicon, Roche and Regeneron. He has received study medication from Astra Zeneca, Bayer, Novo Nordisk and Lexicon. TT has serves or has served on the advisory board for Novo Nordisk, Eli Lilly, Boehringer Ingelheim, AstraZeneca, Sanofi and Merck and on the speaker\u2019s bureau for Novo Nordisk, Sanofi, Eli Lilly, Boehringer Ingelheim, AstraZeneca, Merck, Sharp & Dohme, Servier, Merck and Medtronic. PT serves or has served on the advisory board for Abbott, AstraZeneca, Boehringer Ingelheim, Danone, Eli Lilly, Novo Nordisk and Lifescan. AT has received support for attending meetings from Bayer, Menarini and Novo Nordisk outside the submitted work. He also serves as chair of the EASD Guidelines Oversight Committee. JBB has received research support from Corcept, GentiBio, Novo Nordisk and Sparrow Pharmaceuticals. He is or has acted as a paid consultant\/on the advisory board for Aardvark Therapeutics, Altimmune, Alveus Therapeutics, Amgen, Antag, Aqua Medical, AstraZeneca, Corcept Therapeutics, Eli Lilly, General Medicines Inc, Kayothera, Metsera, Novo Nordisk, Pfizer, Recordati, Roche, Sparrow Pharmaceuticals, Vertex, vTv Therapeutics and Zealand. He is an investor in Aardvark Therapeutics, Glyscend, Mellitus Health, Metsera, Pendulum Therapeutics, Praetego and Stability Health. TS declares that there are no relationships or activities that might bias, or be perceived to bias, his work.","order":4,"name":"Ethics","label":"Authors\u2019 relationships and activities","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All authors were responsible for drafting the article and revising it critically for important intellectual content. All authors approved the version to be published.","order":5,"name":"Ethics","label":"Contribution statement","group":{"name":"EthicsHeading","label":"Ethics"}}]}}